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ABSTRACT 
Background: Nausea and vomiting during pregnancy (NVP) is a common medical 
condition.  Due to possible harmful side-effects that conventional medicine may pose to 
the fetus, many mothers choose not to use it, and are left helpless against NVP. There is a 
need for alternative treatment to relieve NVP symptoms.  
Objectives: This systematic review (SR) investigated current evidence regarding ginger 
for the treatment of NVP. The primary objective was to assess the effectiveness of ginger 
in treating NVP. The secondary objective was to assess the safety of ginger during 
pregnancy, by identifying adverse events or side-effects. 
Search strategy: Electronic search of bibliographic databases (1966-February 2011).  
Selection criteria: Randomized controlled trials (RCTs) of the efficacy of ginger by any 
route, as treatment for NVP in pregnant women regardless of their age or stage of 
pregnancy.  
Data collection and analysis: The principal investigator and independent reviewer 
individually identified relevant studies, extracted data and assessed trial quality.  Data 
analysis was performed using the RevMan5 software. Differences at the level of p<0.05 
were considered to be statistically significant.  
Results: Eleven RCTs involving 1176 pregnant women were included.  The quality of 
evidence was low, hence the high risk of bias and imprecision of results. Ginger 
significantly improved the symptoms of nausea when compared to placebo, when 
comparing the results of this SR to past SRs, and taking into account a meta-analysis 
performed on two relatively large included studies (mean difference (MD) 1.20, 95% 
confidence interval (CI) 0.56-1.84, p=0.0002, I
2
=0%). However, another meta-analysis 
on two smaller studies indicated no significant improvement in nausea.  Ginger did not 
significantly improve nausea when compared to vitamin B6 (MD 0.34, 95% CI -1.52-
2.20, p=0.7, I
2
=91%). Similarly, ginger did not significantly reduce the number of 
vomiting episodes during NVP, when compared to placebo, although there was a trend 
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towards improvement (MD 0.72, 95% CI -0.03-1.46, p=0.06, I
2
=71%). Subgroup 
analyses performed seemed to favor the lower daily dosage of <1500mg ginger to 
possibly be more effective for the relief of nausea.  Ginger did not pose a significant risk 
for spontaneous abortion when compared to placebo (RR 3.14, 95% CI 0.65-15.11, 
p=0.15; I
2
=0%), or to vitamin B6 (RR 0.49, 95% CI 0.17-1.42, p=0.19, I
2
=40%). 
Similarly, ginger did not pose a significant risk for the side effects of heartburn or 
drowsiness when compared to placebo or vitamin B6. When compared to 
dimenhydrinate, ginger posed a smaller risk for drowsiness (RR 0.08, 95% CI 0.03-0.18) 
and no increased risk for heartburn. 
Conclusions: This review suggests potential benefits of ginger in reducing nausea 
symptoms in pregnancy (bearing in mind the limited number of studies, variable outcome 
reporting and quality of evidence). Ginger did not have a significant impact on vomiting 
episodes, nor pose a risk for side effects or adverse events during pregnancy. Based on 
evidence from this SR, ginger could be considered a harmless and possibly effective 
alternative option for women suffering from the symptoms of NVP. Large RCTs are 
necessary to confirm the possible benefit of ginger as treatment for NVP. 
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OPSOMMING  
Agtergrond: Naarheid en vomering tydens swangerskap (NVS) is ‘n algemene mediese 
toestand.  As gevolg van moontlike skadelike newe-effekte wat konvensionele medikasie 
kan veroorsaak vir die fetus, vermy baie moeders dit en word hulpeloos gelaat teen NVS. 
Dus is daar behoefte aan alternatiewe behandeling vir NVS. 
Doelwitte: Hierdie sistematiese literatuuroorsig (SO) het huidige literatuur ondersoek 
wat verband hou met gemmer vir behandeling van NVS.  Die primêre doelwit was om 
effektiwiteit van gemmer as behandeling vir NVS te assesseer.  Die sekondêre doelwit 
was om veiligheid van gemmer tydens swangerskap te assesseer, deur ongunstige 
gebeure en newe-effekte te identifiseer. 
Soektogstrategie: Elektroniese soektog van bibliografiese databasisse (1966-Februarie 
2011). 
Seleksiekriteria: Verewekansigde gekontrolleerde proewe (RCTs) van gemmer deur 
enige roete as behandeling van NVS, in swanger vroue ongeag ouderdom of stadium van 
swangerskap.  
Dataversameling en –analise: Die hoof navorser en ‘n onafhanklike hersiener het 
individueel relevante studies geidentifiseer, data ekstraksie onderneem en studie-kwaliteit 
geassesseer. Data-analise is uitgevoer deur die RevMan5 sagteware te gebruik. Verskille 
by die vlak van p<0.05 was beskou as statisties betekenisvol.  
Hoof resultate: Elf RCTs waarby 1176 swanger vroue betrokke was, is ingesluit. Die 
studie-kwaliteit was swak, dus die hoë risiko vir sydigheid en onakkuraatheid van 
resultate. Gemmer het beduidend die simptome van naarheid verbeter in vergelyking met 
plasebo, wanneer die resultate van hierdie SO met vorige SO’s vergelyk word, en die 
meta-analise in ag geneem word wat op twee relatiewe groot ingeslote studies uitgevoer 
is (gemiddelde verskil (MD) 1.20, 95% vertrouens interval (VI) 0.56-1.84, 
p=0.0002,I
2
=0%). Kontrasterend, het ‘n ander meta-analise van twee kleiner studies geen 
beduidende verbetering in naarheid aangedui nie. Gemmer het nie beduidend naarheid 
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verbeter wanneer dit met vitamien B6 vergelyk word nie (MD 0.34, 95% VI -1.52-2.20, 
p=0.7, I
2
=91%). Soortgelyk, het gemmer nie die aantal vomerings-episodes verminder, in 
verglyking met plasebo nie, maar daar was wel ‘n neiging na verbetering (MD 0.72, 95% 
VI -0.03-1.46, p=0.06, I
2
=71%).  Die subgroup-analise blyk ten gunste te wees van die 
laer daaglikse dosis van <1500mg gemmer om meer effektief te wees vir die behandeling 
van naarheid. 
Gemmer het nie ‘n beduidende risiko ingehou vir spontane aborsie, wanneer dit vergelyk 
word met plasebo (relatiewe risiko (RR) 3.14, 95% VI 0.65-15.11,p=0.15;I
2
=0%), of 
vitamien B6 nie (RR 0.49, 95% VI 0.17-1.42,p=0.19;I
2
=40%).  Soortgelyk, het gemmer 
nie ‘n beduidende risiko ingehou vir newe-effekte van sooibrand of duiseligheid, wanneer 
dit vergelyk word met plasebo of vitamien B6 nie. Wanneer dit vergelyk word met 
dimenhidrinaat, het gemmer ‘n kleiner risiko ingehou vir duiseligheid (RR 0.08, 95% VI 
0.03-0.18) en geen verhoogde risiko vir sooibrand nie. 
Gevolgtrekkings: Hierdie SO dui ‘n potensiële voordeel van gemmer aan in 
vermindering van naarheid tydens swangerskap (inagnemend van die klein hoeveelheid 
studies, wisselende uitkomste-rapportering en studie-kwaliteit). Gemmer het nie ‘n 
beduidnede impak gehad op vomerings-episodes nie, en ook nie ‘n risiko ingehou vir 
newe-efekte of ongunstige gebeure tydens swangerskap nie. Volgens bewyse uit hierdie 
SO, kan gemmer beskou word as ‘n skadelose en moontlike effektiewe alternatiewe opsie 
vir vroue wat lei aan NVP.  Grootskaalse RCTs is nodig om die moontlike voordeel van 
gemmer as behandeling vir NVS te bevestig. 
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LIST OF DEFINITIONS 
Bias:
1
 Bias is a systematic error, or deviation from the truth.  Bias can lead to 
underestimation or overestimation of the true intervention effect.  Biases can vary in 
magnitude – some are small and trivial compared to the observed effect, and some are 
substantial, so that an apparent finding may be entirely due to bias.  Bias should not be 
confused with imprecision.  Bias is a systematic error which will lead to the wrong 
answer on average when the same study is multiplied several times.  Imprecision is a 
random error, meaning that multiple replications of the same study will produce different 
effect estimates due to sample variation, even if they would give the right answer on 
average. 
Blinding:
1
 Blinding (or masking) refers to the process by which study participants, health 
providers and investigators, including people assessing outcomes, are kept unaware of 
intervention allocation after inclusion of participants into the study.    Blinding of study 
participants and personnel (double-blind) may reduce the risk that knowledge of which 
intervention was received, rather than the intervention itself, affects the outcome.  
Effective blinding can also ensure that the compared groups receive the same amount of 
attention, ancillary treatment and diagnostic interventions.  
Chi-squared (Chi
2)
 test:
1
 This is a formal test of heterogeneity and is included in the 
forest plots in Cochrane reviews.  It assesses whether observed differences in results are 
comparable with chance alone.  A low P-value (or a large Chi-squared statistic relative to 
its degree of freedom) provides evidence of the heterogeneity of the intervention effects 
(variation in effect estimates beyond chance).  Care must be taken in the interpretation of 
the Chi
2
 test, since it has an insignificant effect on the situation of meta-analyses when 
studies have a small sample size or are few in number. This means that while a 
statistically significant result may indicate a problem with heterogeneity, a non-
significant result should not be taken as evidence of no heterogeneity.  This is why a p-
value of 0.10, rather than the conventional 0.05 is sometimes used to determine the 
statistical significance. 
Stellenbosch University http://scholar.sun.ac.za
 xxi 
Concealment of allocation:
1 
Allocation concealment seeks to prevent selection bias in 
intervention assignment by protecting the allocation sequence before and until 
assignment, and can always be successfully implemented regardless of the study topic.  
Confidence interval (CI):
1
 Study results are reported with a point estimate together with 
an associated confidence interval (CI). For example: “the odds ratio was 0.75 with a 95% 
confidence interval of 0.70 to 0.80.  The CI describes the uncertainty inherent in this 
estimate and describes a range of values within which we can be reasonably sure that the 
true effect actually lies.  If the CI is relatively narrow, e.g. 0.70 to 0.80, the effect size is 
known precisely.  If the CI is wider, e.g. 0.60 to 0.90, the uncertainty is greater, although 
there may still be enough precision to make decisions about the utility of the intervention.  
If a CI is very wide, e.g. 0.50 to 1.10, it indicates that we have very little knowledge 
about the effect and that further information is needed.   
A 95% CI is often interpreted as indicating a range within which we can be 95% certain 
that the true effect lies.   This statement is a loose interpretation, but useful.  The stricter 
interpretation of a CI is based on the hypothetical notion of considering the results that 
would be obtained if the same study were to be repeated many times.  If a study were 
repeated infinitely, and on each occasion a 95% CI calculated, then 95% of these 
intervals would contain the true effect.  
Confounding:
1
 A confounder is a factor that can significantly affect validity and lead to 
incorrect conclusions being drawn.  Two characteristics are confounded if their 
influences on the intervention effect can not be disentangled.  For example, if a study 
aims to measure the effect of a drug on an illness, but the illness can also be influenced 
by dietary adjustments, then the dietary adjustments made by the participants could act as 
a confounding factor, since we cannot tell if the effects were due to the intervention or 
due to the dietary adjustments.  
Continuous data:
1
 Data which reflect each individual’s outcome as a measurement of a 
numerical quantity that can take any value in a specified range, e.g. weight, height.  
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Dichotomous data:
1
 (Binary data) Data of which each individual’s outcome is one of 
only two possible categorical responses (e.g. yes or no, present or absent). 
Fixed effect meta-analysis: see meta-analysis 
Forest plot:
1
 A forest plot displays estimates and confidence intervals for both individual 
studies and meta-analyses.  Each study is represented by a block at the point estimate of 
intervention effect with a horizontal line extending at each side of the block.   The area of 
the block indicates the weight assigned to that study in the meta-analysis, while the 
horizontal line depicts the confidence interval (usually with a 95% level of confidence).  
The size of the block draws the eye towards the studies with larger weight (usually those 
with narrower confidence intervals) which dominate the calculation of the pooled result. 
Funnel plot:
1
 A funnel plot is a simple scatter plot of the intervention effect estimates 
from individual studies against some measure of each study’s size or precision.   The 
effect estimate is plotted on the horizontal plane, and the measure of the study size on the 
vertical axis.   The name ‘funnel plot’ arises from the fact that the precision of the 
estimated intervention effect increases as the size of the study increases.  Effect estimates 
from small studies will therefore scatter more widely at the bottom of the graph, with the 
spread narrowing among larger studies.  In the absence of bias, the plot should 
approximately resemble a symmetrical (inverted) funnel.  
Heterogeneity:
1
 Any kind of variability or differences among studies included in a 
systematic review may be termed heterogeneity.  Different types of heterogeneity exist.  
Variability in the participants, interventions and outcomes of studies is known as clinical 
diversity or clinical heterogeneity.  Variability in study design and risk of bias is known 
as methodological diversity or heterogeneity.  Variability in the intervention effects being 
measured in the different studies is known as statistical heterogeneity, and this is a 
consequence of clinical or methodological diversity, or both, among studies.  Statistical 
heterogeneity occurs when the observed intervention effects differ more from each other 
than one would expect from random error (chance) alone. 
Stellenbosch University http://scholar.sun.ac.za
 xxiii 
Human chorionic gonadotrophin (hCG):
2
 A hormone that is produced by the placenta 
during pregnancy.  Large amounts are excreted in the urine, and this is used as the basis 
for most pregnancy tests.   
Hyperemesis gravidarum (HG):
2
 Severe vomiting during pregnancy.  It starts in early 
pregnancy and may continue to produce marked dehydration and subsequent liver 
damage.  Rarely, the condition worsens in spite of active treatment; under such 
circumstances it may be necessary to terminate the pregnancy.  
Incomplete outcome data:
1 
Any data that are missing from the study, can lead to risk of 
bias.  When an individual participant’s outcome data is not available, it is referred to a s 
missing.   Missing outcome data can be due to attrition (participants lost to follow-up, 
treatment withdrawals or trial group changes) or exclusions from the analysis.  All the 
participants included in the study analysis should be exactly those who were randomized 
into the trial. If outcome data are missing in both intervention groups, but reasons for 
these are both reported and balanced across groups, then important bias would not be 
expected.  
Intention-to-treat analysis (ITT):
1
 Intention-to-treat (ITT) analysis aims to include all 
participants randomized into a trial, irrespective of what happened subsequently.  ITT 
analyses are generally preferred as they are unbiased, and also because they address a 
more pragmatic and clinically relevant question.   The principles of ITT are: i) Keep the 
participants in the intervention groups to which they were randomized, regardless of the 
intervention they actually received; ii) Measure outcome data on all participants; iii) 
Include all randomized participants in the analyses. There is no consensus about whether 
all three principles should be applied, and it is often difficult to apply these principles.   
Thus, especially in studies with an extended follow-up period and participants get lost to 
follow-up, it is difficult to perform a true ITT analysis without making imputations. 
Likert-type scale:
3
 (also referred to as a Likert scale) A psychometric scale commonly 
used in questionnaires which is a widely used scale in survey research.  The term is often 
interchanged with ‘rating scale’ even though the two are not synonymous.  When 
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responding to a Likert questionnaire item, respondents specify their level of agreement or 
disagreement on a symmetric agree-disagree scale for a series of statements.  Thus the 
scale captures the intensity of their feelings.  For example, a five-point Likert item could 
include “Strongly disagree / disagree / neither disagree or agree / agree / strongly agree”. 
The scale is named after its inventor, psychologists Rensis Likert. 
Mean difference (MD):
1
 The mean difference (more correctly ‘difference in means’) is a 
standard statistic which measures the absolute difference between the mean value in two 
groups in a clinical trail.   It estimates the amount by which the experimental intervention 
changes the outcome on average compared with the control.  It can be used as a summary 
statistic in meta-analysis when outcome measurements in all studies are made on the 
same scale.  
Meta-analysis:
1
 Meta-analysis is the use of statistical methods to summarize or combine 
the results of two or more independent studies.  It can be used to combine the numerical 
results of all or some of the studies included in a systematic review.  This yields an 
overall statistic, together with its confidence interval, that summarizes the effectiveness 
of the experimental intervention compared with the control intervention. Meta-analysis 
focuses on pair-wise comparisons of interventions, such as an experimental intervention 
versus a control intervention, or the comparison of two experimental interventions.  The 
outcomes of two groups treated differently are known as the effect, the treatment effect or 
the intervention effect.  The combination of intervention effects estimates across studies 
may incorporate an assumption that the studies are not all estimating the same 
intervention effect, but rather estimate intervention effects that follow a distribution 
across studies.  This is then a random-effects meta-analysis.  Alternatively, if it is 
assumed that each study is estimating exactly the same quantity, a fixed-effect meta-
analysis is performed. 
Nausea and Vomiting of Pregnancy (NVP):
2
 A condition affecting many pregnant 
women, typically referred to as morning sickness, although it can occur any time of day 
or night.  Nausea, vomiting, retching or a combination of these symptoms can occur.  
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Odds ratio (OR):
1
 The ratio of probability that a particular event will occur to the 
probability that it will not occur, can be any number between zero and infinity. The value 
of 1 indicates that the estimated effects are the same for both interventions. Neither the 
OR nor the risk ratio for a study can be calculated if there are no events in the control 
group, nor if everybody in the intervention group experiences an event.   In health care it 
is the ratio of number of people with the event to the number without.  It is commonly 
expressed as a ratio of two integers.  For example, an OR of 0.01 is often written as 
1:100; an OR of 0.33 as 1:3; and OR of 3 as 3:1.  OR describes the multiplication of the 
odds of the outcome occurring with the use of the intervention. OR is difficult to 
interpret, and it is simplest to first convert it into a risk ratio, and then interpret the risk 
ratio in the context of a typical common group risk. 
Point estimate:
1
 The results for both individual studies and meta-analyses are reported 
with a point estimate together with an associated confidence interval.  The point estimate 
is the best guess of the magnitude and direction of the experimental intervention’s effect 
compared to the control intervention.  
P-value:
1
 A p value is the probability of obtaining the observed effect (or larger) under a 
‘null hypothesis’. A ‘null hypothesis’ is the assumption of ‘no effect of the intervention’, 
or ‘no differences in the effect of intervention between studies’ (no heterogeneity).   
Thus, a p value that is very small indicates that the observed effect is very unlikely to be 
due to chance, and therefore provides evidence against the null hypothesis.  P values less 
than 0.05 (5%),  are often reported as ‘statistically significant’ – meaning there is a 5% 
chance of the observed effect being due to chance, and this being small enough to reject 
the null hypothesis.  To avoid misinterpretations, review authors should always examine 
the effect estimate and its 95% confidence interval, together with the p value.  
Random effects meta-analysis: see meta-analysis 
Randomization:
1
 Randomization means ordering subjects in the sample group in such a 
way that each subject would have the same chance of being selected for each intervention 
and that this allocation should be unpredictable.  Randomization ensures that no biases, 
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conscious or unconscious, on the part of the researchers, influence the choice of 
subjects.
4,5 
 
Randomized controlled trial (RCT):
1
 A clinical trial in which a test and control 
treatment are measured against each other by enrolment and follow-up of the test- and 
control-treated groups of individuals or other units.  The individuals (or other units) 
followed in the trial are assigned prospectively to one of two (or more) alternate forms of 
health care, using random allocation or some quasi-random method allocation.  If the 
authors state explicitly that the groups compared in the trial were established by random 
allocation, then the trial is classified as an RCT.  If it is not clearly stated, but 
randomization cannot be ruled out, then the report is classified as a CCT (controlled 
clinical trial). The classification as RCT or CCT is based solely on what the author has 
written, not the reader’s interpretation.  
Randomized cross-over trial:
1
  In a cross-over trial, all participants receive all 
interventions in sequence.  They are randomized to an ordering of interventions, and each 
participant acts as their own control.  The main concerns over risk of bias in cross-over 
trials are (i) whether the cross-over design is suitable; (ii) whether there is a carry-over 
effect; (iii)whether only first-period data is available; (iv) incorrect analysis; and (v) 
comparability of results with parallel-group trials.  
Review Manager version 5 (RevMan5):
1
 The Cochrane Information Management 
System (IMS) consists of two main components, the Cochrane review writing software, 
Review Manager (RevMan5), which can perform a variety of meta-analyses, and a 
central server for managing documents and contact details, Archie.  RevMan5 is freely 
available for authors preparing a Cochrane review, and used by academic institutions. 
Risk Ratio (RR):
1
 Risk describes the probability with which a healthcare outcome 
(usually an adverse event) will occur.  In research it is commonly expressed as a decimal 
number between 1 and 12, although it is occasionally converted into a percentage.  It is 
simple to grasp the relationship between risk and the likely occurrence of events: in a 
sample of 100 people the number of events observed will on average be the risk 
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multiplied by 100.  For example, when the risk is 0.1, every 10 people out of every 
hundred will have the event; when the risk is 0.5, about 50 people out of every hundred 
will have the event.  RR describes the multiplication of the risk that occurs with the use 
of the experimental intervention. For example, a RR of 3 for a treatment implies that 
events with the treatment are three times more likely to occur, that events without the 
treatment.   
Side-effect:
2
 An unwanted effect produced by a drug in addition to its desired therapeutic 
effects.  
Selective outcome reporting:
1
 The selection of a subset of the original variables 
recorded, on the basis of the results, for inclusion in publication of trials.  The particular 
concern is that statistically non-significant results might be selectively withheld from 
publication. The possibility of within-study selective outcome reporting can be examined 
for each study included in a systematic review, to detect risk of bias. 
Sensitivity analysis:
1
  A sensitivity analysis is a repeat of the primary analysis or meta-
analysis, substituting alternative decisions or ranges of values for decisions that were 
arbitrary or unclear.  For example, if the eligibility of some studies in a meta-analysis is 
dubious because they do not contain full details, then a sensitivity analysis may involve 
undertaking the meta-analysis twice: first, including all studies, and second, including 
only those that are definitely known to be eligible.  
There are many decision nodes in the systematic review process which can generate a 
need for a sensitivity analysis. Examples include: searching for studies, eligibility criteria, 
what data should be analyzed and analyses methods.  Some sensitivity analyses can be 
pre-specified in the protocol, but often issues suitable for sensitivity analysis are only 
identified during the review process.  When sensitivity analyses show that the overall 
result and conclusions are not affected by the different decisions that could be made 
during the review process, the results of the review can be regarded with a high degree of 
certainty.  
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Sequence generation:
1
  This principle addresses the allocation process in a RCT. The 
starting point for an unbiased intervention study is the use of a mechanism that ensures 
that the same kinds of participants receive each intervention.  Several interrelated 
processes need to be considered.  Firstly an allocation sequence must be used that, if 
perfectly implemented, would balance prognostic factors, on average, evenly across 
intervention groups.  Secondly, the most important among the practical aspects of the 
allocation sequence is the use of mechanisms to prevent foreknowledge of the next 
assignment.  
Standardized mean difference (SMD):
1
 This is a summary statistic in meta-analyses 
when the studies all assess the same outcome, but they measure it in a variety of ways, 
using different scales.  In this circumstance it is necessary to standardize the results of the 
studies into a uniform scale before they can be combined.  The SMD expresses the size of 
the intervention effect in each study relative to the variability observed in that study.  (In 
reality the intervention effect is a difference in means and not a mean in differences). 
SMD= [difference between mean outcome in groups] divided by [standard deviation of 
outcomes among participants]. Thus, studies for which the difference in means is in the 
same proportion as the standard deviation will have the same SMD, regardless of the 
actual scales used to make the measurements.  
Subgroup analysis:
1
  Subgroup analyses involve splitting all the participant data into 
subgroups, often so as to make comparisons between them.  The aim is to investigate 
whether an intervention works differently in different subgroups.  Subgroup analyses may 
be done for subsets of participants (e.g. males or females), or subsets of studies (e.g. 
different geographical locations).  Subgroup analyses may be done as a means of 
investigating heterogeneous results, or to answer specific questions about particular 
patient groups, types of interventions or types of studies.  When there are only two 
subgroups, the overlap of the CIs of the summary estimates in the two groups can be 
considered.  Non-overlap of the CIs indicates statistical significance, but the CIs can 
overlap to a small degree and the difference may still be statistically significant. 
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Systematic Review (SR):
1
 A SR attempts to collate all empirical evidence that fits pre-
specified eligibility criteria in order to answer a specific research question.  It uses 
explicit, systematic methods that are selected with a view of minimizing bias, thus 
producing more reliable findings from which conclusions can be drawn and decisions 
made.  The key characteristics of a SR are: (i) a clearly stated set of objectives with pre-
defined eligibility criteria for studies; (ii) an explicit, reproducible methodology; (iii) a 
systematic search that attempts to identify all studies that would meet the eligibility 
criteria; (iv) an assessment of the validity of the findings of the included studies, for 
example, through the assessment of risk of bias; (v) a systematic presentation and 
synthesis of the characteristics and findings of the included studies. Many systematic 
reviews contain meta-analyses (see meta-analysis). 
 Visual analogue scale (VAS):
3
 A psychometric response scale which can be used in 
questionnaires. It is a measurement instrument for subjective characteristics or attitudes 
that cannot be directly measured.  When responding to a VAS item the respondents 
specify their level of agreement to a statement by indicating a position along a continuous 
line between two endpoints. This continuous (or ‘analogue’) aspect of the scale 
differentiates it from discrete scales such as the Likert scale. 
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1.1 INTRODUCTION 
Nausea and vomiting are very common complaints during the early weeks of pregnancy.  
Due to the possible harmful side effects that conventional medicine may pose to the 
unborn fetus, many mothers choose not to use them, and are left helpless in the face of 
this burden.  Pregnancy is a time when a woman should be in optimal health, and the 
feeling of nausea or even worse, actual vomiting, may lead to physical and psychological 
morbidity and complications during pregnancy.
6
 These problems clearly call for an 
alternative treatment for nausea and vomiting during pregnancy.  
1.2 DESCRIPTION OF THE CONDITION   
1.2.1 Nausea and Vomiting 
Nausea can be described as the feeling of being about to vomit.
2
 This feeling often occurs 
in morning sickness during pregnancy, motion sickness or seasickness. Vomiting 
(emesis) occurs when the contents of the stomach are ejected through the mouth, by a 
reflex reaction controlled by the brain. This reflex reaction can be triggered by chemicals 
or drugs, irritating substances in the stomach or intestine, or from balance-disturbances in 
the inner ear.
1 
Retching is described as repeated, unavailing attempts to vomit.
2
 
It is very important to identify the correct cause of the nausea and vomiting, in order to 
treat it effectively.  There are many conditions that may cause or worsen nausea and 
vomiting. These include gastrointestinal causes (gastroenteritis, gastroparesis, hepatitis, 
pancreatitis, appendicitis, helicobacter pylori (H.pylori), intestinal obstruction, billiary 
tract disease); metabolic causes (diabetic ketoacidosis, porphyria, Addison’s disease, 
hyper- or hypothyroidism); neurological disorders (vestibular lesions, migraine 
headaches, tumours of the central nervous system); genitourinary tract (pyelonephritis, 
uremia, ovarian torsion, kidney stones, degenerating uterine leiomyoma); pregnancy 
related conditions (acute fatty liver of pregnancy, preeclampsia); drug toxicity or 
intolerance, infections, psychological and psychiatric disorders.  All these are differential 
diagnoses or causes for nausea and vomiting other than pregnancy.
6,7
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1.2.2 Nausea and Vomiting of Pregnancy (NVP) 
NVP is commonly referred to as morning sickness (although it can occur at any time of 
the day or night), and affects about 80-90% of pregnant women in varying degrees.
6,8
 
Most of these women will experience both nausea and vomiting, and some only nausea 
without vomiting or retching, but vomiting alone is rare.
8
  Symptoms usually appear at 4-
9 weeks of gestation, reaching a peak at 7-12 weeks, and subsiding by week 16. About 
15-30% of pregnant women’s symptoms will persist beyond 20 weeks, or even up to the 
time of delivery.
6,8 
NVP symptoms will appear before 10 weeks of gestation.  When 
symptoms start later than this, it is probably due to another cause, as listed above, and it 
is very important to correctly diagnose and treat the cause.
6
 
Hyperemesis gravidarum (HG) is severe and persistent vomiting during pregnancy, 
which can lead to dehydration, electrolyte disturbances and liver damage, possible fetal 
damage and in extreme cases, even to the death of the mother.
2,6,9,10
  It is usually 
characterized by protracted vomiting, leading to malnutrition and a weight loss of more 
than 5% of the pre-pregnancy weight.  Women with HG usually need to be hospitalized.
6 
HG occurs in approximately 2% of pregnancies.
6,8
 
1.2.3 Causes of NVP 
The exact cause of NVP remains unclear, and is probably multifactorial. Theories include 
the rapid increase in hormones such as estrogen and human chorionic gonadotropin 
(hCG),
7  
or
 
H. pylori infection, and psychological and genetic predisposition.
7,8
 
During pregnancy many women report that they experience a heightened sense of smell 
and taste, and often complain of a metallic taste in the mouth.  These can cause or 
aggravate NVP symptoms, and lead to aversions to certain types of food, especially 
strong tasting vegetables, meats and poultry. One theory is that this is a protective 
mechanism during pregnancy, to cause the mother to avoid potentially toxic or bacteria-
containing foods that could harm her or the fetus.
6
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Generally it has been observed that women who suffer from uncomplicated NVP (thus, 
not HG) have better pregnancy outcomes than women who don’t experience any NVP.6-
8,11 
A meta-analysis conducted by Weigel and Weigel
11 
indicates a strong significant 
association of NVP with a decreased risk of miscarriage, and no consistent associations 
with peri-natal mortality, especially in the first 20 weeks gestation.   
One theory is that NVP may be caused by rapid hCG increase in the blood, possibly 
caused by a more robust placenta secreting high levels of hCG hormones,
6
 and the more 
robust placenta then being more capable of completing a full term pregnancy.
  
The 
improved pregnancy outcomes observed include lower incidences of miscarriages, 
preterm deliveries and stillbirths, fewer cases of low birth weight, growth retardation and 
mortality.
7
 
Many proposals or theories have been suggested for identifying risk factors for 
experiencing NVP. These include younger maternal age, increased placental mass, 
genetic predisposition, previous HG, multipara, fetal gender, and H. pylori infection.
6 
It 
also appears to be more common for urban women to experience NVP than rural women, 
and more housewives tend to experience it, than professional “white collar” women.7 
Results of studies are inconclusive though, and these remain only theories of risk factors 
for NVP.  
Up to 85% of pregnant women will experience at least one symptom associated with 
gastro-intestinal reflux disorders, and usually more than one symptom occur 
simultaneously.  These symptoms include heartburn, reflux, regurgitation, belching, 
flatulence, stomach bloating, indigestion, and a sensation of feeling a lump in the back of 
the throat.  It has been shown that if women experience these together with NVP, they are 
more likely to classify their NVP as severe. Helicobacter pylori infection might aggravate 
any gastrointestinal condition, thus it is important that all patients with these above-
mentioned symptoms and NVP should be tested for H. pylori.
6 
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1.2.4 Negative Effects of NVP and HG 
Severe NVP and HG can lead to maternal malnourishment and weight loss, leading to 
negative fetal outcomes including low birth weight and preterm birth.
6  
Maternal 
complications include acute renal failure, esophageal rupture and coagulopathy.  One rare 
maternal complication of HG is Wernicke’s encephalopathy, caused by thiamine (vitamin 
B1) deficiency, which causes symptoms such as ophtalmoplegia, ataxia, and mental 
confusion.  It can also lead to stupor, coma and even maternal death if not treated 
promptly.
8
 
Negative maternal consequences of NVP can continue even post delivery, including 
longer recovery time from pregnancy and labour, postpartum gallbladder dysfunction, 
aversions to foods which were associated with episodes of nausea and vomiting, muscle 
pain, nausea continuing after delivery, and typical psychological symptoms of post 
traumatic stress disorder (PTSD).
6
 
NVP, especially HG, can be emotionally traumatic.  It has a negative impact on the 
woman’s physical and mental health.  Even without vomiting or retching, nausea alone 
may have a negative effect on the woman’s health status, as it affects her day-to-day 
activities and feelings.  Many women with NVP believe it negatively affects their 
relationship with their spouse, compromises their parenting ability and professional 
performance, and up to 55% feel depressed.
6,8,12 
 A survey done by Smith et al
13
 found 
that women with NVP reported low energy levels, a decrease in physical functioning and 
social functioning.  
In extreme cases it may even lead to elective abortions as they feel they cannot continue 
the pregnancy under such unbearable circumstances,
6,12
 and in one study approximately 
half of the respondents with NVP reported they were less likely to have another child 
after their experience with severe NVP.
14 
 
A study conducted to investigate the factors that determine medical treatment of NVP, 
concluded the following: women with NVP were more likely to obtain a prescription for 
an anti-emetic drug during the first prenatal visit if they worked outside the house, had 
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severe symptoms, or if it was not their first pregnancy.  This study also showed that many 
health practitioners do not address the subject of NVP at the first prenatal visit during the 
early weeks of pregnancy, leaving the woman to her own devices.
12 
Aursenault et al
15
 mentioned that NVP can be very costly to the patient and / or the 
medical scheme or health system of the relevant country.  Doctor’s visits, 
hospitalizations, time lost from work and the expenses of medicines or alternative 
therapies may all be reduced if NVP is treated early. 
The negative effects of NVP described above, clearly show the importance of managing 
and treating NVP and HG as early as possible, and not considering NVP as merely an 
unpleasant part of pregnancy that has to be endured and suffered through.   
1.2.5 Non-Pharmacological Treatment of NVP  
1.2.5.1 Lifestyle 
The following guidelines have been developed by the Motherisk NVP Helpline at 
Toronto’s Hospital for Sick Children.  This program has been counselling women with 
NVP for more than 16 years, and their guidelines are well researched and 
comprehensive.
6 
Table 1 describes this program’s recommendations. 
Other recommendations to relieve NVP include not lying down directly after a meal, 
shortening food preparation time, eating foods that are appealing, eating in a comfortable 
place, avoiding warm odorous places, wearing comfortable clothing, drinking herbal tea 
with honey, or peppermint tea, sucking on a peppermint candy, and brushing teeth after a 
meal.
6
 Sour liquids like lemonade are often better tolerated than water. Adequate amounts 
of sleep and rest are also needed, as fatigue may worsen NVP.
6
 Emotional support from 
family, friends and medical staff is needed, as some women with NVP may become 
depressed as mentioned previously.
6,7
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Table 1: The Motherisk NVP Helpline’s Guidelines for Treating NVP.6 
i. Maintain adequate hydration and electrolyte levels by drinking at least 2 liters of water 
per day. 
ii. Avoid an empty stomach, by having small frequent meals every 1-2 hours, consisting 
of bland foods.  
iii. Prevent a full stomach by avoiding large meals, not mixing liquids and solids, and 
avoid very fatty or oily food.  
iv. Avoid strong tasting, odorous foods (i.e. spicy, metallic tastes) 
v. Consume ice chips, popsicles and very cold beverages to help reduce metallic taste. 
vi. Snack on nuts and high protein foods between meals 
vii. Discontinue iron-containing prenatal multivitamins in early pregnancy and switch to 
children’s chewable tablets and folic acid instead.  Resume iron-containing prenatal 
vitamins after 12 weeks of gestation, when iron is most needed by mother and baby.  
Pregnant women with past or current anemia should not discontinue their prenatal 
vitamins but rather take them in divided doses  
viii. Eat simple dry and salty carbohydrates (i.e. crackers, toast, and biscuits) prior to 
getting out of bed in the morning.  
1.2.5.2 Acupressure 
Acupressure is a complementary medicine technique often used in Chinese medicine.  It 
is closely related to acupuncture, but instead of using dry needles, the pressure points in 
the body are directly stimulated with a finger, palm or electrical device.  The most 
common acupressure location is the pericardium 6 or Neiguan point, located three 
fingerbreadths above the wrist, on the inside of the forearm. Applying direct pressure to 
the point with a finger, palm, or wearing a wrist band (i.e. “Sea Band”, “ReliefBand”) has 
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been shown to relieve nausea and vomiting symptoms.
16 
Articles discussing this topic 
suggest that study results are inconclusive at this stage.
6,7
 Despite a lack of evidence of 
efficacy, acupressure will not do harm and is not invasive, so it is a safe and easy option 
for pregnant women trying to manage their NVP symptoms.
6,7 
1.2.5.3 Ginger 
Ginger is currently considered as an effective non-pharmacological treatment of 
NVP.
5,6,14 
 Because ginger is the topic for this Review, it will not be discussed here, but in 
the paragraph 1.3 “Description of the intervention” on page 11. 
1.2.6 Pharmacological Treatment of NVP  
During pregnancy many physiological changes occur, including gastro-intestinal 
mobility, plasma volume and glomerular filtration.
17
  These factors all influence the 
distribution, absorption and excretion of drugs and due to this reason, not all drugs are 
safe during pregnancy.  Many drugs cross the placenta by simple diffusion and can affect 
the fetus directly.
17
 Several factors such as molecular size, lipid solubility and the protein 
binding ability of a specific drug can affect the rate of diffusion, and some drugs are 
actively metabolized by the placenta. These factors all determine the level of toxicity to 
the fetus.
17 
Research on adverse drug effects during pregnancy is difficult due to the fact 
that it can be potentially very dangerous to the mother and fetus and would in effect be 
unethical to do experimental trials in this regard.  The occurrence of adverse effects has 
thus been reported primarily by means of case reports from practitioners, epidemiological 
studies, both retrospective and prospective, and animal studies.
17
 Evidence from these 
sources should be interpreted with care however, because of the inherent limitations of 
each. In addition, single case reports can be influenced by many other factors as well.  
Epidemiological studies often have difficulty with accurate data collection and a 
statistical correlation does not necessarily prove an etiological relationship.  Animal 
studies are useful, but should be extrapolated to the human race with great care.
17 
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1.2.6.1 Pyridoxine / Vitamin B6 
Vitamin B6 is a water soluble vitamin that functions as a coenzyme for amino acid, lipid 
and carbohydrate metabolism. It has been extensively researched for its antiemetic 
properties, and doses of 30-75 mg per day are effective for relieving NVP, according to 
two RCTs done on this subject.
18,19
 The vitamin B6 dose can be adjusted according to 
need, using maternal weight and severity of NVP as guideline, and doses of up to 500mg 
per day can be safely used.  The current recommendation however, is a maximum dose of 
up to 200mg per day, as suggested by the 2007 Motherisk NVP algorithm.
6,7 
1.2.6.2 Doxyclamine / Pyridoxine combination  
A medication called Bendectin, combining doxyclamine (antihistamine) and pyridoxine, 
was available from 1958 to1983 and often prescribed for women with NVP.  In 1983 the 
manufacturer voluntarily discontinued the product due to litigation and allegations of 
teratogenic effects (later proven to be false).  After this event, a meta-analysis of 30 years 
of Bendectin data and birth defects has been conducted, proving the safety of the 
combination of doxyclamine and pyridoxine.
20
  Although Bendectin is no longer on the 
market, many compounding pharmacies will prepare the combination on request.  A 
single doxylamine tablet (Unisom) can also be taken alone or in combination with 
pyridoxine.  Pyridoxine-doxyclamine is the only medication the U.S. Food and Drug 
Administration (FDA) has ever approved specifically for the treatment of NVP.
6,7,14 
1.2.6.3 Anti-emetics 
Phenothiazines have been reported to reduce NVP compared with a placebo, without 
increased risk to mother or fetus.
6,15
 Cyclizine (e.g. Valoid) and Buclizine (e.g. 
Vomifene) are often prescribed for NVP in South Africa.
21 
1.2.6.4 Antihistamines  
H1 receptor antagonists (antihistamines) such as dimenhydrinate, and diphenhydrinate, 
have been reported to effective as treatment for NVP.  Some types of antihistamines are 
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available in suppository formulation, and this makes them convenient for severe cases of 
nausea and vomiting, where the swallowing of a capsule might be difficult.
6
 
1.2.6.5 Corticosteroids 
Methylprednisolone (Medrol)
21
 may be an effective therapy for HG.  Corticosteroid 
therapy is generally considered safe during pregnancy.
7 
However, a study published by 
the Motherisk program, has demonstrated a marginally increased risk for oral cleft 
incidences in infants exposed to corticosteroids during the first trimester of pregnancy.
6
 
This treatment should be reserved for when other treatments are ineffective, and only be 
administered after the 10th week of pregnancy.
7,8,15
 
1.2.6.6 Motility drugs 
Metoclopramide (e.g. Maxalon, Clopamon, Metalon, Perinorm) increases lower 
esophageal sphincter pressure and speeds up transit time through the stomach.
6,21
 
1.2.6.7 Acid reflux / Heartburn pharmacotherapy 
As described earlier, gastro-intestinal reflux disorders are common conditions during 
pregnancy, and can contribute to the severity of the pregnant woman’s experience of 
NVP.  With exacerbation of NVP symptoms due to heartburn and acid reflux, the use of 
acid-reducing agents such as H2-histamine blockers and proton pump inhibitors, will 
provide relief for many women.
6 
Gaviscon is a popular antacid product among South 
African pregnant women.
21
  
1.2.6.8 Intravenous rehydration, enteral or parenteral nutrition 
When a woman suffering from NVP cannot keep any fluids down or she shows clinical 
signs of dehydration, despite the previously discussed treatments, she will require 
intravenous fluids.  This is usually saline or lactated Ringer’s solution, or some other 
dextrose-containing solution.  It is very important to start supplementing thiamine soon, 
due to the theoretical risk of Wernicke’s encelopathy. When the woman continues to lose 
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weight and cannot keep food down, enteral tube feeding should be tried first, before total 
parenteral nutrition (TPN) is considered, as an absolute last resort.
6,7
   
1.3 DESCRIPTION OF THE INTERVENTION   
Ginger (Zingiber Officinale Roscoe) is a tropical plant with green and purple flowers and 
an aromatic underground stem, called a rhizome.
10,22,23
 
The rhizome (also referred to as the roots) can be peeled and is used as a spice in cooking 
and baking, and has long been used in the traditional Chinese and Indian medicine, or so-
called alternative or complementary medicine, with limited scientific evidence of its 
benefits or safety.
10,22 
 It can be used fresh, dried, powdered, as a tea, juice or oil.  The oil 
can be taken orally or applied to the skin.  
Raw ginger consists of approximately 9% lipids or glycolipids, and about 5-8% oleoresin 
(oily plant secretion).  Ginger contains up to 3% essential oils, accounting for 20-25% of 
the oleoresin.  Another 25% of the oleoresin consists of the pungent factors consisting 
mainly of gingerols.  The main gingerol is [6]-gingerol, and this is more pungent than 
[8]- or [10]-gingerol.  There are many other gingerols, including methylgingerol, 
gingerdiol, dehydrogingerdione, gingerdiones, diarlyheptanoids, diterpenlactones and 
galanolactone.
23
 
In the crude plant material of ginger, several other sulfonated compounds and 
shogasulfonic acids are found.  These phenolic shogaols are much more pungent than 
gingerols, and are mainly found in the semi-dried ginger plant.  Shogaols are rarely found 
in fresh ginger, as they are major degradation products of gingerols (gingerols are 
thermally labile, thus the shogaols will be released when the ginger is heated and dried).  
Zingerone is also a degradation product and this will cause the ginger product to smell 
bad as it ages.
23
 
Gingerols are agonists of a capsaicin-activated receptor.
23  
This means that gingerols can 
bind to this receptor and ‘mimic’ the effect of capsaicin.   Capsaicin is the active and 
irritant component of chilli peppers.
23
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Both ginger and chilli peppers contain irritants (zingerone and capsaicin, respectively) 
that can cause sensations of warmth and burning.  Repeated oral stimulation of zingerone 
can cause desensitization (in other words you get used to the taste), while repeated 
stimulation with capsaicin can cause either desensitization or sensitization (the burning 
feeling can get more and more intense).
23
 
1.4 PHARMACOLOGICAL PROPERTIES OF GINGER 
Ginger is an inexpensive and relatively safe natural remedy
9
 with many reported 
benefits.  The most common ailments currently being treated with ginger include nausea, 
vomiting, pregnancy-associated morning sickness, motion sickness and 
indigestion.
22,25,26-28
   Many authors
10,22,24,25,29 
also claim that ginger has antioxidant, anti-
tumour and anti-inflammatory effects.  A wide variety of disease conditions are being 
treated with ginger in Chinese and Ayurvedic medicine.
24
 These include a variety of 
gastro-intestinal symptoms as mentioned above, also arthritis, rheumatism, cramps, 
dementia, fever, hypertension, infectious diseases, motion sickness,
9
 asthma
10
  and 
helminthiasis.
24
 There is mixed scientific evidence for the use of ginger for nausea and 
vomiting associated with pregnancy.
22
  
1.4.1 In-vitro Effects of Ginger 
Chrubasik, Pittler and Roufogalis
23
 conducted a comprehensive review of relevant 
literature to give an overview of the pharmacological and clinical effects of ginger. Their 
main findings on in-vitro experiments with ginger were that ginger can inhibit platelet 
aggregation, has anti-inflammatory effects, can protect against lipid peroxidation and 
tumour formation (it inhibited human leukemia cell viability), had antibacterial and anti-
fungal properties, as well as destroying many species of worms. 
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1.4.2 In-vivo Effects of Ginger on Animal Models 
Chrubasik et al
23
 have reported that ginger has positive effects on the gastro-intestinal, 
cardiovascular and immune systems, as well as having central effects (may lead to motor 
un-coordination). Interestingly, these authors concluded that a combination of garlic and 
ginger is more beneficial for cardiovascular health, than the ginger alone.   
Ginger is reported to be protective against tumour formation and lipid peroxidation.
23
  It 
also has anti-pyretic, anti-inflammatory and analgesic effects, which may be useful in 
relieving musculoskeletal and osteo-arthritic pain.
23
 
1.5 POTENTIAL ADVERSE EFFECTS OF THE INTERVENTION 
Since 1994, The Food and Drug Administration (FDA) does not regulate herbal 
supplements strictly,
30
 so these remedies can be bought over the counter without 
prescription and can differ in dosage and purity or strength.
10,22,26,30
  Information is easily 
accessible to all on the internet, and consumers might be misled or ill-informed by 
quackery, and unknowingly overdose themselves with complementary or alternative 
medicine, such as ginger.  The amounts ingested as spice in food is probably low enough 
to be safe, but when it is taken in supplement form for medicinal purposes, it might have 
different effects.
26
 Herbal remedies can often interfere with the actions of mainstream 
medicines.
25,30,31
  The ingestion of whole, fresh ginger has relatively few adverse effects, 
since it is not usually ingested in large enough amounts to cause any effects.  Reported 
adverse effects may include stomach upsets or intestinal blockage when whole ginger is 
not chewed properly.
26
 
High doses of concentrated ginger in the form of powder or herbal tinctures, however, 
can increase bleeding risk by decreasing platelet-aggregation, and also increase stomach 
acid production, especially if taken with other herbs or medicines with the same 
effect.
22,25,30
  Thus, ginger supplementation can have additive or competitive interactions 
with some medicines.   
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Fagen
9
 recommends not using large doses of ginger together with aspirin, warfarin or 
other anti-platelet drugs, antihypertensive drugs or hypoglycemic drugs, due to the 
possible additive effect. Very high doses of ginger powder (higher than 6g/day) can 
increase exfoliation of gastric epithelial cells which cause gastric irritation
23
 and can lead 
to gastric bleeding.
10
  Inhalation of ginger-dust may produce and IgE-mediated allergy.
23
 
1.5.1 Possible Teratogenicity 
Teratogenic effects can be described as effects leading to structural abnormalities during 
the stage of embryogenesis.
17
 Studies done on rats showed a higher risk for spontaneous 
abortions in pregnant rats being supplemented with ginger, possibly because of its blood-
thinning properties. Doses of ginger tea up to 50g/liter posed no risk for maternal health 
but the embryonic loss was more than double that of the control group.  Contrastingly, 
the fetuses who survived the exposure to the ginger tea were significantly heavier than 
the controls and their skeletal development was more advanced.
23,25
   
Thus, theoretically ginger taken in large doses can be risky for pregnant women, but it 
should be kept in mind that the doses fed to experimental rats were very high in relation 
to their body weight.  Human intake would almost certainly never be proportionately as 
high. The issue of the safety of ginger during pregnancy will be investigated as part of 
this systematic review. 
1.5.2 Acute Toxicity  
The LD50 (Median lethal dose, or Lethal dose 50%) is the dosage required to kill half of a 
tested population after a specified test duration.
3 
 For ginger oil the acute oral LD50 in rats 
and the acute dermal LD50 in rabbits exceeded 5g/kg body weight.
23
 
Human dosages of ginger intake are much lower than these animal doses, with the 
average dose of ginger supplemented during trials being approximately 1g ginger per 
day.
26
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1.6 HOW THE INTERVENTION MIGHT WORK   
Several studies have been performed on the use of ginger as an anti-emetic for use with 
post-operative nausea and vomiting, motion sickness and vertigo and chemotherapy-
induced nausea and vomiting.
22,25,27,32. 
The ingestion of oral ginger in a fasting state or 
after food intake resulted in an increase in gastro-duodenal motility.
23 
See figure 1.1. 
Further gastro-intestinal effects of ginger include:
23
 
 The occurrence of induced gastric ulcers can be prevented by the ingestion of 
ginger extract. Roasted ginger used in the extract has a stronger anti-ulcer 
tendency than dry ginger.  
 Ginger’s effect on the digestive system is complex. It can increase bile secretion 
in rats, enhance pancreatic lipase activity, intestinal lipase, disaccharidases, 
sucrase and maltase activities.   
 Ginger extracts and its anti-emetic constituents (shogaols and gingerols) 
demonstrate strong anti-emetic effects.  It can enhance gastro-intestinal transport 
of a meal, and can significantly inhibit serotonin-induced diarrhea. 
Thus, the possibility exists that ginger might alleviate pregnancy associated nausea and 
vomiting.  When being researched, the concepts of nausea and vomiting are usually 
interlinked, and not studied separately. 
Source: Chrubasik 
23
 
Figure 1.1 Gastro-intestinal effects of ginger affecting nausea and vomiting  
Ginger’s 
in-vivo 
effects 
affecting 
NVP 
Increased 
contractility of 
fundus 
Increased 
gastric 
emptying 
Increased 
intestinal 
transport of 
meals 
Theoretically 
decreased 
nausea and 
vomiting 
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1.7 EVIDENCE-BASED NUTRITION 
The concept ‘evidence-based nutrition’ (EBN) can be defined as “the application of the 
best available systematically assembled evidence in setting nutrition policy and 
practice.”33 There are vast numbers of research results available from studies, and if these 
results are interpreted alone, or out of the right context, then these findings are of little 
value, or could even be completely useless.  The evidence-based approach would base a 
decision on a review of all the available scientific evidence there is on the subject.   The 
evidence should also be current, using up-to-date methods and skills to acquire the 
results.
26
  
Authorities or decision makers in communities need to have scientific information 
presented to them in a very clear and simple way, and this information needs to be based 
on research done on the relevant topic.  This can be done by reviewing individual original 
research studies, or by reviewing reviews.
33
 Nutritional epidemiology refers to public 
health issues related to nutrition in a community.  Exposure to health risks in a 
community needs to be assessed and reported, to make it possible for authorities to make 
judgments according to these risk assessments.  The goal is to reduce the burden of risk 
in the community, by minimizing the health risks associated with nutritional exposures. 
In the private sector also, medical personnel need to make decisions based on evidence 
not only from one event or study done, but on the compilation of all the relevant evidence 
available, in order to offer their patients the best advice.  
To conclude, there is a definitive need for evidence-based nutrition recommendations.  
The public often perceives nutritional guidelines as confusing and feel that experts 
change their minds, or that recommendations change with time.  The confusion is 
probably not always validated, but it remains a concern as it can discredit the nutritional 
and research profession.
33 
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1.8 DESCRIPTION OF SYSTEMATIC REVIEWS 
There are different types of reviews, namely narrative or systematic.  The difference 
between the two is the gathering of the individual studies to be included.  In a systematic 
review, all the relevant studies available on the topic are included and interpreted to 
prevent publication bias, while in the narrative study, some studies might be left out, thus 
influencing the results.
1,4
 
The Cochrane Handbook of Systematic Reviews defines a systematic review (SR) as “a 
review that attempts to collate all empirical evidence that fits pre-specified eligibility 
criteria in order to answer a specific research question.  It uses explicit, systematic 
methods that are selected with a view to minimizing bias, thus providing more reliable 
findings from which conclusions can be drawn and decisions made.”1 
Many SRs contain meta-analyses.  A meta-analysis is defined as “the use of statistical 
methods to summarize the results of independent studies”.  By combining the findings 
from all relevant studies, more precise estimates of the effect of treatment can be 
provided.
1
 
Both systematic reviews and meta-analyses are used in Evidence-based practice, since 
both these methods allow for standardized methods of compiling new evidence in a 
structured way.  According to Gray’s hierarchy of quality of evidence35, SRs of 
randomized controlled trials are the best quality evidence, and meta-analyses rank as very 
strong evidence according to Porter et al.
34 
 
A systematic review is a complete collection and objective analysis of all available 
relevant studies in a specific area.  A meta-analysis is a statistical integration of separate 
studies which can be considered as combinable, to create a more statistically powerful 
tool.
36,37
 Meta-analyses can form part of a systematic review, when the data included 
allows for this to be done.  
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1.8.1 Characteristics of a Systematic Review 
33,35
 
1.8.1.1 Research question 
A vital starting point for any research is to state a clearly defined research question or 
objective, or set of objectives.  The SR should have a very clear and well-formulated 
question, namely: 
- The persons / patients of interest  
- The intervention  
- The control group  
- The outcomes  
Pre-defined eligibility criteria consisting of both inclusion and exclusion criteria should 
also be clearly stated after the research question.
1,35
 
 
1.8.1.2 Reproducible methodology 
Any SR should have a very clear and explicit description of the exact steps that were 
followed during every stage of the review.  It should be described in such a manner that 
the study can be repeated exactly. 
 
1.8.1.3 Search for answers 
A systematic search should attempt to identify all studies that would meet the eligibility 
criteria.
1
 
The literature suggests Location of studies using the 4S approach, referring to Systems, 
Synopses, Syntheses and Studies as the sources of literature.
 
Systems include 
comprehensive, evidence-based resources, synopses are compilations of structured 
abstracts of high-quality studies, syntheses are systematic reviews, and studies are 
original research articles.
35
  
 
1.8.1.4 Appraisal of evidence   
Appraisal of evidence (by selecting studies) is particularly important when the last ‘S’, 
namely Studies, are used as evidence.  During this step the validity, importance and 
applicability of the individual studies to the SR should be questioned.  Applying the 
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inclusion and exclusion criteria to select studies is part of the appraisal of evidence, as 
this is a way of deciding which studies are relevant and which are not. 
 
1.8.1.5 Assessment of study quality 
An assessment of the validity of the findings of the included studies should be done, for 
example, through the assessment of risk of bias. The Cochrane Handbook for Systematic 
Reviews recommends using the “Risk of bias tool” which includes six domains of 
possible bias.
 
These domains include adequate sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective reporting and other potential 
sources of bias.
1 
 
1.8.1.6 Data extraction 
Extraction of the relevant data from each individual study is important, to select only the 
specific information out of each study which will be applicable to the SR.  The reviewer 
needs to plan exactly how the relevant data will be presented and analyzed.  
 
1.8.1.7 Application of the results 
Once all the studies have been selected and applicable data have been extracted, this data 
must be analyzed to draw new or combined conclusions.  When suitable, a meta-analysis 
can be performed on all or some of the included studies. 
 
Systematic presentation of the findings is crucial, and a meta-analysis must always 
include a graphic visual display of the results.  An SR will usually include tables that 
describe the ‘Characteristics of included studies’ and ‘Summary of findings’, when 
appropriate. 
 
Because systematic reviews and meta-analyses are compiled of collaborations of studies 
of different sizes, this assignment of ‘weight’ or ‘importance’ is crucial.  Statistically, 
smaller studies can be influenced more by chance than larger studies can, and should 
therefore make a smaller contribution to the results of the review.  Two models are used 
in this regard, to determine how much weight should be assigned to each study.
36
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The “Fixed effects model” assumes that random variation is responsible for all variability 
between studies, and that all studies would yield the same results, if they were the same 
size.  The “Random effects model” assumes that each study has different underlying 
variability, and assigns different weights to different studies. According to Egger
36 
when 
heterogeneity is detected, it is best to use a random effects model to determine the 
importance of individual studies. 
 
1.8.1.8 Assessment of the outcomes 
In a systematic review or meta-analysis, assessing the outcomes would refer to 
interpreting the newfound results from the combined studies.  This can then describe the 
general trend that was observed, and new hypotheses can be formulated.
37
 
Discussion of the following topics should be done: limitations of the review, including all 
sources of possible bias; the strength of evidence; applicability of the results to the 
relevant population; and the implications of the newfound results on the relevant medical 
milieu.  
 
1.8.2 Limitations of Systematic Reviews 
 
Systematic reviews and meta-analyses aim to answer a question by pooling together 
answers from different sources.  A big challenge for such an attempt is to agree on the 
comparability of the collected data, in terms of the design, conduct and presentation of 
data.
4
 Issues such as size of studies, quality of the studies, randomization procedures and 
time spans should be comparable.
37
 
Nutritional studies are more difficult, particularly when compared to pharmacological 
experimental studies, in respect of controlling exposures, and to make sure that all 
subjects receive exactly the same exposures.  The outcome data used in different studies 
are not always the same either.
33
 
 
Another challenge in conducting a SR is to obtain all the relevant literature and to ensure 
a thorough and complete collection of all studies done on the subject.  If all available 
literature is not included, the summary estimate may be misleading.
4
 When the original 
studies included in the SR are of poor quality, the findings of the SR or meta-analysis 
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conducted will also be of poor quality or weak strength of evidence.
37 
It is the 
responsibility of the author of the SR to include honest assessments of the study quality, 
the possible methodological flaws, the risk of bias and the comparability of the studies.  
This will allow for readers to interpret the results with caution, when necessary, and to 
bear these shortcomings in mind when drawing conclusions.  
Because of all these challenges, SRs can aid, but never replace sound clinical reasoning.  
 
1.8.3 Goal of Systematic Reviews 
In medical practice there is a need for clear and explicit recommendations based on solid 
facts.  Without conducting a SR on a subject, decisions on what should be recommended 
will be made on personal opinion or hearsay, or on individual trials or single pieces of 
evidence, which can lead to bias and inaccurate conclusions. The Cochrane Collaboration 
is an international initiative that aims to facilitate an evidence-based approach by 
bringing together scientific evidence on RCTs.
4
 Its primary aim is to “help people make 
well-informed decisions about healthcare and health policy by preparing and maintaining 
high quality systematic reviews.” It is a non-profit organization and draws significantly 
on volunteer effort. The Cochrane Library is published on behalf of The Cochrane 
Collaboration and includes SRs done on medical topics.
38 
 Not all SRs done are 
necessarily included in the Cochrane Collaboration – good SRs can be conducted that are 
not Cochrane Reviews. 
1.9 SUMMARY AND MOTIVATION FOR THE STUDY   
Nausea and vomiting during pregnancy can limit the mother’s nutritional intake, and 
have a negative impact on the developing fetus.  Some anti-emetic drugs can be used, but 
may cause side effects and pose a possible threat to the developing fetus.
9
 Adjustments to 
the mother’s dietary intake can play a role in the prevention or treatment of nausea and 
vomiting, but it is limited.
9,10
  The use of natural remedies, such as ginger, for treating 
nausea and vomiting can be very beneficial for these women.  
Currently no clear guidelines are available for ginger’s use in the treatment of pregnancy-
associated nausea and vomiting, despite systematic reviews done on the subject to some 
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extent.
26,39,40
   These reviews were published between 2000 and 2005, which included 
studies up to June 2004. The findings of these reviews were that ginger may be effective 
in treating pregnancy-associated nausea and vomiting, but that the safety aspect needed 
more research.  In the meantime, additional studies have been conducted, prompting the 
researchers to ask these and other questions once more.  This review involves the studies 
already included in the above-mentioned reviews, where they fulfilled the inclusion 
criteria for this review, and also includes the more recent studies, to establish whether any 
new discoveries have been made regarding the effectiveness and safety of using ginger as 
a treatment for pregnancy-associated nausea and vomiting. The findings could ultimately 
lead to clearer guidelines regarding the use of ginger for pregnancy-associated nausea and 
vomiting. 
A systematic review of the available literature is needed to provide the best current 
evidence regarding possible benefits or risks for the clinical use of ginger to treat NVP.  
The results will be discussed and conclusions drawn to make recommendations for the 
practical use of ginger to treat nausea and vomiting during pregnancy. 
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CHAPTER 2:   METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 24 
2.1 OBJECTIVES 
2.1.1 Purpose of the Study 
To investigate the current evidence regarding the efficacy and safety of ginger for the 
treatment of nausea and vomiting during pregnancy. 
2.1.2 Specific Objectives 
Primary objective 
The primary objective of this systematic review was to assess the effectiveness of ginger 
in the treatment of pregnancy-associated nausea and vomiting. 
Secondary objective 
The secondary objective of this systematic review was to assess the safety of orally 
administered ginger in the treatment of pregnancy-associated nausea and vomiting, by 
identifying adverse events or side effects (if any), and to classify them as major (serious 
complications detrimental to the mother or fetus), or minor (discomfort, but manageable 
side effects). 
Implementation objectives 
To make recommendations if possible, on the use of ginger to treat patients with 
pregnancy-associated nausea and vomiting, and the dosage, duration and form in which 
the ginger should be ingested. 
The results will be published in the peer-reviewed literature.  These recommendations 
can be made available to doctors, dieticians, homeopaths, gynaecologists and midwives 
to inform their clinical practice. 
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2.2 CRITERIA FOR CONSIDERING STUDIES FOR INCLUSION   
2.2.1 Types of Studies 
Randomized controlled trials (RCTs), involving human participants and investigating 
ginger for the treatment of pregnancy-associated nausea and vomiting were included in 
this systematic review. Trials were included despite lack of blinding or placebo 
treatment.  
2.2.2 Types of Participants                                                                                     
Women suffering from pregnancy-associated nausea and vomiting were included, with 
no restriction on their age or stage of pregnancy.  
2.2.3 Types of Interventions 
Any form of ginger intervention (fresh root, dried root, powder, tablets, capsules, liquid 
extract, and tea) compared with an inert (placebo) or active ingredient, all via the oral 
route of administration, was included. 
2.2.4 Types of Outcome Measures 
Outcome measures include:  
 Symptom scores on the subjective feeling of nausea, measured by standardized 
scales or methods (e.g. Visual Analogue Scale (VAS) ) 
 The incidence of vomiting episodes, measured by daily recording 
 The general response to the treatment, measured by standardized scales or 
methods (e.g the 5-point Likert-type scale) 
 The occurrence of adverse events and side effects 
 Effect modifiers and confounders 
 compliance with treatment 
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 any co-treatment that can influence ginger’s effects (e.g. dietary, medicinal, 
herbal or physical intervention) was considered a confounder. 
2.3 SEARCH METHODS FOR IDENTIFICATION OF STUDIES   
Literature searches were conducted in computerized databases, by a qualified medical 
librarian (Ms. Wilhelmine Pool). Databases searched: Medline (accessed via Pubmed); 
EBSCO host (Elton B Stephen’s Company), including Academic Search Premier 
(provides full-text coverage on biology, chemistry, engineering, physics, psychology, 
religion), CINAHL (nursing & allied health research database), and CAB abstracts 
(produced by CABI Publishing, this database covers the significant research and 
development literature in agriculture, forestry, human nutrition, veterinary medicine and 
the environment); CENTRAL (Cochrane Central Register of Controlled Trials); Science 
Direct; ISI Web of Science, ISAP (Index to South African Periodicals – National Library 
of South Africa); Proquest; Scopus (abstract and citation database of peer-reviewed 
literature); Africa Wide; SABINET (South African Bibliographic Information Network); 
Current Controlled Trials (www.controlled-trials.com) and Clinical trials.gov 
(www.clinicaltrials.gov).  Studies were selected regardless of publication status. The 
author also searched for additional studies by searching the reference lists of the included 
trials and other articles identified by the electronic search.  The dates for inclusion were 
from 1966 up to the most recent publications, the latest date of electronic searches done 
being 28 February 2011.  
Search words used on first attempt: Pregnan* AND (nausea OR vomiting OR morning 
sickness OR hyperemesis gravidarum) AND (ginger OR zingiber officinale roscoe). The 
only limitation was the stipulation that these searches should apply to humans. 
In the Pubmed database this first attempt of search words lead to more than 40 000 
references, mostly due to cases of vomiting relating to a variety of causes such as 
chemotherapy and many other illnesses, and many studies done on pregnant women, not 
necessarily with NVP, clearly irrelevant to our search.  The search string was then further 
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refined to specifically identify trials related to this systematic review topic and a language 
filter was used to limit the studies to English publications. 
The search word string was adapted to ‘pregnancy AND (nausea OR vomiting OR 
morning sickness OR hyperemesis gravidarum) AND (ginger OR zingiber officinale 
roscoe)’ to be more sensitive on the second attempt. This then referred only to nausea and 
vomiting due to pregnancy. The only limitation was the application to humans alone. 
Finally, an even stricter search strategy was employed to focus on the required study 
design and thus included only RCTs. The final complete search word string was: 
Pregnan* AND (nausea OR vomit* OR morning sickness OR hyperemesis gravidarum) 
AND (ginger OR zingiber officinale roscoe) AND (clinical trial* OR randomized control 
trial* OR random allocation OR placebo* OR random research OR comparative OR 
“evaluation stud*” OR follow up OR prospective* OR control* OR volunteer* OR single 
mask* OR double mask* OR treble mask* OR tripl* mask* OR single-blind OR double-
blind OR treble blind OR tripl* blind*).  This search word string was implemented for 
Pubmed and the rest of the databases as well. 
2.4 DATA COLLECTION AND ANALYSIS   
2.4.1 Selection of Studies   
The principal investigator (EV) and a second reviewer (LV, a qualified dietician) 
independently did the screening of titles and abstracts of studies identified by the search 
and applied the pre-specified criteria in order to identify eligible studies. This process 
was recorded on a specifically designed study eligibility form (Appendix 6.1). Where at 
least one author considered a study to be relevant, the full text was obtained with the help 
of the qualified medical librarian, and independently assessed for eligibility.  
Disagreements were resolved by discussion until consensus was reached between the 
reviewers. Where there was missing information or clarity was needed, the authors of the 
primary studies were contacted via e-mail.  Studies that at first were thought to be 
relevant, but later excluded, are discussed in the section ‘Excluded studies’ together with 
the reasons for exclusion.   
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2.4.2 Data Extraction and Management   
The principal investigator and reviewer independently undertook the data extraction from 
the full text of the selected studies, using a specifically designed standardized, pre-piloted 
data extraction form (Appendix 6.2). 
For each study, the following items were recorded: administrative details, study 
methodology, participant characteristics, setting of study, interventions, outcomes, study 
findings and limitations, ethical approval and funding sources. 
Disagreements or uncertainties concerning the data extraction and methodological quality 
were discussed and resolved and consensus was reached in all cases.  There were 
uncertainties in three articles, and the researchers were contacted via email to answer 
these queries. One author could not be reached, and two responded with answers to the 
queries.  During the process of data analysis, the author and statistician detected some 
missing information from two studies, and the relevant authors were contacted with the 
queries. There was no response in this regard. (See Appendix 6.3, Letters to research 
authors). 
After discussion of all issues, the two sets of corresponding data were then merged into 
one standard table for each study, to summarize all relevant information. (This data is 
presented later: refer to Table 3.3, Characteristics of included studies). 
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2.5 ASSESSMENT OF METHODOLOGICAL QUALITY OF INCLUDED 
STUDIES    
The principal investigator and the independent reviewer independently assessed the 
components of each of the included studies for risk of bias, using a pre-piloted Risk of 
bias tool to record judgments and comments (see Appendix 6.4).  The recommended tool 
for assessing the risk of bias, as described in the Cochrane Handbook for Systematic 
Review of Interventions
1 
(Table 2.1) was used to evaluate the potential sources of bias in 
the methodology of the included trials. The methodological domains of the trials were 
evaluated and classified as adequate, inadequate or unclear, as described below.  The 
specific detailed criteria appear in Appendix 6.5.  The domains of the methodology that 
were assessed are sequence generation, allocation concealment, blinding, incomplete 
outcome data, selective outcome reporting, and other potential threats to validity (Table 
2.1).  Assessment was done by answering a pre-specified question about the adequacy of 
the study in relation to the entry, in such a way that the judgment of ‘yes’ can be 
indicative of low risk of bias, ‘no’ can be indicative of high risk of bias, and ‘unclear’ can 
be indicative of uncertain risk of bias.  Disagreements between the author's and the 
reviewer's judgments were resolved by discussion, and consensus was reached in all 
cases. 
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Table 2.1    The Cochrane Collaboration’s tool for assessing risk of bias 
DOMAIN DESCRIPTION REVIEW AUTHOR’S 
JUDGEMENT 
Sequence 
generation 
Describe the method used to generate 
the allocation sequence in sufficient 
detail to allow an assessment of whether 
it should produce comparable groups. 
Was the allocation 
sequence adequately 
generated? 
Allocation 
concealment 
Describe the method used to conceal the 
allocation sequence in sufficient detail 
to determine whether intervention 
allocations could have been foreseen in 
advance of, or during enrolment  
Was allocation adequately 
concealed? 
Blinding of 
participants, 
personnel and 
outcome assessors 
Describe all measures used to blind 
study personnel and participants from 
knowledge of which intervention 
relating to whether the intended blinding 
was effective.  
Was knowledge of the 
allocated intervention 
adequately prevented 
during the study? 
Incomplete 
outcome data 
Describe the completeness of outcome 
data for each main outcome, including 
attrition and exclusions from the 
analysis.  State whether attrition and 
exclusions were reported, the numbers 
in each intervention group (compared to 
total randomized participants), reasons 
for attrition / exclusions where reported, 
and any re-inclusions in analyses 
performed by the review authors.   
Were incomplete outcome 
data adequately addressed, 
regarding the amount, 
nature and handling of 
incomplete data? 
Selective outcome 
reporting 
State how the possibility of selective 
outcome reporting was examined by the 
review authors, and what was found.  
Are reports or the study 
free of suggestion of 
selective outcome 
reporting? 
Other sources of 
bias 
State any important concerns about bias 
not addressed in the other domains of 
the tool.  
Was the study apparently 
free of other problems, not 
covered elsewhere in the 
table, that could put it at a 
high risk of bias? 
Source: Higgins
1
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2.6 MEASURES OF TREATMENT EFFECT 
2.6.1 Dichotomous Data 
Dichotomous outcomes like adverse events, nausea and vomiting, were expressed as risk 
ratios (RR) with 95% confidence intervals (CI).   
 
2.6.2 Continuous Data 
Continuous outcomes such as symptom scores (for example, as measured by a VAS), 
were expressed as mean differences (MD) with 95% CI’s.  
 
2.6.3 Incidence data 
Incidence outcomes such as the incidence of nausea and vomiting would have been 
expressed as incidence rate ratios (IRR) with 95% confidence intervals, but none of the 
outcomes were reported in the form of incidence rates. 
 
2.6.4 Dealing with Duplicate Publications 
Often, the same research paper was identified by different electronic databases. It was 
then checked to make sure that it was indeed the same paper, and only one was then 
included. The original paper (or the oldest version) was used in the case of duplicate 
publications.   
 
2.6.5 Assessment of Heterogeneity 
Heterogeneity was assessed by both the visual inspection of the forest plots (where non-
overlapping of confidence intervals indicated the likelihood of heterogeneity) and by 
using the Chi
2
-test for heterogeneity. Differences at the level of p<0.05 were considered 
to be statistically significant. Heterogeneity was quantified using the I
2
 test, using the 
following guidelines for interpretation of I
2
 statistic values:
1
 
 0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity 
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2.6.6. Assessment of Reporting Biases 
The investigators undertook to assess funnel plots to explore the possibility of small 
study bias where at least ten included studies would be included per analysis. (As a rule 
of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 
studies included in the meta-analysis, because when there are fewer studies the power of 
the test is too low to distinguish chance from real asymmetry.
1
) Different explanations for 
funnel plot asymmetry would be considered, such as publication bias, the effect of 
different study sizes and poor study design.  
 
2.6.7 Data Synthesis or Meta-analysis 
Data were analyzed using Review Manager 5 (RevMan 2008) software.  A random 
effects model of meta-analysis was used in the presence of moderate heterogeneity of 
treatment effects, and a fixed effect model in the absence of heterogeneity. The Mantel-
Haenszel (M-H) method of meta-analysis was used for dichotomous outcomes and the 
Inverse-Variance (IV) method was used for continuous outcomes. 
 
2.6.8 Subgroup Analysis and Investigation of Heterogeneity 
In the presence of significant statistical heterogeneity, an attempt to investigate 
potentially influential study characteristics had been planned, should sufficient studies 
exist, by conducting subgroup analyses with respect to the following: 
 different dosages administered in the various studies (low dosage of < 1.5g ginger per 
day versus high dosage of ≥ 1.5g ginger per day). 
 different durations of intervention in the various studies (short treatment of < 7days 
versus long treatment of ≥ 7 days) 
 
2.6.9 Sensitivity Analysis  
The investigators had planned to perform sensitivity analyses, should sufficient studies 
exist, in order to explore the influence of the following factors on effect size: 
 study quality (allocation concealment versus none) 
 source of funding (industry versus other) 
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2.7. ETHICS AND LEGAL ASPECTS 
Since this is a systematic review and not a trial involving human participation, no ethical 
approval was needed.  The Health Research Ethics Committee of Stellenbosch University 
was informed of the proposed systematic review and did register the project for record 
purposes (see Ethics letter, Appendix 6.6). 
The protocol was also submitted to the PROSPERO register (International Prospective 
Register of Systematic Reviews) and published on the register. PROSPERO is an 
international database of prospectively registered systematic reviews on health and social 
care. The registration number is CRD42011001237, 
http://www.crd.york.ac.uk/PROSPERO.  
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3.1 DESCRIPTION OF STUDIES   
3.1.1 Results of the Search 
Across all searched databases [CINAHL, Cochrane Library, Medline (via Pubmed), 
Science Direct, Academic Search Premier, CAB abstracts, Web of Science, Proquest, 
Africa Wide, ISAP and Scopus], 240 titles were identified, using the final search word 
string as described in chapter 2.  Table 3.1 indicates the number of titles identified in each 
database.  
Table 3.1 Summary of electronic database search 
Database Amount of titles found 
CINAHL 59 
Cochrane 1 
Medline (accessed via Pubmed) 15 
Science Direct 5 
Academic Search Premier 15 
CAB abstracts 11 
Web of science 89 
Proquest 12 
Africa Wide 9 
ISAP (SA journals on SABINET) 1 
Scopus 23 
TOTAL 240 
 
Seventy six titles were rejected on the initial screen because of repetitions. It then left 164 
titles, from which the abstracts were requested for further review by the principal 
investigator (EV) and an independent reviewer (LV) (Mrs. Lorette Venter: qualified and 
registered dietician). 
Another 20 repetitions were detected, which left 144 abstracts for assessment. Ninety-
four abstracts were excluded for the following reasons:  study type other than RCT 
(n=76); participants other than pregnant women with NVP (n=9); brief items / 
commentary / letters (n=5); animal research (n=3) and intervention other than ginger 
(n=1). 
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Fifty studies were identified by both the investigator and independent reviewer as 
possibly relevant to the SR, and these studies were again assessed independently.  
The investigator and reviewer then reviewed the abstracts of the 50 studies identified, and 
applied the pre-specified criteria in order to identify eligible studies. This process was 
recorded on a specifically designed and pre-piloted Eligibility form (Appendix 6.1). This 
closer inspection of the abstracts revealed another nine titles as being part of a comment / 
brief summary / short article or letter, and therefore not a research article. This left 41 
studies, of which 28 were excluded due to study type other than RCT, and 1 due to 
intervention other than ginger. 
The remaining 12 abstracts were considered relevant and eligible for the SR and the 
author requested the full texts.  The reference lists of these full text articles were 
reviewed to search for more possible relevant titles. The 15 titles that were found using 
this method were repetitions of titles already included in the initial electronic searches.  
One of the 12 studies was at first thought to be relevant, but later excluded due to study 
type. This study is described in section 3.1.2. “Excluded studies,” together with the rest 
of the excluded studies, as well as the reasons for their exclusion (see appendix 6.4: 
“Table of excluded studies”). Thus a total of 11 studies were included in this SR (Figure 
3.1), which are all described under section 3.1.4 “General Description of the Included 
Studies.” 
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Figure 3.1 Summary of study selection 
164 abstracts 
Wrong study 
type: 76 
 
Participants: 9 
Animal 
research: 3 
Intervention: 1 
12 studies 
included for data 
extraction 
Included in review 
(final): 
11 studies 
Wrong study 
type: 1 
Reasons for exclusion: 
Database search: 240 
titles and / abstracts 76 repetitions 
94 irrelevant 
abstracts 
50 abstracts 
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Eligiblity forms 
38 
exclusions 
Wrong study 
type: 28 
 
Brief items / 
letters / 
comments: 9 
 
Intervention: 1 
20  
repetitions 
Brief items / 
letters / 
comments: 5 
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3.1.2 Excluded Studies 
The main reason for exclusion of studies (N=133) was study type other than RCT 
(N=105); followed by no abstract or full text published, only brief summaries, letters or 
comments on research articles (N=14); subjects other than pregnant women with NVP 
(N=9); animal research (N=3) and subjects not receiving ginger as intervention (N=2). 
(see “Table of excluded studies”: Appendix 6.7). One study (Portnoi41) was originally 
thought to be relevant and included for data extraction, but excluded on closer inspection.  
This observational study compared the efficacy of different forms of ginger taken by 
pregnant women with NVP, who called in to the Motherisk Program’s call centre for 
advice on managing their symptoms.  As this is not a RCT, it could not be included in 
this SR. 
3.1.3 Included Studies 
Eleven studies
42-52
 met the aforementioned inclusion criteria and were included in this 
SR.  Their study IDs and reference numbers are listed in Table 3.2.   
Table 3.2 Study ID and reference index of included studies (n=11) 
Study ID (alphabetical order) Reference  
Basirat 2009 42 
Chittumma 2007 43 
Ensiyeh 2009 44 
Fischer-Rassmussen 1991 45 
Keating 2002 46 
Ozgoli 2009 47 
Pongrojpaw 2007 48 
Smith 2004 49 
Sripramote 2003 50 
Vutyavanich 2001 51 
Willetts 2003 52 
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3.1.4 General Description of the Included Studies 
Included studies were published from 1991 to 2009.  Key data of the included studies is 
summarized in Table 3.3, and the main findings, as reported by the relevant authors, are 
briefly described below. 
Basirat:
42
 The study done by Basirat et al was a double-blind parallel RCT in Iran.  It 
included 65 pregnant women, of which 62 completed the trial.  Participants received 
either ginger biscuits (500mg ginger per biscuit) or placebo biscuits, 5 times per day for 4 
days (total of 2500mg ginger per day) for 4 days. No other anti-emetics were allowed 
during the trial.  Outcomes included the severity of nausea, number of vomiting episodes 
and the patients’ general response to the treatment.  The severity of nausea was measured 
on the baseline day before treatment started, and again once per day at bedtime on days 
1-4 of the treatment.  A visual analogue scale was used, consisting of a 10 centimetre 
scale of 0–10, 0 being no nausea, and 10 being the worst nausea.  The number of 
vomiting episodes were measured on the baseline day to record the number of episodes 
during the previous 24 hours, and recorded on days 1-4 as the vomiting occurred.  The 
general response to treatment was measured on day 7, using a 5-point Likert type scale 
where patients had to indicate if they felt much worse, worse, the same, better or much 
better.  The results showed that the ginger biscuits provided significantly greater relief 
from the severity of nausea (p=0.01), and to some extent vomiting (p=0.24). Vomiting 
incidences were reduced in both groups, but no significant differences were detected 
between the groups.  Side effects were experienced only in the ginger group, namely 
dizziness and heartburn. 
Chittumma:
43
 Chittumma et al conducted a double-blind parallel RCT in Thailand.  One 
hundred and twenty-six women were included, and 123 completed the trial.  They 
received either ginger root powder capsules (325mg per capsule, 2 capsules 3 times per 
day, resulting in a total of 1950mg ginger per day), or vitamin B6 capsules (12.5mg per 
capsule, 2 capsules 3 times per day, total 75mg vitamin B6 per day) for 4 days.  Some 
participants continued to use other medicines throughout the trial, including some other 
ginger products. Dietary advice was given to both groups before start of treatment, on 
Stellenbosch University http://scholar.sun.ac.za
 40 
guidelines for reducing nausea and vomiting.  Outcomes included a change in nausea and 
vomiting scores and the occurrence of side effects.  The nausea and vomiting scores 
included 3 physical symptoms of the Rhode’s score: episodes of nausea, duration of 
nausea, and number of vomits. These scores were taken on baseline day, and at noon of 
each day of the 4 days of treatment. Results showed that ginger is more effective in 
relieving NVP than vitamin B6 (p<0.05).   Side effects included heartburn (both groups), 
sedation (both groups), arrhythmia (only in the ginger group) and headaches (only in the 
vitamin B6 group). The authors concluded that the side effects were minor and not 
significantly different between the two groups (p=0.795). 
Ensiyeh:
44
 The study conducted by Ensiyeh et al was a RCT done in Iran. Seventy 
pregnant women were included and 69 finished the trial.  They were randomized to 
receive either ginger root powder capsules (500mg ginger per capsule, twice per day, 
total 1000mg per day), or vitamin B6 capsules (20mg vitamin B6 per capsule, twice per 
day, total of 40mg vitamin B6 per day) for 4 days. Dietary advice was given to both 
groups before start of treatment, on guidelines for reducing nausea and vomiting.  
Outcomes included the severity of nausea, vomiting incidences, the women’s response to 
treatment, and the occurrence of side effects. The severity of nausea was measured on the 
baseline day before treatment started, and again three times per day (morning, noon and 
bedtime) on days 1-4 of the treatment.  A visual analogue scale was used, consisting of a 
10 centimetre scale of 0–10; 0 indicating no nausea, and 10 indicating the worst nausea.  
The number of vomiting episodes were measured on the baseline day to record the 
number of episodes during the previous 24 hours, and recorded on days 1-4 as the 
vomiting occurred.  The general response to treatment was measured on day 7, using a 5-
point Likert type scale where patients had to indicate if they felt much worse, worse, the 
same, better or much better. The occurrence of side effects was measured for up to 12 
weeks after delivery, to include any adverse pregnancy outcomes as well.  The results 
showed that the ginger is more effective than vitamin B6 for relieving the severity of 
nausea (p<0.024), and equally effective for reducing the number of vomiting episodes. 
The general response to treatment was better in the ginger group (p=0.52).  No side 
effects occurred and spontaneous abortions occurred in both groups, but the authors felt 
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that the number of subjects was not large enough to draw conclusions about these adverse 
events.  
Fischer-Rasmussen:
45
 This was a double-blind randomized cross-over trial done in 
Denmark, and included 30 pregnant women who were hospitalized, suffering from HG.  
Twenty-seven women completed the trial. Patients received either ginger root capsules 
(250mg ginger per capsule, 4 times per day, total of 1000mg ginger per day), or placebo 
capsules (250mg lactose powder per capsule, 4 times per day, total 1000mg lactose per 
day). Each treatment was given for 4 days, and the wash-out period between the two 
treatments was two days.  No other anti-emetic medications were allowed, but 
intravenous fluids were given to prevent dehydration.  Outcomes included the preference 
of treatment period (assessed after concluding both treatments), and the relief scores 
(point-system regarding nausea, vomiting, change in body weight, personal opinion about 
the treatment), and the outcome of the pregnancy.  The results showed that ginger was 
more effective than the placebo in eliminating or minimizing HG (p=0.035). No side 
effects were reported, and 1 spontaneous abortion occurred, non-significant.  
Keating:
46
 This double-blind RCT done in the USA by Keating et al included 26 
pregnant women, of which 21 completed the trial.   They received either a tablespoon of 
ginger syrup (250mg ginger, honey and water) or placebo syrup (lemon oil, honey and 
water) 4 times per day in hot or cold water, resulting in 1000mg ginger per day, for 14 
days. Dietary advice was given to both groups before start of treatment, on guidelines for 
reducing nausea and vomiting. Outcomes included the level of nausea, and the number of 
vomiting episodes.  Baseline scores were measured before treatment started.  The level of 
nausea was recorded daily for days 1-14 in a diary, using a numerical scale 1-10.  The 
vomiting episodes were recorded daily as they occurred.  The results showed that ginger 
had a greater effect on the relieving of NVP, but due to the small study sample the results 
were not statistically analyzed.  The authors concluded that ginger syrup may be more 
effective than placebo syrup in the treatment of NVP.  No adverse outcomes were 
reported. 
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Ozgoli:
47 
This RCT done in Iran included 70 pregnant women of whom 67 finished the 
trial.  They were randomized to receive either a ginger root capsule (250mg ginger per 
capsue, 4 times per day , total 1000mg ginger per day), or a placebo capsule (250mg 
lactose powder per capsule, 4 times per day, total 1000mg lactose per day) for 4 days.  
Dietary advice was given to both groups before start of treatment, on guidelines for 
reducing nausea and vomiting. Outcomes included the nausea intensity and vomiting 
incidences.  A baseline day pre-treatment questionnaire was completed using a visual 
analogue scale of 0-10 to indicate nausea intensity, and again twice per day on each 
treatment day.  The vomiting incidences were measured on the baseline day, and 
recorded on days 1-4 of treatment as the vomiting occurred.  The results showed that 
ginger was more effective than the placebo in improving symptoms of NVP (p<0.05), 
without any reported side effects or adverse events. 
Pongrojpaw:
48
 This RCT done in Thailand was done on 170 pregnant women, and 151 
completed the trial.  They received either ginger capsules (500mg ginger per capsule 
twice per day, total 1000mg ginger per day) or dimenhydrinate capsules (50mg per 
capsule, twice per day, total 100mg dimenhydrinate per day) for 7 days.  Outcomes 
included the degree of nausea, number of vomiting incidences, and the occurrence of side 
effects.  The degree of nausea was measured on baseline day and twice per day (morning 
and evening) on days 1-7 of treatment, by using a visual analogue scale of 0-10. The 
vomiting incidences were recorded on baseline day for the previous 24 hours, and again 
on days 1-7 as vomiting occurred.  The occurrence of side effects was measured at the 
follow-up on day 7.  Side effects reported were drowsiness (more in the dimenhydrinate 
group than the ginger group, p<0.01) and heartburn (more in the ginger group than the 
dimenhydrinate group, p=0.403). The results showed that ginger is as effective as 
dimenhydrinate in the treatment of NVP, with fewer side effects.  
Smith:
49
 Smith et al conducted a RCT in Australia which included 291 pregnant women 
of which 235 completed the trial.  They received either ginger capsules (350mg per 
capsule, 3 times per day, total 1050mg ginger per day) or vitamin B6 capsules (25mg per 
capsule, 3 times per day, total 75mg vitamin B6 per day), for 21 days.  Participants were 
allowed to continue with other medications throughout the trial.  The first outcome 
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measured was the women’s experience of nausea, dry retching and vomiting, and this 
was measured on days 0,7,14 and 21 using the Rhodes Index of Nausea and Vomiting 
Form 2 (a 5-point, 5-item Likert type scale). The second outcome measured was the 
change in the women’s health status, measured on days 0 and 21 on the Medical 
Outcomes Survey 36 Short form (an 8 multi-item scale, the higher score indicating a 
better outcome). The third outcome measured was the occurrence of side effects and 
adverse pregnancy outcomes.  Belching occurred more in the ginger group than the 
vitamin B6 group.  Adverse events compared well with national standards and were 
considered non-significant.  The results indicated that ginger is equivalent to vitamin B6 
in improving nausea (MD=0.2), dry retching (MD=0.3) and vomiting (MD=0.5) in 
pregnancy. All p-values were <0.001. 
Sripramote:
50
 This double-blind RCT conducted in Thailand included 138 pregnant 
women, of whom 128 finished the trial.  They were randomized to receive either ginger 
powder capsules (500mg per capsule, 3 times per day before meals, total 1500mg per 
day), or vitamin B6 capsules (10mg per capsule, 3 times per day, total 30mg vitamin B6 
per day), for 3 days.  Dietary advice was given to both groups before start of treatment, 
on guidelines for reducing nausea and vomiting.  Outcomes measured were improvement 
in nausea symptoms, number of vomiting episodes per day, and occurrence of side effects 
or adverse events.  The nausea symptoms were measured on the baseline day, and three 
times per day on days 1-3 of treatment (morning, noon, bedtime), by using a visual 
analogue scale 0-10.  The number of vomiting episodes was measured on day 0 for the 
previous 24 hours, and again daily as they occurred on days 1-3 of the treatment.  The 
occurrence of side effects was recorded during the treatment and reported at the follow-
up on day 7.  Side effects included heartburn (more in the ginger group than the vitamin 
B6 group) and drowsiness (more in the vitamin B6 group than the ginger group). The 
results indicated that both ginger and vitamin B6 were effective for treating NVP 
(p<0.001), and there were no significant differences between the two treatments’ 
efficacy. 
Vutyavanich:
51
 This double-blind RCT conducted in Thailand included 70 women, and 
67 completed the trial.  They received either ginger root capsules (250mg per capsule 4 x 
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per day, total 1000mg ginger per day) or placebo capsules (250mg placebo per capsule, 
4x/day), for 4 days. The placebo was not specified.  Dietary advice was given to both 
groups before start of treatment, on guidelines for reducing nausea and vomiting.  The 
outcomes measured were improvement in nausea symptoms (measured on baseline day, 
and twice per day on days 1-4 of treatment, using a visual analogue scale 0-10); the 
number of vomiting episodes (recorded daily as it occurred); and the severity of nausea 
after 1 week (measured on day 7 with a 5-item Likert scale indicating if the patient felt 
much worse, worse, the same, better or much better); as well as the occurrence of side 
effects or adverse pregnancy outcomes.  Headaches occurred in both groups, and only in 
the ginger group did heartburn, abdominal discomfort and diarrhea for 1 day occur. 
Spontaneous abortions occurred in both groups, but the difference between the 
occurrences in the two groups was not significant (p=0.615). The results showed that 
ginger was more effective than the placebo in relieving the severity of nausea in 
pregnancy (p=0.014).   
Willetts:
52
 Willetts et al conducted a double blind RCT in Australia, including 120 
women of whom 99 finished the trial.  They were randomized to receive either ginger 
extract capsules (125mg ginger extract per capsule, 4 times per day, total 1000mg per 
day), or placebo capsules (consisting of soy bean oil, 4 times per day, the amount not 
specified), for 4 days.  Outcomes measured were nausea experience reduction, vomiting 
and retching (measured using the Rhodes Index of Nausea, Vomiting and Retching tool) 
and birth outcomes.  The results show that ginger was more effective than the placebo for 
improving symptoms of nausea and retching during pregnancy, but no difference in the 
vomiting episodes were observed. No p-values were provided. 
3.1.5 Characteristics of Study Settings 
Ten (90.9%) of the eleven included trials were designed as parallel group studies. Only 
one study
45
 had a cross-over design.   
Four studies
43,48,50,51
 were done in Thailand; three studies
42, 44, 47
 were done in Iran, 
two
49,52  
in Australia, one in Denmark
45
 and one in the USA.
46
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Seven studies
42,43,44,48,50,51,52
 were done at antenatal clinics at hospitals, two
45,49
 at 
University hospitals, one
47
 in several health centres and city hospitals, and one in a 
private practice office.
46   
Thus, only one trial
47
 was a multi-centre trial. 
3.1.6 Funding 
Three studies
46,49,52
 were funded by pharmaceutical companies; two studies
42,50
 were 
funded by the research ethics council from the relevant hospital where the study was 
conducted. Two studies
44,47
 acknowledged individual persons involved in their research 
ethics councils, and the remaining four studies
43,45,48,51 
did not provide any information on 
funding.  
3.1.7 Characteristics of Participants     
A total of 1176 participants were included in the respective studies, ranging from 26 in 
the smallest trial
46
 to 291 participants in the largest trial.
49
 Only 2 trials
48,49
 recruited 
more than 150 participants (Figure 3.2). All the included trials included pregnant women 
who were before or at 20 weeks gestation.  The inclusion criteria for this review do not 
specify a stage of pregnancy, or maternal age.  Ten of the eleven included studies
42-44,46-52
 
(90.9%), included women suffering from NVP, and one study
45
 (9.1%) included women 
suffering from HG.  
 
Figure 3.2: The number of trials by number of included participants 
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3.1.8 Characteristics of the Interventions 
The study intervention (ginger) was clearly described in each included study.  Most of the 
studies (n=8) (72.7%)
43,44,45,47,48,49,50,51
 used ginger powder capsules as intervention, 
ranging from 1000mg to 1950mg ginger per day. One study
42
 (9.1%) used Ginger 
biscuits as intervention, with a total dose of 2500mg ginger per day.  One study
46
 (9.1%) 
used a total of 1000mg ginger syrup per day, dissolved in water; and one study
52
 (9.1%) 
used 1000mg ginger extract per day, in capsule form. 
The dosage that was used in the majority of the included clinical trials
44,45,46,47,48,51,52
 was 
1000 milligram (mg) of ginger powder per day. This was also the lowest dose, and thus 
theoretically the safest dose. The remaining studies used 1050mg per day,
49  
1500mg per 
day,
50
 1950mg per day
43
 and 2500mg per day.
42 
 The majority of the studies used a 
duration of 4 days.
42,43,4,45,47,51,52 
The remaining studies used a duration of 3 days,
50
 
7days,
48
 14 days 
46
 and 21 days.
49
 
The comparator was clearly described in most of the included studies.
43-50,52
   A placebo 
was used as the control in 6 studies. Two studies
45, 47
 used lactose as the placebo, one 
used lemon oil
46
 and one used soy bean oil.
52
 One study
42
 used placebo biscuits but did 
not specify the content of the biscuit, and one study
51
 did not specify the content of the 
placebo capsule. Four studies used Vitamin B6 as active comparator. Two studies
43,49
 
used 70mg per day, one
44
 used 40mg per day and one
50
 used 30mg per day. The 
remaining study 
48
 used 100mg Dimenhydrinate per day as active comparator. See table 
3.3 for details. 
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Table 3.3 Table of characteristics of included studies 
Study ID Risk of 
bias 
NPB/ 
NME 
(treatment) 
Intervention                
(Ginger dose 
per day) 
Compara-
tor *                               
(dose per 
day) 
LT Main outcome measures Main results 
Basirat 
2009 
42
 
High 65 / 62  
(32G, 30C) 
Ginger biscuits         
(500mg 5 times 
daily = 2500mg 
/ day) 
Placebo 
biscuit                    
(5 biscuits per 
day, dose not 
specified) 
4 days Severity of nausea (VAS 0-10); 
number of vomiting episodes; general 
response to treatment (5-item Likert 
scale) 
Ginger in biscuit form was more effective 
than placebo in relieving severity of 
nausea in pregnancy, and to some extent, 
vomiting 
Chit-
tumma 
2007 
43
 
High 126 / 123 
(61G, 62C) 
Ginger powder 
capsules                
(325mg x2, 
three times 
daily, = 
1950mg/day) 
Vitamin B6 
capsules 
(12.5mg x2, 
three times 
daily 
=75mg/day) 
4 days Change in nausea and vomiting scores 
(3 symptoms on Rhodes index); 
occurrence of side effects) 
Ginger was more effective than vitamin 
B6 for relief from NVP 
Ensiyeh 
2009 
44
 
High 70 / 69 
(35G,34C) 
Ginger powder 
capsules                
(500mg 2x/d 
=1000mg /day) 
Vitamin B6 
capsules 
(20mg twice 
per day 
=40mg/day) 
4 days Severity of nausea (VAS 0-10); 
number of vomiting episodes; general 
response to treatment (5-item Likert 
scale); occurrence of side effects or 
adverse pregnancy outcome 
 
Ginger was more effective than vitamin 
B6 for relieving the severity of nausea, 
and was equally effective for decreasing 
the number of vomiting episodes in 
pregnancy 
Fischer-
Rass-
mussen 
1991 
45
 
Mode-
rate 
30 / 27 
(27G,27C) 
(cross-over 
**) 
Ginger powder 
capsules               
(250mg 4 times 
per day 
=1000mg /day) 
Placebo 
capsules 
(lactose) 
(250mg 4 
times per day 
=1000mg / 
day) 
4 days   Preference of treatment period; relief 
scores (4-point scoring system); 
outcome of pregnancy 
Ginger was more effective than placebo 
in relieving symptoms of HG  
Keating 
2002 
46
 
High 26 / 21  
(12G, 9C) 
Ginger syrup in 
water (250mg 4 
times per day 
=1000mg/day) 
Placebo syrup 
(lemon oil) 
4x/day (dose 
not specified) 
14 
days 
Level of nausea (numerical scale 1-
10); number of vomiting episodes 
Ginger syrup may be more effective than 
placebo syrup in the treatment of NVP.  
No side effects or adverse pregnancy 
outcomes occurred 
Ozgoli 
2009 
47
 
Mode-
rate 
70 / 67 
(32G,53C) 
Ginger powder 
capsules                
(250mg 4 times 
per day  = 
Placebo 
capsules 
(lactose) 
(250mg 4 x/d 
4 days Nausea intensity (VAS 0-10); number 
of vomiting incidences 
Ginger was more effective than the 
placebo in improving symptoms of NVP, 
without any side effects or adverse events 
Stellenbosch University http://scholar.sun.ac.za
 48 
1000mg/day) 1000mg/day) 
Pongroj-
paw   
2007 
48
 
High 170 / 151 
(77G,74C) 
Ginger powder 
capsules                
(500mg 2x/d 
=1000mg /day) 
Dimenhydrina
te capsules 
(50mg 2x/d = 
100mg/day) 
 
7 days Degree of nausea (VAS 0-10); number 
of vomiting incidences; occurrence of 
side effects 
Ginger was as effective as 
dimenhydrinate in the treatment of NVP, 
and has fewer side effects 
Smith 
2004 
49
 
High 291 / 235 
(120G,115
C) 
Ginger capsules                
(350mg 3times 
per day = 
1050mg/day) 
Vitamin B6 
capsules 
(25mg 3 x/d 
=75mg/day) 
21 
days 
Nausea, vomiting and dry retching on 
days 0,7,14,21 (Rhodes Index of 
Nausea and Vomiting Form2) (5-point 
Likert scale); change in health status 
on day 0,21 (MOS 36 Short Form 
Health Survey, 8-multi-item scale, 
higher core = better outcome); 
occurrence of side effects and adverse 
pregnancy outcomes 
Ginger was equivalent to vitamin B6 in 
improving nausea, vomiting and dry 
retching in pregnancy 
Sripra-
mote 
2003 
50
 
High 138 / 128 
(64G,64C) 
Ginger powder 
capsules                
(500mg 3x/d 
1500mg/day) 
Vitamin B6 
capsules 
(10mg 3x/d 
=30mg/day) 
3 days Severity of nausea (VAS 0-10); 
number of vomiting incidences; 
occurrence of side effects 
Both ginger and vitamin B6 were 
effective in improving symptoms of 
NVP, no difference between the two 
treatments’ efficacy 
Vutya-
vanich 
2001 
51
 
High 70 / 67 
(32G,35C) 
Ginger powder 
capsules                
(250mg 4x/day 
=1000mg/day) 
Placebo 
capsules (not 
specified) 
(250mg 
4x/day = 
1000mg/day) 
4 days Severity of nausea (VAS 0-10); 
number of vomiting episodes; general 
response to treatment after 1 week(5-
item Likert scale); occurrence of side 
effects and adverse pregnancy 
outcomes 
Ginger was more effective than placebo 
for relieving NVP 
Willetts 
2003 
52
 
Mode-
rate 
120 / 99 
(48G, 51C) 
Ginger extract 
capsules 
(125mg4x/d 
=1000mg/day) 
Placebo 
capsules (soy 
bean oil 4x/d) 
(dose not 
specified) 
4 days Used RINVR to measure frequency, 
duration, distress caused by nausea, 
vomiting and retching; long term 
follow-up for birth outcome 
Ginger is more effective than placebo for 
nausea and retching during pregnancy. 
No difference was seen in vomiting 
symptoms 
* Comparator: includes placebo and active ingredients.  **Cross-over design RCT. All the other studies were parallel design RCT’s.    
RCT: Randomized controlled trial;  NVP: Nausea and vomiting of pregnancy; HG: Hyperemesis gravidarum; NPB:Number of patients at beginning of trial; NPE: Number of patients at end of 
trial; LT: Length of treatment; G: patients in Ginger group; C: patients in comparator group VAS: Visual analogue scale; MOS: Medical outcome study; RINVR: Rhodes Index of Nausea, 
Vomiting and Retching. 5-point Likert type tool with 8 items. 
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3.1.9 Characteristics of outcome measures 
3.1.9.1 Nausea 
Nausea (the feeling of being about to vomit) is a subjective feeling, thus, another person 
cannot be aware of this feeling unless the patient tells him that she feels nauseated, and 
the degree of distress caused by this feeling cannot be observed.  For this reason, several 
tools have been developed to reliably measure nausea.   A tool often used by the included 
studies is called the Rhodes Index of Nausea and Vomiting (RINV).  It is also referred to 
as the Rhodes Index of Nausea, Vomiting and Retching (RINVR).
53
 After the completion 
of pilot studies to test validity and reliability of the original tool, the RINV, the 
developers of the tool realized the need to include symptom measurement of dry heaving 
or retching as well. Retching refers to no actual ejection of vomit, but similar gastric 
contractions occur during these heaves, and are similarly distressing for the patient.
53
 
The RINVR tool was originally developed for the assessment of nausea and vomiting in 
cancer patients receiving chemotherapy.  The pilot studies and tests were however, 
performed on patients with nausea and vomiting, regardless of cancer diagnosis.
53
 
The included studies
42,44,47,48,51
 which used the Visual analogue scale (VAS) described the 
measurements as 0 being no nausea, and 10 being the most severe condition of nausea. 
The scale is divided into increments of 1 centimeter on which the patient plots the 
relevant number according to her feeling of nausea.  Table 3.4 describes the different 
tools that the included studies used as measures for nausea as the outcome.  
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Table 3.4 Outcome measure: Nausea  
Nausea-grading scales used in included 
studies (Subjective) 
Studies Scales 
Visual analogue scale (VAS) Basirat 2009, Ensiyeh 
2009, Ozgoli 2009, 
Pongrojpaw 2007, 
Sripramote 2004, 
Vutyavanich 2001 
0-10 
(centimetres) 
Numerical scale  Keating 2002 1-10 
3 Physical symptoms of Rhodes’ score: 
episodes of nausea, duration of nausea, 
number of vomits) 
Chittumma 2007 Change in nausea 
and vomiting 
scores 
Point-system regarding nausea, vomiting, 
change in body weight, patient’s opinion 
about the treatment. 
Fischer-Rassmussen 
1991 
Point system 
Rhodes Index of Nausea and Vomiting 
Form 2 (RINV) 
Smith 2004  5-point, 5-item 
Likert-type scale. 
Rhodes Index of Nausea, Vomiting and 
Retching (RINVR) 
Willetts 2003 8-item, 5-point 
Likert-type tool. 
3.1.9.2 Vomiting 
In contrast to nausea, vomiting is a readily observable occurrence which can be measured 
or reported without information from the patient.  Still, the distress caused by vomiting 
cannot be observed by another person, and remains a subjective feeling.  The RINVR 
tool, as described above, can also be used to measure vomiting incidence and distress 
caused by this event.
53 Because the outcome ‘Vomiting incidences’ simply requires the 
number of vomiting episodes, it can easily be recorded by the patient or an observer.  
Table 3.5 describes the tools the different included studies used to measure the vomiting 
incidences outcome. 
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Table 3.5 Outcome measure: Vomiting incidences 
Vomiting recording method used in 
included studies (Objective) 
Studies Recording 
method 
Participant records the number of vomiting 
episodes as they occur during the treatment 
period.   
Basirat 2009, Ensinyeh 
2009, Keating 2002, 
Ozgoli 2009, Pongrojpaw 
2007, Sripramote 2003, 
Vutyavanich 2001 
Recorded daily, 
as vomiting 
occurred 
Three physical symptoms of Rhodes’ 
score: episodes of nausea, duration of 
nausea, number of vomits 
Chittumma 2007 Change in nausea 
and vomiting 
scores 
Point-system regarding nausea, vomiting, 
change in body weight, patient’s opinion 
about the treatment. 
Fischer-Rassmussen 
1991 
Point system 
Rhodes Index of Nausea and Vomiting 
Form 2 (RINV) 
Smith 2004  5-item, 5-point 
Likert scale 
Rhodes Index of Nausea, Vomiting and 
Retching (RINVR) 
Willetts 2003 8-item, 5-point 
Likert-type tool 
3.1.9.3 General response to treatment 
It often occurs in RCTs that one of the outcomes includes a subjective measure of 
symptoms or quality of life – as is seen in this SR. Gyuatt et al3 did a comparative study 
of Likert scales and VAS instruments to determine if these were reliable tools to measure 
subjective feelings or symptoms, and quality of life responses from participants.  Their 
conclusions were that these two tools resulted in comparable responses, and could be of 
great benefit for use in clinical trials. Their easy administration and interpretation makes 
it user-friendly for the participants as well as the interpreters.
3
 
The SF-36 Health Survey is a multi-purpose short-form health survey that measures 
functional health and well-being from the patient's point of view.
 
It consists of 36 
questions referring to the following indicators of health: functioning at the behavioural 
level, perceived well-being, social life and central life roles and direct personal 
perception of total health.
54 
  Many versions of this survey exist, for disease- or age-
specific purposes, and these are all available in many different languages and formats, 
including online formats for easy administration.
55
  Table 3.6 describes the tools the 
different included studies used to measure the general response to treatment outcome. 
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Table 3.6 Outcome measure: General response to treatment 
Opinion about treatment Studies Scale 
Patients’ general idea or response to the 
treatment 
Basirat 2009, 
Ensiyeh 2009, 
Vutyavanich 2001 
5-point Likert scale 
(much worse, worse, 
same, better, much 
better) 
Relief scores including women’s 
opinion about the treatment 
Fischer-Rassmussen 
1991 
Point-system 
Change in women’s health status Smith 2004 MOS SF-36 Health 
Survey (8 multi-item 
scale, higher 
score=better outcome)  
MOS SF: Medical outcome survey Short form 
3.1.9.4 Adverse events and side effects 
Adverse events and side effects reported in the studies are listed in Table 3.7.  During 
assessment of side effects, it should be kept in mind that any event occurring during 
pregnancy should be interpreted with care. Pregnancy is a condition that affects many 
physiological functions in a woman’s body which can lead to a wide variety of symptoms 
occurring, and often the spectrum differs from person to person. Thus, many of the 
symptoms that are often seen as the side effects to an intervention could actually be 
related to the condition, rather than to the treatment.
56
 
The judgments made on the seriousness of the reported side effects or adverse events are 
the review author’s own subjective judgments, also taking into account the fact that some 
of these events do occur in any normal pregnancy as well, without interventions. 
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Table 3.7 Outcome measure: Adverse events and side effects  
Adverse events or side effects 
reported 
(Sorted from least to most 
commonly reported, first major 
then minor events) 
Author’s 
judgment if 
effect is minor* 
or major** 
Studies 
Allergic reaction Major Willetts 2004 
Arrhythmia Major Chittuma 2007 
Dehydration Major  Willetts2004 
Spontaneous abortion Major Ensiyeh 2009, Fischer-Rasmussen 
1991, Vutyavanich 2001 
Abdominal discomfort Minor Vutyavanich 2001 
Belching Minor Smith 2004 
Burning sensation after capsule 
ingestion 
Minor Smith 2004 
Diarrhea Minor Vutyavanich 2001 
Dry retching after capsule 
ingestion 
Minor Smith 2004 
Vomiting after capsule 
ingestion 
Minor Smith 2004 
Headaches Minor Chittuma 2007, Vutyavanich 2001 
Drowsiness  Minor Basirat 2009, Chittuma 2007, 
Pongrojpaw 2007, Sripramote 
2003 
Heartburn Minor Basirat 2009, Chittuma 2007, 
Pongrojpaw 2007, Sripramote 
2003, Vutyavanich 2001, Willets 
2004 
*minor (discomfort, but manageable side effects) 
 **major (serious complications, possibly detrimental to the mother or fetus) 
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3.2 RISK OF BIAS IN INCLUDED STUDIES 
Appendix 6.8 includes tables with the details of the specific risk of bias judgments per 
each included study across the six methodological quality domains.  These domains 
included adequate sequence generation, allocation concealment, blinding, incomplete 
outcome data, selective reporting and other potential sources of bias.  
3.2.1 Adequate Sequence Generation   
Random sequence generation was adequate (Yes, (+)) in nine
42-46,49-52
 of the eleven 
studies (81.8 %, Figure 3.2).  It was unclear (Unclear, (?)) in two
47,48
 studies (18.2 %), 
and no studies posed a high risk of bias in this domain.  
3.2.2 Allocation Concealment 
The concealment of allocation was adequate (Yes, (+)) in five
42,43,46,51,52
 of the eleven 
studies (45.5%), unclear (Unclear, (?)) in the remaining six
44,45,47-50
 studies (54.5%) and 
no studies posed a high risk of bias in this domain.  
3.2.3 Blinding 
Blinding of participants and personnel was adequate (Yes, (+)) in five
45,47,50-52
 of the 
eleven studies (45.5%), unclear (Unclear, (?)) in two
44,48
 studies (18.2%), and inadequate 
(No, (-)) in four
42,43,46,49
 studies (36.4%). 
There were four studies
42,43,46,49
 in which participants could identify the treatment that 
they were taking, and the review author considered this as ‘unblinding’, and posing a 
high risk for bias. 
3.2.4 Incomplete Outcome Data 
Five
42,45-47,52
 of the eleven studies (45.5%) had addressed incomplete data adequately 
(Yes, (+)), five
43,44,48-50
 studies (45.5%) were unclear (Unclear, (?)), and one
51
 study 
(9.1%) was inadequate (No, (-)) in this domain.  
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3.2.5 Selective Reporting 
The author did not have access to any of the included studies’ protocols, thus no 
comparison could be made between original outcome goals and actual described 
outcomes, but in ten
42-45,47-52
 of the eleven studies (90.9%) no apparent selective outcome 
reporting was found (Yes, (+)).  In one
46
 study (9.1%), there was selective outcome 
reporting detected (No, (-)), when an outcome was clearly stated in the beginning of the 
study, but not described later in the article.    
3.2.6 Other Potential Sources of Bias 
Only one
42
 of the eleven studies (9.1%) had no risk of other bias (Yes, (+)). Five 
45-47,49,52
 
of the studies (45.5%) had an unclear risk of other bias (Unclear, (?)), and five
43,44,48,50,51
 
studies (45.5%) had a high risk of other bias (No, (-)).  The high risk studies all included 
dietary counseling as part of their treatment in both the experimental and the control 
groups.  The author considered this as a confounding factor, since change in outcome 
scores could be affected by the dietary adjustments made, rather than the intervention 
itself. No reporting was done on the dietary measures in any of these mentioned studies. 
The quality assessments of the trial methodology reported for each of the included 11 
trials are demonstrated in Figure 3.3. The author and reviewer judgments about each 
methodological quality assessment factor across all included studies (Figure 3.4) indicate  
high risk of bias in “blinding” and “other bias” categories. 
 
There were insufficient studies per comparison and outcome to permit the use of funnel 
plots to assess publication bias. 
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Figure 3.3 Methodological quality summary: judgments about each methodological 
quality item for each included study 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Figure 3.4 Methodological quality graph: judgments about each methodological 
quality item presented as percentages for all included studies (n=11) 
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Individual studies were assessed for methodological quality by the author and the 
independent reviewer, using the six domains in the Cochrane Risk of Bias tool, as 
previously described in Chapters 2 and 3. See table 2.1 for the specific criteria on how the 
judgments were made for each included study, and Appendix 6.8 for details on the 
judgments. Table 3.8 provides a summary of the risk of bias conclusions for each study. 
Table 3.8 Risk of bias summary: review authors' judgments within each study  
Study ID  Risk of bias  
Basirat 2009 High risk of bias 
Chittumma 2007 High risk of bias 
Ensiyeh 2009 High risk of bias 
Fischer-Rassmussen 1991 Moderate risk of bias 
Keating 2002 High risk of bias 
Ozgoli 2009 Moderate risk of bias 
Pongrojpaw 2007 High risk of bias 
Smith 2004 High risk of bias 
Sripramote 2003 High risk of bias 
Vutyavanich 2001 High risk of bias 
Willetts 2003 Moderate risk of bias 
 
3.3 METHODOLOGICAL QUALITY OF GROUPS OF STUDIES  
The Grades of Recommendation, Assessment, Development and Evaluation Working 
Group (GRADE Working Group) has developed a system for grading the quality of 
evidence.  For purposes of systematic reviews, the GRADE approach defines the quality 
of evidence for each individual outcome reported in a SR as the extent to which one can 
be confident that an estimate of effect or association is close to the quantity of specific 
interest.  Quality of a body of evidence involves consideration of within-study risk of bias 
(methodological quality), directness of evidence, heterogeneity, precision of effect 
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estimates and risk of publication bias.  The Cochrane Collaboration has adopted these 
principles of the GRADE system.
1
  
 
Taking into account that this SR included only 11 studies, which were split into 3 groups 
according to their comparators, and the largest group consisted of only 6 studies, no 
GRADE assessment was done. Meta-analyses performed on selected outcomes included 
at the most 3 studies per analyses. These small study numbers have lead to the decision 
that GRADE assessment were beyond the scope of the SR at this stage.  
Referencing in the remaining part of the results section is done following the Cochrane 
format (i.e. Author and Year) for included studies, to enable easy identification of 
relevant studies.  
3.4 EFFECTS OF INTERVENTIONS   
The primary outcomes for this review were as follows: 
To assess the effectiveness of ginger in the treatment of pregnancy-associated nausea and 
vomiting, by assessing: 
1) Symptomatic relief of nausea 
2) Number of vomiting episodes 
3) General response to treatment 
The secondary objective of this systematic review was to assess the safety of ginger in 
the treatment of pregnancy-associated nausea and vomiting, by assessing: 
1) adverse events or side effects (if any),  
2) and to classify them as major (serious complications detrimental to the mother or 
fetus), or minor (discomfort, but manageable side effects). 
The included studies were split into three groups, according to the comparison substance 
used.  Placebo was used in six studies, and this was considered as a control substance. 
However, four studies used Vitamin B6 and one study used Dimenhydrinate as 
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comparator, and these two substances were considered active ingredients, and not 
controls.   The analyses were done separately as these were different comparisons and 
they could not be pooled in one meta-analysis.      
 
Subgroup analysis addressing dosage and duration aspects were performed for the 
primary objectives, namely the effectiveness of ginger for reduction in nausea and 
vomiting.  Sensitivity analysis had been planned to explore the influence of study quality 
and source of funding, however, no sensitivity analyses could be performed as a result of 
an insufficient number of studies per comparison group. 
 
3.4.1 Comparison 1: Ginger versus Placebo   
There were six studies assessing the effect of ginger versus placebo (Basirat 2009, 
Fischer-Rasmussen 1990, Keating 2002, Ozgoli 2009, Vutyavanich 2001, Willets 2003) 
of which one study (Fischer-Rasmussen 1990) was a crossover design and the remaining 
five studies were parallel group randomized controlled trials. 
3.4.1.1 Improvement in nausea symptoms 
All six studies assessing the effect of ginger versus placebo reported this outcome but 
their results could not all be pooled in a meta-analysis. Two studies (Basirat 2009, 
Vutyavanich 2001) reported the reduction in the visual analogue scale of post-therapy 
minus baseline nausea as mean standard deviation (MSD) and their results were pooled in 
a meta-analysis. Ginger significantly decreased nausea symptoms when compared to the 
placebo (MD 1.20, 95% CI: 0.56 to 1.84, p=0.0002 Figure 3.5) and there was no 
significant heterogeneity detected between the two studies (Chi
2
=0.00, p=1.00, I
2
=0%, 
Figure 3.5) 
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Study or Subgroup
Basirat 2009
Vutyavanich 2001
Total (95% CI)
Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 3.67 (P = 0.0002)
Mean
2.6
2.1
SD
1.77
1.9
Total
32
32
64
Mean
1.4
0.9
SD
1.62
2.2
Total
30
35
65
Weight
57.5%
42.5%
100.0%
IV, Fixed, 95% CI
1.20 [0.36, 2.04]
1.20 [0.22, 2.18]
1.20 [0.56, 1.84]
Ginger Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours placebo Favours ginger
Figure 3.5: Forest plot of the improvement in nausea symptoms measured by 
change in VAS scores (ginger versus placebo) 
3.4.1.1.1 Improvement in nausea symptoms: subgroup analyses regarding dose 
There were no significant subgroup differences between the higher dose (≥1500 mg 
daily) and the lower dose (<1500 mg daily) with respect to the improvement in nausea 
symptoms (change in VAS scores) as shown in the figure below (Chi
2
=0.00, p=1.00, 
I
2
=0%, Figure 3.6). This implies there was no dose-response effect on this outcome. 
Study or Subgroup
1.1.1 Higher dose (>=1500mg daily)
Basirat 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.79 (P = 0.005)
1.1.2 Lower dose (<1500mg daily)
Vutyavanich 2001
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.39 (P = 0.02)
Total (95% CI)
Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 3.67 (P = 0.0002)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%
Mean
2.6
2.1
SD
1.77
1.9
Total
32
32
32
32
64
Mean
1.4
0.9
SD
1.62
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Figure 3.6: Forest plot of the improvement in nausea symptoms (ginger versus 
placebo): subgroup analysis regarding dose (≥1500 mg versus <1500 mg) 
No subgroup analysis with respect to duration was undertaken, as the two studies had the 
same duration of 4 days. 
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One study (Willets 2003) reported the trend in mean nausea experience scores for both 
the ginger and placebo groups in the form of a figure only, from which no MSD values 
could be extracted. No treatment effect could therefore be calculated.  The author was 
contacted via e-mail to enquire about the missing data, but did not respond (see Appendix 
6.3 “Letters to the authors”). 
Two studies (Keating 2002, Ozgoli 2009) reported this outcome in terms of the number 
of women showing improvement in nausea symptoms (again measured by VAS scores). 
Meta-analysis of the results from these two studies shows that ginger failed to 
significantly decrease nausea symptoms when compared to the placebo (RR 2.00, 95% 
CI: 0.77 to 5.19, p=0.15, Figure 3.7) and there may be moderate heterogeneity between 
the two studies (Chi
2
=2.42, p=0.12, I
2
=59%, Figure 3.6). 
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Figure 3.7: Forest plot of the improvement in nausea symptoms, measured by the 
number of participants showing significant improvement 
3.4.1.1.2 Improvement in nausea symptoms: subgroup analyses regarding duration 
There were no significant subgroup differences between the longer duration (≥7 days) 
and the shorter duration (<7 days) with respect to the improvement in nausea symptoms 
(number showing significant improvement) as shown in the figure below (Chi
2
=2.04, 
p=0.15, I
2
=50.9%, Figure 3.8).  
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Figure 3.8: Forest plot of the improvement in nausea symptoms (number showing 
significant improvement): subgroup analysis regarding duration (≥7 days versus <7 
days) 
No subgroup analysis with respect to dose was undertaken, as the two studies had the 
same dosage of 1000 mg/day. 
The remaining study (Fischer-Rasmussen 1991) was a crossover study which reported the 
relief scores on symptoms of a combination of nausea, vomiting, change in body weight, 
and patient’s opinion about the treatment. The observed values for the relief scores were 
reported for each patient during the two periods of the crossover study in the form of a 
table. These values were used in calculating the MD and its standard error (SE) using a 
paired analysis and the 95% CIs were calculated using the generic-inverse variance 
method in RevMan 5. A significantly greater relief of the symptoms was found after 
ginger treatment compared to the placebo (MD 3.52, 95%CI: 0.27 to 6.77). 
3.4.1.3 Reduction in the number of vomiting episodes 
All six studies in this comparison reported a reduction in the number of vomiting 
episodes, but not all their results could be pooled in a meta-analysis. Two studies (Basirat 
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2009, Vutyavanich 2001) reported this outcome in the form of MSD, and their results 
could be pooled in a meta-analysis. According to the meta-analysis, ginger failed to 
significantly reduce the number of vomiting episodes compared to the placebo, although 
it did approach significance (MD 0.72, 95% CI: -0.03 to 1.46, p=0.06, Figure 3.7) and 
statistically significant heterogeneity was detected between the two studies (Chi
2
=3.44, 
p=0.06, I
2
=71%, Figure 3.9). 
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Figure 3.9: Forest plot of the reduction in the number of vomiting episodes (ginger 
versus placebo) 
 
3.4.1.3.1 Reduction in the number of vomiting episodes: subgroup analyses 
regarding dose 
There were no significant subgroup differences between the higher dose (≥1500 mg 
daily) and the lower dose (<1500 mg daily) with respect to the reduction in the number of 
vomiting episodes as shown in the figure below (Chi
2
=3.44, p=0.06, I
2
=71%, Figure 
3.10). No dose-response effect was found on this outcome. 
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Figure 3.10: Forest plot of the reduction in the number of vomiting episodes (ginger 
versus placebo): subgroup analyses regarding dose (>1500mg versus < 1500mg) 
No subgroup analysis with respect to duration was undertaken, as the two studies had the 
same duration of 4 days. 
One study (Fischer-Rasmussen 1990) reported vomiting in conjunction with nausea 
scores (as mentioned above, in section 3.1.1.1 Improvement in nausea symptoms). 
One study (Keating 2002) reported the number of women who stopped vomiting by day 6 
of treatment. Treatment with ginger failed to significantly reduce the number of women 
who stopped vomiting by day 6, when compared to the placebo treatment (RR 3.33, 95% 
CI: 0.91 to 12.26). 
One study (Ozgoli 2009) reported that incidence of vomiting decreased by 50% in the 
ginger group and 9% in the placebo group, but this information is insufficient for 
calculation of a treatment effect. 
One study (Willets 2003) only reported that there was no significant difference between 
ginger extract and placebo groups for any of the vomiting symptoms but failed to give 
any values for the calculation of a treatment effect, as mentioned earlier. 
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3.4.1.3 Patients’ subjective responses to treatment  
Only one study (Basirat 2009) measured this outcome using a Likert scale on which the 
women indicated improvement in symptoms. Ginger failed to significantly increase the 
number reporting improvement compared to the placebo (RR 1.25, 95% CI: 0.96 to 1.63). 
3.4.1.4 The occurrence of adverse events  
Four studies (Basirat 2009, Keating 2002, Ozgoli 2009, Vutyavanich 2001) reported that 
none of the participants experienced any adverse events from ginger during the treatment 
period. 
One study (Fischer-Rasmussen 1990) reported that one patient had a spontaneous 
abortion and one patient asked for a legal abortion.  Because this trial had a crossover 
design and all patients received both treatments, no treatment effect could be calculated 
for the occurrence of spontaneous abortion after the treatment period. 
Two studies (Vutyavanich 2001, Willets 2003) reported results on spontaneous abortions 
(major adverse event) and their results were pooled in a meta-analysis. No significant 
difference in the occurrence of spontaneous abortions was found between the ginger and 
placebo treated groups (RR 3.14, 95% CI: 0.65 to 15.11, p=0.15, Figure 3.8) and there 
was no statistically significant heterogeneity detected between the two studies 
(Chi
2
=0.00, p=0.96, I
2
=0%, Figure 3.11). The confidence interval is wide (with upper 
limit 15.11) as the numbers of events in both treatment arms are too small.  
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Figure 3.11: Forest plot of the occurrence of spontaneous abortions (ginger versus 
placebo)  
One study (Willets 2003) reported results on treatment intolerance (minor side effect) and 
there was no statistically significant difference found between the ginger and placebo 
treated groups (RR 9.00, 95%CI: 0.50 to 163.58). 
One study (Willets 2003) reported results on worsening of symptoms requiring medical 
assistance (minor side effect). There was no statistically significant difference found 
between the ginger and placebo treated groups (RR 0.50, 95%CI: 0.05 to 5.37). 
3.4.1.5 The occurrence of side effects 
Three studies (Fischer-Rasmussen 1990, Keating 2002, Ozgoli 2009) reported that none 
of the participants experienced any side effects from ginger during the treatment period. 
Three studies (Basirat 2009, Vutyavanich 2001, Willets 2003) reported heartburn (minor 
side effect) and their results were pooled in a meta-analysis. No significant difference in 
the occurrence of heartburn was found between the ginger and placebo treated groups 
(RR 5.03, 95% CI: 0.89 to 28.61, Figure 3.12) and no statistically significant 
heterogeneity was detected between the two studies (Chi
2
=0.35, p=0.84, I
2
=0%, Figure 
3.12). 
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Study or Subgroup
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Figure 3.12: Forest plot of the occurrence of heartburn (ginger versus placebo) 
One study (Basirat 2009) reported results on drowsiness (minor side effect) and there was 
no statistically significant difference found between the ginger and placebo treated 
groups (RR 2.82, 95%CI: 0.12 to 66.62). 
One study (Vutyavanich 2001) reported results on headache (minor side effect) and there 
was no statistically significant difference found between the ginger and placebo treated 
groups (RR 1.31, 95%CI: 0.44 to 3.89). 
One study (Vutyavanich 2001) also reported results on abdominal discomfort and 
diarrhea (minor side effects) and the frequencies were the same for each of these side 
effects (one in the ginger group and none in the placebo group). These two side effects 
were represented in the same calculation of treatment effect which found no statistically 
significant difference between the ginger and placebo treated groups (RR 3.27, 95% CI: 
0.14 to 77.57). 
One study (Willets 2003) reported results on dehydration and allergic reaction to the 
treatment (major side effects), and the frequencies were the same for each of these side 
effects (one in the ginger group and none in the placebo group). These two side effects 
were represented in the same calculation of treatment effect which found no statistically 
significant difference between the ginger and placebo treated groups (RR 3.00, 95% CI: 
0.12 to 72.20). 
One study (Willets 2003) also reported results on worsening of symptoms requiring 
pharmaceutical treatment (minor side effect) and there was no statistically significant 
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difference found between the ginger and placebo treated groups (RR 0.33, 95% CI: 0.01 
to 8.02). 
3.4.1.6 Effect modifiers and confounders 
Four studies (Basirat 2009, Ozgoli 2009, Vutyavanich 2007, Willets 2003) reported on 
compliance with treatment, but their results could not all be pooled in a meta-analysis. 
One study (Basirat 2009) reported that all of the women who finished the study complied 
with their respective treatments. Results from the remaining three studies (Ozgoli 2009, 
Vutyavanich 2007, Willets 2003) were pooled in a meta-analysis, and this indicated that 
the women taking ginger were more likely to comply with treatment compared to those 
taking the placebo (RR 1.11, 95% CI: 1.00 to 1.24, p=0.04, Figure 3.13) and there was no 
statistically significant heterogeneity between the three studies (Chi
2
=1.57, p=0.46, 
I
2
=0%, Figure 3.13). 
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Figure 3.13: Forest plot of participants’ compliance with treatment (ginger versus 
placebo) 
Co-treatment that could influence ginger’s effects was considered as a possible 
confounder.  The three studies (Basirat 2009, Ozgoli 2009, Vutyavanich 2007) that 
assessed this outcome reported that none of the participants took any other medication for 
nausea or vomiting. 
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3.4.2 Comparison 2: Ginger versus Vitamin B6 
Four of the included studies assessed the effect of ginger versus vitamin B6 (Chittumma 
2007, Ensiyeh 2009, Smith 2004, Sripramote 2003).  
3.4.2.1 Improvement in nausea symptoms 
All four studies assessing the effect of ginger versus vitamin B6 reported this outcome, 
but their results could not all be pooled in a meta-analysis. Two studies (Ensiyeh 2009, 
Sripramote 2003) reported the reduction in the VAS scores of post-therapy minus 
baseline nausea as MSD and their results were pooled in a meta-analysis. According to 
this meta-analysis, ginger failed to significantly decrease nausea symptoms when 
compared to vitamin B6 (MD 0.34, 95% CI: -1.52 to 2.20, p=0.72, Figure 3.14) and 
significant heterogeneity was detected between the two studies (Chi
2
=10.64, p=0.001, 
I
2
=91%, Figure 3.14). 
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Figure 3.14: Forest plot of the improvement in nausea symptoms, as measured by 
change in VAS scores (ginger versus vitamin B6) 
3.4.2.1.1 Improvement in nausea symptoms: subgroup analyses regarding dose 
There were significant subgroup differences between the higher dose (≥1500 mg daily) 
and the lower dose (<1500 mg daily) with respect to the improvement in nausea 
symptoms (change in VAS scores) as shown in the figure below (Chi
2
=10.64, p=0.001, 
I
2
=90.6%, Figure 3.15). This implies there was a dose-response effect on this outcome in 
favour of lower dosage. The different dosages between the two studies may be the source 
of heterogeneity detected in this meta-analysis. 
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Figure 3.15: Forest plot of the improvement in nausea symptoms as measured by the 
change in VAS scores (ginger versus Vitamin B6): subgroup analysis regarding dose 
(≥1500mg versus < 1500mg) 
No subgroup analysis with respect to duration was undertaken, as the two studies had the 
similar short durations of 4 days and 3 days. 
One study (Smith 2004) reported the reduction in nausea symptoms from baseline using 
the Rhodes Index of Nausea (ranging from 0 to 12, with larger scores indicating more 
symptoms). The results were reported in the form of mean standard errors (MSE) and 
these values were used in calculating the SDs. The means and SDs were used in 
calculating the mean difference (MD) and its 95% CIs. There was no statistically 
significant improvement of nausea symptoms with ginger treatment compared to vitamin 
B6 treatment (MD -0.3, 95% CI: -0.85 to 0.25).  
The remaining study (Chittumma 2007) reported the reduction in nausea vomiting scales 
(episodes of nausea, duration of nausea, and number of vomits) using a modified Rhodes’ 
score. The results were reported in form of MSD and were used in calculating the MD 
which showed that ginger treatment significantly improved the nausea and vomiting 
symptoms compared to vitamin B6 treatment (MD 0.70, 95% CI: 0.20 to 1.20). 
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3.4.2.2 Reduction in the number of vomiting episodes 
All four studies in this comparison group reported a reduction in the number of vomiting 
episodes, but not all the results could be pooled in a meta-analysis. Results from three 
studies (Ensiyeh 2009, Smith 2004, Sripramote 2003) were reported in the form of MSD 
which were pooled in a meta-analysis. According to this meta-analysis, ginger failed to 
significantly reduce the number of vomiting episodes when compared to vitamin B6 (MD 
-0.07, 95% CI: -0.48 to 0.35, p=0.76, Figure 3.16) and there may have been moderate 
heterogeneity between the three studies (Chi
2
=3.58, p=0.17, I
2
=44%, Figure 3.16). 
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Figure 3.16: Forest plot of the reduction in the number of vomiting episodes (ginger 
versus vitamin B6) 
 
3.4.2.2.1 Reduction in the number of vomiting episodes: subgroup analyses 
regarding dose 
There were no significant subgroup differences between the higher dose (>1500 mg 
daily) and the lower dose (<1500 mg daily) with respect to the reduction in the number of 
vomiting episodes as shown in the figure below (Chi
2
=0.72, p=0.40, I
2
=0%, Figure 3.17). 
This implies there was no dose-response effect on this outcome. 
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Figure 3.17: Forest plot of the reduction in the number of vomiting episodes (ginger 
versus vitamin B6): subgroup analysis regarding dose (>1500mg versus <1500mg) 
3.4.2.2.2 Reduction in the number of vomiting episodes: subgroup analyses 
regarding duration 
There were no significant subgroup differences between the longer duration (≥7 days) 
and the shorter duration (<7 days) with respect to the reduction in the number of vomiting 
episodes as shown in the figure below (Chi
2
=3.51, p=0.06, I
2
=71.5%, Figure 3.18). This 
implies there was no duration-response effect on this outcome. 
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Figure 3.18: Forest plot of the reduction in the number of vomiting episodes (ginger 
versus vitamin B6): subgroup analysis regarding duration (≥7days versus <7days) 
The remaining one study (Chittumma 2007) reported vomiting in conjunction with 
nausea as mentioned above. 
3.4.2.3 Patients’ subjective responses to treatment 
Only two studies (Ensiyeh 2009, Smith 2004) measured this outcome using a Likert scale 
and reported the number of participants who indicated improvement of NVP symptoms 
during treatment. Ginger failed to significantly increase the number reporting 
improvement compared to the placebo (RR 1.08, 95% CI: 0.85 to 1.36, p=0.54, Figure 
3.19) and there may have been moderate heterogeneity between the three studies 
(Chi
2
=1.74, p=0.19, I
2
=42%, Figure 3.19). 
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Study or Subgroup
Ensiyeh 2009
Smith 2004
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 1.74, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 0.61 (P = 0.54)
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M-H, Random, 95% CI
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Favours vitamin B6 Favours ginger
Figure 3.19: Forest plot of the participants’ general response to treatment (ginger 
versus placebo) 
3.4.2.4 The occurrence of adverse events  
Two studies (Chittumma 2007, Sripramote 2003) reported that none of the participants 
experienced any adverse events from either ginger or vitamin B6 during the treatment 
period. 
Two studies (Ensiyeh 2009, Smith 2004) reported results on spontaneous abortions 
(major adverse events) and their results were pooled in a meta-analysis. No significant 
difference in the occurrence of spontaneous abortions was found between the ginger and 
vitamin B6 treated groups (RR 0.49, 95% CI: 0.17 to 1.42, p=0.19, Figure 3.20) and there 
was no statistically significant heterogeneity detected between the two studies 
(Chi
2
=1.67,p=0.20,I
2
=40%,Figure3.20).
Study or Subgroup
Ensiyeh 2009
Smith 2004
Total (95% CI)
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Heterogeneity: Chi² = 1.67, df = 1 (P = 0.20); I² = 40%
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Figure 3.20: Forest plot of the occurrence of spontaneous abortions (ginger versus 
vitamin B6) 
 
 
Stellenbosch University http://scholar.sun.ac.za
 75 
3.4.2.5 The occurrence of side effects 
Only one study (Ensiyeh 2009 ) reported that none of the participants experienced any 
side effects of either ginger or vitamin B6 during the treatment period. 
Two studies (Chittumma 2007, Sripramote 2003) reported the side effect of heartburn 
(minor side-effect) and their results were pooled in a meta-analysis. No significant 
difference in the occurrence of heartburn was found between the ginger and vitamin B6 
treated groups (RR 2.35, 95% CI: 0.93 to 5.93, p=0.07, Figure 3.21) and there was no 
statistically significant heterogeneity detected between the two studies (Chi
2
=1.03, 
p=0.31,I
2
=3%,Figure3.21). 
Study or Subgroup
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Figure 3.21: Forest plot of the occurrence of heartburn (ginger versus vitamin B6) 
The above-mentioned two studies (Chittumma 2007, Sripramote 2003) also reported 
drowsiness (minor side effect) and their results were pooled in a meta-analysis. No 
significant difference in the occurrence of drowsiness was found between the ginger and 
vitamin B6 treated groups (RR 0.75, 95% CI: 0.48 to 1.19, p=0.23, Figure 3.22) and there 
was no statistically significant heterogeneity detected between the two studies 
(Chi
2
=0.18, p=0.67, I
2
=0%, Figure 3.22). 
Study or Subgroup
Chittumma 2007
Sripramote 2003
Total (95% CI)
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Heterogeneity: Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
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Figure 3.22: Forest plot of the occurrence of drowsiness (ginger versus vitamin B6) 
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One study (Chittumma 2007) reported results on arrhythmia (major side effect) and there 
was no statistically significant difference found between the ginger and vitamin B6 
treated groups (RR 0.51, 95% CI: 0.05 to 5.46) 
One study (Smith 2004) reported results on belching (minor side effect). Ginger 
significantly increased the risk of belching compared to vitamin B6 (RR 27.18, 95%CI: 
1.63 to 453.06).  One study (Smith 2004) reported results on dry retching after capsule 
ingestion (minor side effect) and there was no statistically significant difference found 
between the ginger and vitamin B6 treated groups (RR 0.93, 95%CI: 0.76 to 1.15). 
One study (Smith 2004) also reported results on vomiting after ingestion of capsule 
(minor side effect), and there was no statistically significant difference found between the 
ginger and vitamin B6 treated groups (RR 1.51, 95%CI: 0.26 to 8.91).  This study (Smith 
2004) also reported results on burning sensation after ingestion of capsule (minor side 
effect), and there was no statistically significant difference found between the ginger and 
vitamin B6 treated groups (RR 1.01, 95%CI: 0.21 to 4.91). 
3.4.2.6 Effect modifiers and confounders 
Only one study (Chittumma 2007) reported on compliance with treatment, and a 
treatment effect was calculated. There was no statistically significant difference in the 
number of women who complied with treatment between the ginger and vitamin B6 
treatment groups (RR 0.98, 95%CI: 0.91 to 1.06). 
Only one study (Chittumma 2007) reported on co-treatment that could influence ginger’s 
effects and a treatment effect was calculated. There was no statistically significant 
difference in the number of women who took other medications for nausea and vomiting 
between the ginger and vitamin B6 treatment groups (RR 0.25, 95%CI: 0.03 to 2.21). 
3.4.3 Comparison 3: Ginger versus Dimenhydrinate 
Only one included study (Pongrojpaw 2007) assessed the effect of ginger versus 
dimenhydrinate. 
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3.4.3.1 Improvement in nausea symptoms  
This study (Pongrojpaw 2007) reported a reduction in the VAS scores of post-therapy 
minus baseline nausea in the form of a figure only, from which no MSD values could be 
extracted. No treatment effect could therefore be calculated.  The author was contacted 
via e-mail to enquire about the missing data, but did not respond (see Appendix 6.3 
“Letters to Research Authors”). 
3.4.3.2 Reduction in the number of vomiting episodes  
This study (Pongrojpaw 2007) reported a reduction in the number of vomiting episodes in 
form of a figure from which the values for mean (SD) could not be extracted accurately. 
No treatment effect could therefore be calculated, as mentioned above. 
3.4.3.3 Patients’ subjective responses to treatment  
This outcome was not reported. 
3.4.3.4 The occurrence of adverse events and side effects 
 No adverse events were reported. The study reported results on drowsiness (minor side 
effect). Dimenhydrinate significantly increased the risk of drowsiness compared to ginger 
(RR 0.08, 95%CI: 0.03 to 0.18). 
The study also reported results on heartburn (minor side effect) and there was no 
statistically significant difference found between the ginger and dimenhydrinate treated 
groups (RR 1.44, 95%CI: 0.65 to 3.20). 
3.4.3.5 Effect modifiers and confounders 
Compliance with treatment and co-treatments that could influence ginger’s effects was 
not reported. 
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4.1. GENERAL 
The majority of the included RCTs and other study types in general (not included in this 
SR) indicate the possibility that ginger may be effective for the treatment of NVP. 
 However, the small sample sizes and few study numbers analyzed per outcome, as well 
as differences in dosage and duration of treatment lead to high levels of inconsistency and 
heterogeneity in the results of the review. Unfortunately, many of the included studies did 
not present data in a usable form for inclusion in meta-analysis, or similar outcomes were 
reported differently and could not be pooled together.  These factors limit the strength of 
evidence and cause uncertainty when interpreting the results. Therefore, these results can 
not be generalized to the pregnant population with confidence.  
The assessment of nausea remains a subjective modality, despite standardized objective 
measurement tools specifically designed for this purpose. The outcomes of nausea 
improvement and general response to treatment (and also in most cases the occurrence of 
side effects) were based on the patient’s own report thereof.  The findings of this SR 
should be considered in context with general medical and nutritional management of 
pregnant women with NVP.  
4.2 PRIMARY OUTCOMES 
4.2.1 Symptomatic Relief of Nausea 
Ginger versus placebo was assessed in six of the included studies.
42,45,46,47,52
  Individually, 
all six studies concluded that ginger was more effective than the placebo in relieving the 
intensity of nausea, or NVP in general. One meta-analysis performed on two relatively 
large studies
42,51 
(the total combined number of participants were 135) showed significant 
improvement of NVP with ginger when compared to the placebo. A meta-analysis on two 
other studies
46,47
 (total number of participants were 96) showed that that ginger did not 
significantly improve NVP compared to the placebo.  The single crossover design study
45
 
showed significantly greater relief from ginger than from the placebo, and the treatment 
effect of the remaining study
52
 could not be calculated. These few studies could lead to a 
simple ‘majority vote’ that ginger might significantly improve nausea symptoms when 
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compared to the placebo, but the reality is that this evidence is too little and of too poor 
quality to draw conclusions.  When taking into account that other SRs
26,39,40,58
 and 
individual studies also concluded that ginger had beneficial effects on nausea during 
pregnancy, it is probably safe to assume that ginger has potential as a possible anti-emetic 
drug-alternative during pregnancy. The subgroup analyses performed in this SR found no 
duration-response effect to relieve nausea. The results of the subgroup analyses should 
however be interpreted with care, bearing in mind the limited number of studies included 
in these analyses. The theoretical physiological mechanism by which ginger affects the 
digestive system also supports this theory. Ginger can increase gastric contractility, 
speeding up gastric emptying, and therefore increasing the gastro-intestinal transit time of 
meals, which can decrease the feeling of nausea.
23
 This topic is discussed in chapter 1.  
Four studies
43,44,49,50
 assessed ginger versus vitamin B6 for the treatment of NVP. The 
majority of this limited evidence showed that ginger does not seem to improve nausea 
symptoms significantly when compared to vitamin B6, or at best the two treatments could 
be considered as equally effective. The subgroup analysis found no dose-response effect 
to relieve nausea. 
The study comparing ginger to dimenhydrinate concluded that ginger was as effective as 
dimenhydrinate in relieving symptoms of NVP, but no treatment effect could be 
calculated for any of the primary outcomes in this single study, thus no conclusions can 
be drawn from this limited evidence. 
4.2.2 Number of Vomiting Episodes 
Although three studies
45,47,51
of the six studies that assessed ginger versus placebo 
concluded individually that ginger was more effective than placebo in reducing the 
number of vomiting episodes, the remaining evidence and meta-analysis performed lead 
to the conclusion that ginger did not significantly reduce the number of vomiting 
episodes during NVP when compared to the placebo.  The subgroup analysis performed 
indicated that the lower dosage of <1500mg ginger per day could possibly be more 
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effective than the higher dosage of ≥1500mg (again, bearing in mind the limited value of 
the subgroup analyses). 
A meta-analysis of three studies
44,49,50
 showed that ginger did not significantly reduce 
vomiting episodes when compared to vitamin B6. One study
43
 reported the nausea and 
vomiting symptoms together, which could influence the vomiting results, and 
significantly favoured ginger. Based on currently available evidence, the review author 
concluded that ginger does not seem to reduce the number of vomiting episodes 
significantly when compared to vitamin B6. The subgroup analysis performed found no 
duration-response effect. 
4.2.3 General Response to Treatment 
Only 3 of the 11 studies included in this SR reported on this outcome. One study
42
 
reported that ginger did not significantly result in better responses to the treatment, when 
compared to the placebo. A meta-analysis of two studies
44,49
 showed that ginger did not 
significantly increase the number reporting improvement when compared to vitamin B6.  
Due to the small number of studies reporting this outcome, no conclusions can be drawn 
in this regard.  
4.3 SECONDARY OUTCOMES 
4.3.1 Adverse Events or Side effects 
Four studies
42,46,47,51
 reported no adverse events when comparing ginger to placebo.  
Spontaneous abortion was reported in two studies,
45,52
 both administering 1000mg ginger 
per day, but the difference was insignificant between the occurrences during treatment 
with ginger compared to treatment with the  placebo.  
Also, during the crossover trial
45
 it cannot be determined which of the treatment groups 
would be the cause of abortion, since each participant received each intervention. 
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To conclude, ginger does not appear to pose a significant risk for spontaneous abortion 
during pregnancy when compared to the placebo, but due to the very large confidence 
intervals of most of the analyses, no firm conclusions can be drawn. 
Heartburn, dizziness, headache, abdominal discomfort and diarrhea, allergic reaction, 
dehydration, and worsening of symptoms were reported as side effects in studies 
comparing ginger and placebo. No significant differences were found between the two 
treatment groups in any of these cases. Also, as discussed earlier, it should be kept in 
mind that many of these symptoms do occur spontaneously in pregnancy, due to 
physiological changes occurring in the body during this time. To conclude, ginger does 
not seem to pose a significant risk for side effects during pregnancy, when compared to 
placebo. Again, large CIs prevent firm conclusions from being drawn. 
Two studies
43,50
 reported that no adverse events occurred in either ginger or vitamin B6 
groups.  Two studies
44,49
 reported spontaneous abortion occurring, and no significant 
difference was found between ginger and vitamin B6 groups. According to this evidence, 
ginger does not pose a greater risk for spontaneous abortion, when compared to vitamin 
B6. 
One study
44
 reported that no side effects occurred in either ginger or vitamin B6 groups.  
Two studies
43,50
 reported heartburn and drowsiness as side effects, but no significant 
difference was found between the two groups. One study
49
 reported belching as side 
effect, and it was shown to be significantly increased by ginger, when compared to 
vitamin B6. Due to its very large CI, no firm conclusion can be drawn on this effect.  
Arrhythmia, dry retching, vomiting after ingestion, and burning sensation after ingestion 
was reported in studies comparing ginger and vitamin B6, but there was no significant 
difference between the two treatment groups for any of these side effects. To conclude, 
there is no increased risk for side effects occurring during ginger treatment, when 
compared to vitamin B6 treatment, but due to large CIs we cannot be absolutely sure of 
the treatment effect. 
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Only one study
48
 compared ginger and dimenhydrinate. This study showed a significantly 
increased risk of drowsiness in the dimenhydrinate group, compared to ginger.  Heartburn 
was also reported, but no significant difference was found between the two groups. This 
single study concluded that ginger posed less of a risk for the side effect of drowsiness, 
when compared to dimenhydrinate.  
4.3.2 Classification of Adverse Events or Side effects as Major or Minor 
The author made subjective judgments to classify the occurring side effects as major 
(serious complications detrimental to the mother or fetus), or minor (discomfort, but 
manageable side effects). These judgments can be viewed in Table 3.7.  The events 
classified as major were arrhythmia, spontaneous abortion, allergic reaction to treatment, 
and dehydration. All the other events were classified as minor. According to the evidence 
as described above, ginger does not pose a risk for any side effects or adverse events 
occurring, thus no risk for any serious complications detrimental to the mother or fetus. 
4.3.3 Effect Modifiers and Confounders 
Women taking ginger were more likely to comply with the treatment, than those taking 
the placebo. No conclusions can be drawn from the studies comparing ginger and vitamin 
B6, as only one study reported this outcome. 
4.4 OVERALL COMPLETENESS AND QUALITY OF EVIDENCE  
Eleven RCTs involving 1176 pregnant women were included in this SR. The search 
strategy was as inclusive as possible. Literature included in the review was researched in 
Europe, Australia, Iran, Thailand and the USA, thus including a wide spectrum of 
different continents and cultures.  
The methodological quality of the included studies was varied.  All studies were either at 
moderate risk for bias, or at high risk for bias, mainly due to lack of blinding.  The 
overall quality of evidence was low, due to heterogenic data (regarding the dose, duration 
and control treatments, as well as the outcome measures) hence the high risk of bias and 
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the imprecision of results, as seen in the wide confidence intervals obtained from the 
statistical analyses. 
The small study numbers per comparison group have lead to the decision that GRADE 
assessment were beyond the scope of the SR at this stage.  
4.5 POTENTIAL BIASES IN THE REVIEW PROCESS   
Publication bias is always a concern when a SR is conducted, as it is known that studies 
with a negative result are often not published, and therefore more easily missed or 
overlooked during the study search and selection process.  This may lead to misleading 
overall results and overestimation of effects in systematic reviews. Ginger is considered 
as a complementary and/or alternative medicine (CAM).
57
 The publication of literature 
on CAM therapies might be suboptimal.
26,57 
The electronic database search was limited to 
studies published in English, leading to studies published in another language being 
overlooked.   
As with all SRs, there was potential for bias at all stages of the reviewing process. 
Minimizing bias was attempted by having two persons independently assess quality and 
extract data, but these were still subjective judgments which could have differed from 
another review team’s judgments.  
4.6 AGREEMENTS AND DISAGREEMENTS WITH OTHER REVIEWS  
Recent SRs done on the same subject include Ernst,
26
 Betz,
32
 Borrelli,
39
 Jewel
40
 and 
Matthews.
58
  The Cochrane review by Jewel et al has been updated and replaced by the 
Cochrane review done by Matthews et al.  
Borrelli et al
39
 conducted a SR in 2005 similar to this one, also evaluating the 
effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and 
vomiting.  They included six studies 
35, 36, 39, 40, 41, 42
 (all of which are also included in this 
SR).  The conclusion was that ginger may be a safe and effective option for the treatment 
of nausea and vomiting in pregnancy.  They based their conclusion on the fact that results 
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of the studies were largely positive, and the absence of adverse effects on pregnancy 
outcome. Meta-analyses were not performed. They recommended that randomized 
clinical trials with larger sample sizes be conducted to confirm the issue of safety of 
ginger during pregnancy.  
Ernst and Pittler
26
 did a SR in 2000 on the efficacy of ginger for nausea and vomiting, 
not necessarily related to pregnancy, but including different causes for the nausea and 
vomiting. They included six trials, namely three trials done on post-operative nausea and 
vomiting, one on seasickness, one on chemotherapy-induced nausea, and one study on 
NVP (the study done by Fischer-Rasmussen
45
, on hyperemesis gravidarum). Meta-
analyses were not performed. They concluded that ginger is a promising anti-emetic 
herbal remedy, but the clinical data are insufficient to draw firm conclusions.  The 
majority of their studies reported that 1 gram of ginger powder per day alleviated clinical 
nausea, resulting from diverse causes. As Borelli et al recommended, these authors also 
felt that there is a need for more observational studies with larger sample sizes, especially 
to confirm ginger safety.  
Betz et al
32
 conducted a SR in 2005 on ginger’s clinical role as an anti-emetic against 
kinetosis, post-operative nausea and vomiting, as well as NVP and HG.  They concluded 
that no clear evidence was found for ginger as treatment for kinetosis and post-operative 
nausea and vomiting, but the evidence for ginger as treatment for NVP was encouraging.  
They warned that ginger should, for the time being, be administered in controlled clinical 
studies only, until safety has been proven.  They observed that a dosage of up to 6g per 
day resulted in few or no side effects.  
Fugh-Berman and Kronenberg
57
 performed a review in 2002 of RCTs done on women 
of reproductive age who use complementary and alternative medicine (CAM). This 
included women with premenstrual syndrome, dysmenorrhea, infertility and a range of 
pregnancy-associated problems including NVP, pain, cramping and edema. The 
interventions included a range of vitamins, minerals, herbs, dietary changes, exercise, 
massage and acupressure. Meta-analyses were not performed. The authors concluded that 
both ginger and vitamin B6 have potential as treatment for nausea during pregnancy and 
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should be investigated further, and also that acupuncture point stimulation (by 
acupressure) has great potential as a non-invasive treatment for NVP, as also described 
by Steele et al.
16
 
Matthews et al
58
 published a SR in 2010, this is an updated version of the SR done by 
Jewel et al
 
which was published in 2003.  This SR reviewed interventions for nausea and 
vomiting in early pregnancy.  The interventions included acupressure, acustimulation, 
acupuncture, ginger, vitamin B6, and several anti-emetic drugs. Due to the heterogeneity 
in participants, interventions, outcomes and comparison groups, the findings could not be 
pooled. Twenty-seven trials were included, of which nine trials
43,44,46-52
 examined the use 
of ginger for NVP. These nine studies are also included in this current SR.  Their 
conclusion was that “the use of ginger products may be helpful to women, but the 
evidence of effectiveness was limited and not consistent.” 
To conclude, the findings of this current SR compare well with the findings of the five 
above-mentioned reviews.  None of these SR’s were able to statistically pool their results 
into meta-analyses, due to the heterogeneity in participants, interventions, outcome 
measures and comparison groups.  This clearly shows the need for more research on the 
topic, with larger studies and standardization of methods and materials.   All these 
reviews did agree that ginger may be effective for the treatment of NVP, but data is 
insufficient to draw firm conclusions regarding the dosage and duration of treatment.  
They all also agree that ginger seems to be a safe option during pregnancy, with only 
minor side effects occurring, but again insufficient data prevent firm conclusions from 
being drawn.  
Chrubasik et al
23
 and Betz et al
32
 have observed that doses of up to 6g per day resulted in 
few or no side effects, but because this SR did not observe these high daily doses, this 
recommendation cannot be seconded. Animal studies done on this subject have explored 
the issue of safety and dosage in more detail than any human studies performed in this 
regard.  Two studies performed on rats have yielded contradictory results. The study done 
by Weidner and Sigwart
59
 concluded that ginger extract in doses of up to 1000mg/kg 
body weight administered to pregnant rats, during the early weeks of pregnancy and 
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organogenesis, caused no maternal nor fetal toxicity or complications, and was thus safe 
during pregnancy.  
In contradiction, the study conducted by Wilkinson,
60
 also performed on rats, concluded 
that ginger tea of up to 50g per litre posed no risk for maternal toxicity, but the 
embryonic loss in the treatment group was double that of the control group.  Strangely, 
the surviving fetuses exposed to ginger were heavier and had more advanced skeletal 
development. Of course, as with most animal studies, it should be kept in mind that 
experimental animals are exposed to proportionately much higher dosages than human 
intake would be.   
4.7 STRENGHTS AND LIMITATIONS OF THIS SYSTEMATIC REVIEW 
One of the strengths of this SR is that it includes more studies than any other previous SR 
has done on this topic.  A major limitation however, is the introduction of publication 
bias by excluding foreign language reports in the search for studies.  This was done to 
minimize the search items. The majority of studies had a small sample size and patients 
were recruited from a single site, introducing bias related to small study effects.  
None of the eleven studies included in this SR described any form of chemical or 
chromatographic tests to verify the exact composition of the active compounds in the 
ginger preparations. Six studies
42,4547,48,49,52
 gave no description of the preparation or 
testing of the ginger formulae, and the remaining 5 studies
43,44,46,50,51
 described the 
preparation of the formulae, but no testing of the final product. One study (Vutyavanich 
2001
51
) mentioned that they considered this absence of chemical or chromatographic 
testing as a limitation of their study.   
4.7.1 Confounding Factors 
4.7.1.1 Dietary advice given in some studies 
Many of the included studies
43,44,46,47,50,51
 mentioned in their methodology that dietary 
advice was given to all the participants, in both the experimental and the control groups.  
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This advice was given before the starting of treatment, and the advice was to eat smaller 
meals more regularly, and to decrease fatty foods and increase starchy foods, in order to 
mange their nausea and vomiting symptoms better.  None of these studies gave any 
further information on the dietary advice – they did not follow up on this to see which of 
the participants followed the advice, or to what extent any of the dietary adjustments 
were made.   
Because the advice was given to both the experimental and the control groups, one could 
argue that it ‘balances out’ and would not confound any results. But one could also argue 
that some participants might have followed the dietary advice religiously, and could have 
made really drastic dietary adjustments which could have improved their NVP symptoms 
significantly, whether on treatment or on placebo. This should then be taken into account 
when considering the results of that study, as the dietary changes could be a confounding 
factor. 
As with all nutritional research studies, it is difficult to control every exposure and it is 
almost impossible to keep all dietary exposures identical for all participants.  
4.7.1.2 The use of other medications during some trials 
Two studies
43,49
 allowed the participants to continue using medication throughout the 
trials. The study done by Chittumma
43
 allowed the participants to continue with other 
medicines, which included medicines for headaches and the common cold, other ginger 
products, and also anti-emetics.  The study by Smith et al
49
 allowed the use of any 
existing medicines, except for ginger and vitamin B6 products.  Many women (75%) 
reported using anti-emetics during the course of this trial. The researchers documented 
the use before and after the trial, and the analyses were adjusted to accommodate this 
factor.  One could argue that as long as the medicine was used continuously throughout 
the trial, then the intervention would still be the only change, thus any changes in NVP 
symptoms occurring could still be attributed to the intervention. But still many 
medications (especially anti-emetics) can have an influence on gastro-intestinal factors, 
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which can contribute to, or lessen the symptoms of NVP, thus acting as a confounding 
factor.  
4.7.1.3 Adjustment of control intervention 
The study done by Pongrojpaw
48
 compared ginger and dimenhydrinate.  In the 
methodology of the study, the authors mention that they decreased the dosage of the 
dimenhydrinate to improve patient compliance, due to the unpleasant side effect of 
drowsiness. The usual dose for dimenhydrinamte is 50mg three times daily, and they 
decreased it to 50mg twice daily, to prevent patient drop-outs.  This could have affected 
results, as the usual dose is the one that will be taken in real life situations.  When 
considering the analysis for this specific outcome, it showed a significantly increased risk 
of drowsiness in the dimenhydrinate group, compared to the ginger group (RR 0.08, 95% 
CI 0.03, 0.18). Thus, ginger poses less of a risk for the side effect of drowsiness, when 
compared to dimenhydrinate – and the risk would be even less when compared to the 
usual larger daily dose.  
4.7.2 Limitations of the Intervention Itself 
Ginger has a very characteristic and recognizable taste, which makes it difficult to mask 
during trials.  Even when the ginger is in powdered form contained inside a capsule, the 
taste may still be recognized when ‘belching’.  Also, due to the somewhat uncomfortable 
side effects of heartburn and belching, the taste or smell of ginger can be aggravated.  In 
a few of the included studies, it was mentioned that some of the participants could 
correctly identify what they were taking, when asked after completion of the trial.  This 
fact could act as a potential confounder, as it can be considered ‘unblinding’.  
A possible solution to this problem is to do pre-trial testing, as was done in the study by 
Vutyavanich et al,
52
 to test if the patients are able to identify the treatment before the start 
of the trial.   
The comparator compound can also have limitations.  Vitamin B6 or pyridoxine has been 
shown to be an effective emetic when used together with doxyclamine.
6,7
 Individual 
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studies have indicated that vitamin B6 on its own can also be effective against NVP.
18,19
 
The RCT performed by Vutyavanich et al
19
 concluded that 30mg of vitamin B6 per day is 
effective against nausea, but not against vomiting during pregnancy.  Sahakian et al
18
 
concluded that 75mg vitamin B6 per day is effective for both nausea and vomiting during 
pregnancy. SRs on this subject are lacking, and two SRs done on different treatments for 
NVP
39,57
 have concluded that there are insufficient studies available on vitamin B6 and 
NVP to draw conclusions about efficacy. This could be a possible subject for future 
research.  
4.6.3 Differences between Protocol and Review 
 Language restriction in search method: Initially no language restriction was 
planned, but later we restricted it to English language, to make the search more 
practical.  
 Sensitivity analyses were planned, if practical and possible.  However, due to the 
small number of studies per comparison, no sensitivity analyses could be 
performed.  
 Classification of the identified adverse effects and side effects (if any) as major or 
minor was planned in the protocol.  The statistical analyses performed concluded 
that ginger did not pose a significant risk for side effects or adverse events when 
compared to any of the comparator groups, and therefore the classification was 
not explored further.  
 It was envisaged that clear conclusions would be drawn and recommendations 
made about the duration and dosage of ginger for the treatment of NVP, and that 
these recommendations would be available to doctors, gynaecologists, midwives 
and dieticians. Recommendations were made according to the results obtained 
from the subgroup analyses, but should however, be interpreted with care, due to 
the limited number of studies included per comparison group. 
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CHAPTER 5:  CONCLUSION 
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5.1 AUTHOR’S CONCLUSIONS   
The present literature indicate that there is little known about the exact cause and 
treatment of NVP.
42-52,56,58
 Currently there is only weak evidence suggesting a significant 
benefit from ginger supplementation for symptom relief in this regard. A review of RCTs 
on Complementary and alternative medicine (CAM) usage in women of reproductive age 
reported that women are more frequent users of CAM than men.
57
   Women who are 
trying to conceive and pregnant women are also regular users of CAM. Therefore there is 
a definitive need for clear recommendations on CAM usage with regard to dosage and 
duration of treatment, especially for pregnant women.  
According to the comparisons made and analyses done in this SR, no firm conclusions 
can be drawn due to the small study numbers per comparison, and also the relatively 
small sample sizes in the studies. Taking these limitations into account, the investigators 
still came to the following conclusions: 
There appears to be a trend towards a lessening of nausea when treating NVP with 
ginger, compared to placebo, but ginger does not appear to improve nausea symptoms 
when compared to vitamin B6. Vomiting episodes are not significantly reduced by 
ginger, when compared to placebo or to vitamin B6. No improvement has been observed 
in terms of the patients’ general response to ginger treatment.  The few subgroup analyses 
performed addressing dosage and duration aspects, indicated a favoring of the lower 
dosage of <1500mg of ginger per day for reduction in nausea, and no duration-response 
effect was observed. The subgroup analyses should however, be interpreted with extreme 
caution due to the limited number of studies per group. 
There appears to be no significant indication of harm, since the evidence concluded that 
ginger during the first trimester of pregnancy does not pose a significant risk for side 
effects or adverse events, including spontaneous abortion during pregnancy, when 
compared to placebo or vitamin B6. In fact, ginger poses less of a risk for the side effect 
of drowsiness, when compared to dimenhydrinate, and was observed to be as effective as 
dimenhydrinate.   
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When looking at these apparently positive results, and the absence of side effects and 
adverse events, ginger may possibly be considered an effective and safe option for 
women suffering from NVP. However, when the statistical analyses done in the SR are 
taken into account, it can be seen that ginger actually did not have a significant impact on 
the vomiting episodes, and it did not pose a risk for side effects or adverse events during 
pregnancy. Thus, even though there is not enough evidence to draw conclusions with 
absolute certainty, the review authors conclude that the use of ginger products may be 
helpful to pregnant women to relieve nausea, but the evidence of the effectiveness and 
safety was limited and not consistent.  It can be considered a harmless (and possibly 
effective) alternative option for women suffering from the unpleasant symptoms of NVP, 
who choose not to use conventional medication during pregnancy.  
5.2 RECOMMENDATIONS FOR PRACTICE 
Due to this SR’s unclear findings, no specific recommendations can be made on the 
dosage or duration of the ginger treatment. As described in chapter 3, the dosage that was 
used in the majority of the included clinical trials
44,45,46,47,48,51,52
 was 1000mg of ginger 
powder per day. This was also the lowest dose, and thus theoretically the safest dose. The 
majority of the studies used this dose for a duration of 4 days.
42,43,4,45,47,51,52 
 
Due to the possible positive effect for some women, and the fact that no significant 
adverse events or side effects were demonstrated in this SR, the authors would 
recommend that medical personnel working with pregnant women (including general 
practitioners, gynaecologists, midwives, nurses and dieticians) be informed about the 
possible benefit that 1000mg of ginger per day can have on NVP during the first trimester 
of pregnancy. The evidence
44-48,51,52
 suggests taking the dose in three to four divided 
doses during the day, irrespective of mealtimes.  Due to the absence of harmful effects on 
the mother or baby, it can, based on the current available evidence be considered a safe 
and ‘natural’ alternative to other anti-emetics.  The mother should be informed that no 
guarantees can be given that this treatment will bring relief of symptoms, but at least 
evidence suggests that there is no risk of damage to the fetus involved. 
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Currently in South Africa ginger capsules are not widely available, but there are quite a 
few ginger products on the market, including ginger tea and ginger lollipops specifically 
aimed at pregnant women (the ‘Mama’ range, from Purity), ginger biscuits, and a variety 
of different teas with ginger blends, as well as ginger ale or ginger beer soft drinks.  
Fresh, ground or crushed ginger is also readily available.  
Medical personnel can advise mothers to use ginger freely in their cooking, to drink 
ginger tea and soft drinks, and have dry ginger biscuits as needed.  The amounts of ginger 
powder found in teas, soft drinks and biscuits are difficult to determine, and each 
manufacturing company will have to be contacted for this information.  When 
considering the fact that 1000mg of ginger powder is equal to 3ml (just more than half a 
teaspoon), ingesting 1000 mg of powdered ginger fresh in food is unlikely because of its 
strong and pungent taste.  However, it is clear that the safety aspect needs to be 
researched further, in order to specify the recommended dosage and duration of use. 
5.3. RECOMMENDATIONS FOR FUTURE RESEARCH 
As other authors have indicated, it is recommended that further research be done on this 
subject, since the current recommendations are vague due to the small study numbers and 
sample sizes.  Larger scale studies (RCTs) need to be conducted, and GRADE 
assessments could be included in future SR’s.  
5.3.1 Standardization of Methods and Materials 
The way that the outcome data were measured and reported was inconsistent in most of 
the studies included in this review, and this should be kept in mind when interpreting the 
results. Future research should aim for consistent outcome measures among different 
studies, and the tools with which outcomes are measured should be standardized to suit 
the needs of interventions for nausea and vomiting in pregnancy.  For instance, a 
standardized visual analogue scale can be developed for nausea intensity, or the Rhode’s 
Index for Nausea and Vomiting can be included in all studies measuring NVP.  With 
these clearer outcome measures, and more and larger studies, hopefully some clear-cut 
conclusions can be made with regard to the dosage and duration of treatment. 
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Differences among studies’ interventions also contribute to problems when analyzing the 
results.  Differences in the dosage, duration, quality and composition of the ginger 
powder or ginger extract may influence results.  If studies are to be reproducible, the 
ginger composition and dosages need to be standardized.
61
 High-performance liquid-
chromatography is a well-established method for determining the concentrations of the 
active components of ginger (namely 6-gingerol, 6-shaogal, 8-gingerol and 10-gingerol) 
in dietary supplements, as used by Schwertner et al,
 61
 and can be considered as an option 
for use in future clinical trials. As mentioned in chapter 4, none of the 11 included studies 
reviewed in this SR, did any form of chemical or chromatographic testing on the ginger 
formulae administered to the participants. 
The authors recommend that future research on this subject take into account the dietary 
factor as well, and standardize the dietary advice provided to the trial participants, as 
dietary and lifestyle adjustments can also affect the symptoms of NVP.  Future SRs done 
on this topic should also attempt to include all studies regardless of the published 
language.   
The physiological cause of NVP, as well as the mechanisms of action for ginger’s effects 
on NVP are still relatively unknown
57
 and could be a topic of interest for future research.  
5.3.2 Funding of Research 
Unfortunately, herbs, vitamins and other natural products (including ginger) have limited 
patent potential and funding will therefore remain a problem for any CAM product. 
Industry-sponsored research will probably be limited and researchers will need funding 
from the relevant government or private institutions.
57
  
5.3.3 Labeling of Ginger Supplementation 
CAM therapies are often presumed to be safe because they are natural products from 
plant origin, but the isolated and concentrated components might have different effects 
than in its original state.
57
 Lack of labeling legislation or product quality control might 
lead to very high dosages being ingested, when a consumer buys a ginger supplement 
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over the counter. A study done in the USA by Schwertner et al
61
  on the variation in 
concentration and labeling of ginger root dietary supplements found that there is a very 
wide variation in the composition of the active compound, namely gingerol, and the 
suggested serving sizes of these ginger root capsules, from different manufacturers.  
Serving size recommendations were not found on all products in this study, and those that 
did make recommendations, varied from 0.25g to 4.77g ginger per day. This study also 
found that many supplements claim to contain certain amounts of active compounds in 
specific quantities (namely 6-gingerol, 6-shaogal, 8-gingerol and 10-gingerol) but then 
the high-performance liquid chromatography revealed that these claims were false or 
incorrect in many cases. The cause of the variation in these compounds is not known, but 
might be due to the source of the ginger, the age of the fresh product used for processing, 
processing methods, exposure to heat or other environmental factors.
61
  
Many dietary supplements are imported from other countries into South Africa and 
therefore this problem should also be of concern in our country. Future research should 
aim to establish a safe upper limit for daily ginger ingestion and distribute this 
information to CAM manufacturing companies. The recommendation for the daily 
ingested dose should be expressed in many ways, including the amount of fresh ginger 
per day, of ginger extract per day, of ginger root powder per day, and amounts of 6-, 8-, 
or 10-gingerol or 6-shoagaol per day. 
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APPENDIX 6.1: Eligibility form  
Eligibility Form:   A Systematic review of the effects and safety of Ginger in the treatment of                 
pregnancy-associated nausea and vomiting. 
Study ID: __________________________________________________________________ 
Reviewer  ID : _____________________________________________________________________________ 
Type of Study 
Is the study a Randomised Controlled Trial? YES 
 
UNCLEAR 
 
NO 
 
Go to next question Exclude: Study type 
Trial Intervention 
Was the intervention treatment with ginger (e.g. fresh, 
powdered, extract, tea, liquid)? 
YES 
 
UNCLEAR 
 
NO 
 
 Go to next question Exclude: Intervention 
Was a proper control used (placebo, other dietary 
intervention; pharmacological strategy, etc.)? 
YES 
 
UNCLEAR 
 
NO 
 
 Go to next question Exclude: No proper 
control 
Trial Participants 
Were the trial participants pregnant women? YES 
 
UNCLEAR 
 
NO 
 
 Go to next question Exclude: Animal research 
Do the trial participants present with nausea and / or 
vomiting? 
YES 
 
UNCLEAR 
 
NO 
 
 Go to next question Exclude 
Other 
Any other reasons for excluding study? 
Specify: 
NO 
 
YES 
 
 Include, subject to clarification of ‘unclear 
points’ 
Exclude: Specified reason 
Final decision: Include Unclear Exclude 
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APPENDIX 6.2:  Data extraction form   
Data Extraction Form   
A. Source 
Review author ID  
Study ID  
Title  
 
Authors (1
st
 six)  
Contact details  
Published Yes  / No  
If yes,  
provide citation: 
 
Journal name Year; Volume (Issue): page 
Source: e.g. Medline / 
Cochrane … 
 
Type of publication Full paper / Abstract / Dissertation / Unpublished report 
 
B. Methods 
 
C.Participants 
Total number  
Country and setting  
 
D. Interventions 
 Intervention Control 
Specific treatment  
 
 
Dose per tablet, and frequency 
of administration 
(e.g. 100mg ginger powder per 
tablet, 2 tablets daily) 
  
Duration of intervention and 
follow-up period (e.g. 1 month 
intervention; follow-up 1 week 
after termination of 
intervention) 
  
Route of administration   
Concomitant treatments (e.g. 
dietary advice / medication) 
If yes: 
Yes No 
Description: 
Reason(s) for usage 
Did this treatment confound the effect of ginger’s treatment?   Yes / No 
Was a proper control put in place for the confounder?                  Yes / No 
Ethics approval  
obtained 
Yes   No   Unclear   Not reported 
If yes, which board? 
Study design Parallel-group RCT       Randomized cross-over trial 
Patients blinded  Yes No Unsure 
Investigators blinded Yes No Unsure 
Study duration  
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E. Outcomes 
 Description of outcome Time point(s) 
collected 
Unit of measurement 
Outcome 1  
 
 
  
Outcome 2  
 
 
  
Outcome 3  
 
 
  
Outcome 4  
 
 
  
 
F. Results  
 Intervention Control 
Nr of participants randomised   
Nr of randomized participants who 
finished the trial 
  
Missing 
participants 
Number   
Reason(s)  
 
 
 
Changes in clinical outcomes: 
 
 
 
 
 
 
All-cause mortality   
Adverse events: 
Serious 
 
  
Adverse events: 
Non-serious 
 
  
G. Miscellaneous 
Correspondence required? If 
yes, what should be asked? 
 
 
H. Limitations (as mentioned by authors) 
________________________________________________________________________ 
 
I. Final Conclusion 
______________________________________________________________________________________
______________________________________________________________________________________ 
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Appendix 6.3 Letters to Research Authors 
 
Letter 1: Regarding Ensiyeh 2009 
from Estelle Viljoen estelleviljoen00@gmail.com  
to enciehjenabi@yahoo.ca 
date Sun, Apr 17, 2011 at 10:47 AM 
subject Ginger RCT 
mailed-by gmail.com 
 
 
  
 
Good day,  
I am currently busy with a Systematic Review on the efficacy of ginger for the treatment 
of pregnancy-induced nausea and vomiting.  Your study "Comparing ginger and vitamin 
B6 for the treatment of nausea and vomiting in pregnancy: a randomized controlled trial", 
2007, is included in my review.  I have two questions, if you would please be so kind as 
to clarify this for me? 
 
1.  Was only verbal informed consent given, or written as well? 
2.  Regarding the follow-up period of 7 days - is it 7 days after the baseline day, or 7 days 
after the termination of the treatment? 
 
Thank you, I look forward to hearing from you. 
 
Regards,  
 
Estelle Viljoen (Dietician, Masters degree student at University of Stellenbosch, South 
Africa) 
 
 
from encieh jenabi enciehjenabi@yahoo.ca  
to Estelle Viljoen <estelleviljoen00@gmail.com> 
date Sun, Apr 17, 2011 at 7:36 PM 
subject Re: Ginger RCT 
signed-by yahoo.ca 
 
 
  
 
Hi 
1-verbal informed 
2-7 days after the termination of  treatment 
yours sincerely 
Ensiyeh Jenabi 
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from Estelle Viljoen estelleviljoen00@gmail.com  
to encieh jenabi <enciehjenabi@yahoo.ca> 
date Sun, Apr 17, 2011 at 9:13 PM 
subject Re: Ginger RCT 
mailed-by gmail.com 
 
 
 
Thank you for your fast response! 
regards,  
Estelle Viljoen 
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Letter 2: Regarding Pongrojpaw 2007 
from Estelle Viljoen estelleviljoen00@gmail.com  
to pongrojpaw@hotmail.com 
date Sun, Apr 17, 2011 at 9:50 PM 
subject Ginger RCT 
mailed-by gmail.com 
 
 
 
Good day,  
I am currently busy with a Systematic Review on the efficacy of ginger for the treatment 
of pregnancy-induced nausea and vomiting.  Your study "A randomized comparison of 
ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy", 2007, 
is included in my review.  I have a question, if you would please be so kind as to clarify 
this for me? 
 
1.  In your article you talk about 'post-treatment' days, but I can only find results for the 7 
days of treatment.  When you refer to , for example, "days 3-7 post treatment", do you 
mean days 3-7 during treatment? 
  
 
Thank you, I look forward to hearing from you. 
 
Regards, 
Estelle Viljoen (Dietitian, and Masters degree student at University of Stellenbosch, 
South Africa 
 _____________________________________________________________________ 
 
from DENSAK PONGROJPAW pongrojpaw@hotmail.com  
to estelleviljoen00@gmail.com 
date Mon, Apr 18, 2011 at 4:38 AM 
subject RE: Ginger RCT 
mailed-by hotmail.com 
 
 
hide details Apr 18   
 
 
Dear Estelle Viljoen . 
Thank you very much for your interest.In the method, the pregnant were given 
medication ( ginger or dimenhydrinate ) for 7 days.On the following 7 days ,the records 
were taken and they came for the next visit at the end of Day 7 .So,I mean 3-7 day during 
Rx.I apologise for making you questioned. 
Best Regards. 
  
Densak Pongrojpaw, M.D. 
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Associate Professor 
Maternal Fetal Medicine Division 
Department of Obstetrics and Gynecology 
Faculty of Medicine ,Thammasat University,  
Pathumthani,THAILAND 12120 
Tel:  (662) 02-926-9343 
Mobile: 081-987-8817 
Fax: (662) 02-926-9485 
E-mail: pongrojpaw@hotmaiil.com 
 
 
from estelleviljoen00@gmail.com  
reply-to estelleviljoen00@gmail.com 
to DENSAK PONGROJPAW <pongrojpaw@hotmail.com> 
date Mon, Apr 18, 2011 at 10:32 AM 
subject Re: Ginger RCT 
mailed-by gmail.com 
 
 
  
 
Thank you very much for your fast response and clear answer.  
Regards,  
Estelle 
Sent via my BlackBerry from Vodacom - let your email find you! 
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Letter 3: Regarding  Smith 2004 (no response from author) 
from Estelle Viljoen estelleviljoen00@gmail.com  
to caroline.smith@unisa.edu.au 
date Mon, Apr 18, 2011 at 4:49 PM 
subject Ginger RCT 
mailed-by gmail.com 
 
 
  
Good day,  
 
I am currently busy with a Systematic Review on the efficacy of ginger for the treatment 
of pregnancy-induced nausea and vomiting.  Your study "A randomized controlled trial 
of ginger to treat nausea and vomiting in pregnancy", 2004, is included in my review.  I 
have two questions, if you would please be so kind as to clarify this for me? 
 
1. The fact that the women were allowed to continue with other medications, including 
anti-emetics, sounds like a confounder. But then, you account for this by saying that it 
was the same between the two groups, and the analyses were adjusted accordingly.  Also 
the fact that it was used straight through the treatment period - I guess it could then be 
justified because the ginger would still then be the only 'changing factor'?? ... Am I 
correct in making these conclusions? 
 
2.  Regarding the "Discontinued ginger" mentioned in Figure 1 - could you please 
elaborate on this? It confuses me that it is mentioned at both the ginger and the Vit B6 
groups? 
 
Thank you, I look forward to hearing from you. 
 
Regards,  
 
Estelle Viljoen (Dietitian, and Masters degree student at University of Stellenbosch, 
South Africa)  
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Letter 4: Regarding Pongrojpaw 2007, missing information. (No response from 
author) 
from Estelle Viljoen estelleviljoen00@gmail.com  
to pongrojpaw@hotmail.com 
date Mon, Sep 26, 2011 at 1:27 PM 
subject more specific question regarding Ginger RCT 
mailed-by gmail.com 
 
 
Good day,  
I am currently busy with a Systematic Review on the efficacy of ginger for the treatment 
of pregnancy-induced nausea and vomiting.  Your study "A Randomized comparison of 
ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy", 2007, 
is included in my review.  I have a question regarding missing data, if you would please 
be so kind as to clarify this for me? 
 
- Some results are reported in terms of figures, but with no actual values for mean (SD).  
This is specifically in the improvement in nausea symptoms, and the reduction in the 
number of vomiting episodes.  
Can you kindly provide the actual values of means (SD) in the tables provided in 1 and 2 
below? 
 
Thank you , I look forward to hearing from you.  
Estelle Viljoen 
1. Reduction in nausea symptoms as measured by VAS scores (day 1-7).       
Ginger Dimenhydrinate 
Mean Standard 
Deviation 
(SD) 
n Mean Standard 
Deviation 
(SD) 
n 
? ? ? ? ? ? 
  
2. Reduction in the number of vomiting episodes (day 1-7).  
Ginger Dimenhydrinate 
Mean Standard 
Deviation 
(SD) 
n Mean Standard 
Deviation 
(SD) 
n 
? ? ? ? ? ? 
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Letter 5: Regarding Willetts 2007, missing information. (No response from author) 
 
from Estelle Viljoen estelleviljoen00@gmail.com  
to j.eden@unsw.edu.au 
date Mon, Sep 26, 2011 at 1:29 PM 
subject more specific questions regarding the ginger RCT 
mailed-by gmail.com 
 
 
  
 
Good day,  
I am currently busy with a Systematic Review on the efficacy of ginger for the treatment 
of pregnancy-induced nausea and vomiting.  Your study "”Effect of a ginger extract on 
pregnancy-induced nausea: a randomized controlled trial”, 2003, is included in my 
review.  I have a question regarding missing data, if you would please be so kind as to 
clarify this for me? 
 
- Some results are reported in terms of figures, but with no actual values for mean (SD).  
This is specifically in the improvement in nausea symptoms, and the reduction in the 
number of vomiting episodes.  
Can you kindly provide the actual values of means (SD) in the tables provided in 1 and 2 
below? 
 
Thank you, I look forward to hearing from you 
Estelle Viljoen 
1. Reduction in nausea symptoms as measured by VAS scores (day 1-7).       
Ginger Dimenhydrinate 
Mean Standard 
Deviation 
(SD) 
n Mean Standard 
Deviation 
(SD) 
n 
? ? ? ? ? ? 
  
2. Reduction in the number of vomiting episodes (day 1-7).  
Ginger Dimenhydrinate 
Mean Standard 
Deviation 
(SD) 
n Mean Standard 
Deviation 
(SD) 
n 
? ? ? ? ? ? 
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APPENDIX 6.4:  Methodological quality / Risk of bias Tool  
STUDY ID___________________       Reviewer ID ______________ 
For each of the included studies, each domain will receive a judgment of "Yes" (low risk of bias), "No" (high risk of bias) or "Unclear" (unclear risk of bias). 
ITEM Judgment Description 
Sequence generation 
 Adequate: investigators described a random component in the sequence generation process such as the use of 
random number table, coin tossing, cards or envelops shuffling etc 
 Inadequate: investigators described a non-random component in the sequence generation process such as the 
use of odd or even date of birth, algorithm based on the day/date of birth, hospital or clinic record number 
 Unclear: insufficient information to permit judgment of the sequence generation process 
  
Allocation concealment 
 Adequate: Participants and the investigators enrolling participants cannot foresee assignment 
 Inadequate: participants and investigators enrolling participants can foresee upcoming assignment 
 Unclear: insufficient information to permit judgment of the allocation concealment or the method not described 
  
Blinding 
 Adequate: blinding of either the participants, key study personnel or outcome assessor, and unlikely that the 
blinding could have been broken. No blinding in the situation where non-blinding is not likely to introduce bias 
 Inadequate: no blinding, incomplete blinding and the outcome is likely to be influence by lack of blinding 
 Unclear: insufficient information to permit judgment of adequacy or otherwise of the blinding 
  
Incomplete outcome data  
 Adequate: no missing outcome data, reasons for missing outcome data unlikely to be related to true outcome, or 
missing outcome data balanced in number across groups 
 Inadequate: reason for missing outcome data likely to be related to true outcome, with either imbalance in 
number across groups or reasons for missing data 
 Unclear: insufficient reporting of attrition or exclusions 
  
Selective Reporting 
 Adequate: a protocol is available which clearly states the primary outcome as the same as in the final trial 
report. If no protocol: the outcomes are clearly stated and then reported adequately. 
 Inadequate: the primary outcome differs between the protocol and final trial report.  No clear outcome 
statement or reporting. 
 Unclear: no trial protocol available or there is insufficient reporting to determine if selective reporting is present 
  
Other forms of bias 
 Adequate: there is no evidence of bias from other sources 
 Inadequate: there is potential bias present from other sources (e.g. early stopping of trial, fraudulent activity) 
 Unclear:insufficient information to permit judgment of adequacy or otherwise of other forms of bias 
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APPENDIX 6.5:  Criteria for methodological components 
 
SEQUENCE GENERATION 
Was the allocation sequence adequately generated?  [Adequate sequence generation?] 
 
Criteria for a judgement of 
‘YES’   
(i.e. low risk of bias) 
 
The investigators describe a random component in the sequence generation 
process such as: 
 Referring to a random number table; 
 Using a computer random number generator; 
 Coin tossing; 
 Shuffling cards or envelopes; 
 Throwing dice; 
 Drawing of lots; 
 Minimization*. 
 
Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
The investigators describe a non-random component in the sequence generation 
process. Usually, the description would involve some systematic, non-random 
approach, for example: 
 Sequence generated by odd or even date of birth; 
 Sequence generated by some rule based on date (or day) of admission; 
 Sequence generated by some rule based on hospital or clinic record 
number. 
Other non-random approaches happen much less frequently than the systematic 
approaches mentioned above and tend to be obvious.  They usually involve 
judgement or some method of non-random categorization of participants, for 
example: 
 Allocation by judgement of the clinician; 
 Allocation by preference of the participant; 
 Allocation based on the results of a laboratory test or a series of tests; 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
 
Insufficient information about the sequence generation process to permit 
judgement of ‘Yes’ or ‘No’. 
 
ALLOCATION CONCEALMENT 
Was allocation adequately concealed? [Adequate allocation concealment?] 
 
Criteria for a judgement of 
‘YES’   
Participants and investigators enrolling participants could not foresee 
assignment because one of the following, or an equivalent method, was used to 
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(i.e. low risk of bias) 
 
conceal allocation: 
 Central allocation (including telephone, web-based and pharmacy-
controlled randomization); 
 Sequentially numbered drug containers of identical appearance; 
 
Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
Participants or investigators enrolling participants could possibly foresee 
assignments and thus introduce selection bias, such as allocation based on:  
 Using an open random allocation schedule (e.g. a list of random 
numbers); 
 Assignment envelopes were used without appropriate safeguards (e.g. 
if envelopes were unsealed or non-opaque or not sequentially 
numbered); 
 Alternation or rotation; 
 Date of birth; 
 Case record number; 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
 
 
Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is usually 
the case if the method of concealment is not described or not described in 
sufficient detail to allow a definite judgement – for example if the use of 
assignment envelopes is described, but it remains unclear whether envelopes 
were sequentially numbered, opaque and sealed 
BLINDING OF PARTICIPANTS, PERSONNEL AND OUTCOME ASSESSORS  
Was knowledge of the allocated interventions adequately prevented during the study? [ Blinding?] 
 
Criteria for a judgement of 
‘YES’   
(i.e. low risk of bias) 
 
Any one of the following: 
 No blinding, but the review authors judge that the outcome and the 
outcome measurement are not likely to be influenced by lack of 
blinding; 
 Blinding of participants and key study personnel ensured, and unlikely 
that the blinding could have been broken; 
 
Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
Any one of the following: 
 No blinding or incomplete blinding, and the outcome or outcome 
measurement is likely to be influenced by lack of blinding; 
 Blinding of key study participants and personnel attempted, but likely 
that the blinding could have been broken; 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
 
Any one of the following: 
 Insufficient information to permit judgement of ‘Yes’ or ‘No’;  
 The study did not address this outcome. 
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INCOMPLETE OUTCOME DATA 
Were incomplete outcome data adequately addressed? 
 
Criteria for a judgement of 
‘YES’   
(i.e. low risk of bias) 
 
Any one of the following: 
 No missing outcome data; 
 Reasons for missing outcome data unlikely to be related to true 
outcome (for survival data, censoring unlikely to be introducing bias); 
 Missing outcome data balanced in numbers across intervention 
groups, with similar reasons for missing data across groups; 
 For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk not enough to have a clinically 
relevant impact on the intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in 
means or standardized difference in means) among missing outcomes 
not enough to have a clinically relevant impact on observed effect 
size; 
 
Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
Any one of the following: 
 Reason for missing outcome data likely to be related to true outcome, 
with either imbalance in numbers or reasons for missing data across 
intervention groups; 
 For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk enough to induce clinically 
relevant bias in intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in 
means or standardized difference in means) among missing outcomes 
enough to induce clinically relevant bias in observed effect size; 
 ‘As-treated’ analysis done with substantial departure of the 
intervention received from that assigned at randomization; 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
 
 
Any one of the following: 
 Insufficient reporting of attrition/exclusions to permit judgement of 
‘Yes’ or ‘No’ (e.g. number randomized not stated, no reasons for 
missing data provided); 
 The study did not address this outcome. 
SELECTIVE OUTCOME REPORTING 
Are reports of the study free of suggestion of selective outcome reporting? [Free of selective reporting?] 
 
Criteria for a judgement of 
‘YES’   
(i.e. low risk of bias) 
 
Any of the following: 
 The study protocol is available and all of the study’s pre-specified 
(primary and secondary) outcomes that are of interest in the review 
have been reported in the pre-specified way; 
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Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
Any one of the following: 
 Not all of the study’s pre-specified primary outcomes have been 
reported; 
 One or more primary outcomes is reported using measurements, 
analysis methods or subsets of the data (e.g. subscales) that were not 
pre-specified; 
 One or more reported primary outcomes were not pre-specified 
(unless clear justification for their reporting is provided, such as an 
unexpected adverse effect); 
 One or more outcomes of interest in the review are reported 
incompletely so that they cannot be entered in a meta-analysis; 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
Insufficient information to permit judgement of ‘Yes’ or ‘No’. It is likely 
that the majority of studies will fall into this category. 
OTHER POTENTIAL THREATS TO VALIDITY 
Was the study apparently free of other problems that could put it at a risk of bias? [Free of other bias?] 
 
Criteria for a judgement of 
‘YES’   
(i.e. low risk of bias) 
 
The study appears to be free of other potential sources of bias 
 
Criteria for the judgement of 
‘NO’  
(i.e. high risk of bias) 
There is at least one important risk of bias. For example, the study: 
 Had a potential source of bias related to the specific study design used; 
or 
 Stopped early due to some data-dependent process (including a 
formal-stopping rule); or 
 Had extreme baseline imbalance; or 
 Has been claimed to have been fraudulent; or 
 
Criteria for the judgement of 
‘UNCLEAR’  
(uncertain risk of bias). 
 
There may be a risk of bias, but there is either: 
 Insufficient information to assess whether an important risk of bias 
exists; or 
 Insufficient rationale or evidence that an identified problem will 
introduce bias. 
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APPENDIX 6.6:  Ethics Letter 
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Appendix 6.7: Table of Excluded Studies 
 
Reason for exclusion: Study type other than RCT (n=105) 
 
Abascal K, Yarnell E. Clinical Uses of Zingiber officinale (Ginger). Alternative & Complementary 
Therapies, 2009; 15 (5): 231-237. 
 
All A, Gilani AH. Medicinal value of ginger with focus on its use in nausea and vomiting of pregnancy. 
International journal of food properties 2007;10 (2):269-275. 
 
Allen R. Are we failing women? Advice for nausea and vomiting in pregnancy. Pract Midwife 2001; 4 
(4):20-22. 
 
Al-Achi, A. A current look at ginger use: complementary medicine. Journal of Modern Pharmacy, 2002;10 
(4). 
 
Anderson FWJ, Johnson CT. Complementary and alternative medicine in obstetrics. Int J Gynecol Obstet 
2005; 91(2):116-124 
 
Anon. Ginger root effective against pregnancy-related nausea and vomiting: freshness and quality may 
hold the key to benefits. Acupuncture Today, 2001 Nov; 2 (11): 1, 24. 
 
Anon. Herbal medicine during pregnancy and lactation. JNMA J Nepal Med Assoc 2006;45(163):1. 
 
Anon. Nausea and vomiting during pregnancy. J Midwifery Women’s Health 2006; 51(6):303-4. 
 
Anon. Zingiber officinale (ginger). Monograph. Altern Med Rev 2003;8(3):331-5. 
 
Bayles BP. Herbal and other complementary medicine use by midwives. Journal of midwifery and 
women’s health 2007;52: 473-478. 
 
Badell, ML, Ramin SM, Smith JA. Treatment options for nausea and vomiting during pregnancy 
Pharmacotherapy, 2006; 26 (9 I): 1273-1287. 
 
Baggley A, Navioz Y, Maltepe C, et al. Determinants of women’s decision making on whether to treat 
nausea and vomiting of pregnancy pharmacologically. Journal of midwifery and women’s health 
2004;49(4):350-354. 
 
Blumenthal M . Ginger as an antiemetic during pregnancy. Alternative Therapies in Health and Medicine, 
2003; 9 (1):19-21. 
 
Boone SA, Shields KM. Treating pregnancy-related nausea and vomiting with ginger.  Annals of 
Pharmacotherapy, 2005; 39 (10): 1710-3.  
 
Borrelli F, Capasso R, Aviello G, et al. Effectiveness and Safety of Ginger in the Treatment of Pregnancy-
Induced Nausea and Vomiting. Obstetrics & Gynecology, 2005; 105 (4,):849-856 
 
Bottomley C, Boume T. Management and strategies for hypermesis gravidarum. Best practice and research 
in clinical obstetrics and gynecology 2009; 23 (4):549-564. 
 
Buckner KD, Chavez ML, Raney EC, et al. Health food store’s recommendations for nausea and migraines 
during pregnancy. Annals of Pharmacotherapy 2005; 39(2):274-279. 
 
Bryer E. A literature review of the effectiveness of ginger in alleviating mild-to-moderate nausea and 
vomiting of pregnancy. J Midwifery Women’s Health 2005; 50(1):1-3. 
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Cassileth B. Complementary therapies, herbs, and other OTC agents. Oncology 2009; 23(10):904. 
 
Castleman, M. The 55 best herbal remedies (cover story). Natural Health, 2004; 35 (8):168-11 
 
Challem J. Medical journal watch: context and applications. Alternative & Complementary Therapies, 
2009; 15 (5): 267-72. 
 
Chandra K, Einarson A, Koren G. Taking ginger for nausea and vomiting during pregnancy. Canadian 
Family Physician 2002; 48: 1441-2. 
 
Chrubasik S, Pittler MH, Roufogalis BD,  Zingiberis rhizome: A comprehensive review on the ginger 
effect and efficacy profiles.  Phytomedicine 2005 (12): 684-701. 
 
Davis M. Nasuea and vomiting of pregnancy – an evidence based review. Journal of perinatal and neonatal 
nursing 2004; 16(4):312-328. 
 
Dennehy C, Tsourounis C, Bui L et al. The use of herbs by California midwives. JOGNN-Journal of 
obstetric gynecologic and neonatal nursing 2010; 39 (6):634-693. 
 
De Smet, P.A.G.M.
 
The role of plant-derived drugs and herbal medicines in healthcare 
Drugs,1997; 54 (6): 801-840. 
 
Dog TL. The use of botanicals during pregnancy and lactation. Alt Ther in Health and Medicine 2009; 15 
(1):54-58. 
 
Einarson A, Maltepa C, Boskovic R, et al. Treatment of nausea in pregnancy- an updated algorithm. Can 
Fam Physician 2007; 53: 2109-2111. 
 
Einarson A, Maltepe C, Navioz Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: 
a prospective comparative study. BJOG- An Internationsal journal of obstetrics and gynecology 
2004;111(9):940-943. 
 
Ernst E; Smith C. Ginger vs. vitamin B6 for morning sickness.  Focus on Alternative & Complementary 
Therapies, 2005; 10 (1): 23-4. 
 
Ernst E, Schmidt K. The health risks over the internet: advice offered by “medical herbalists” to a pregnant 
woman. Wien Med Wochenschr 2002;152(7-8):190-192. 
 
Flake ZA; Scalley RD; Bailey AG; Shaughnessy AF. Practical selection of antiemetics. American Family 
Physician, 2004; 69 (5): 1169-74, 1176, 1039-41.  
 
Festin M. Nausea and vomiting in early pregnancy. Clinical Evidence(online) 2007. 
 
Fotinos C. Ginger was equivalent to pyridoxine hydrochloride (vitamin B6) for reducing nausea and 
vomiting in pregnancy. Evidence-Based Medicine, 2005; 10 (1): 14. 
 
Freeman VL. Heal thyself. Rx: natural ways to combat morning sickness. Alternative Medicine Magazine, 
2006; (90): 58-9.  
 
Fugh-Berman, Adriane; Kronenberg, Fredi. Complementary and alternative medicine (CAM) in 
reproductive-age women: a review of randomized controlled trials. Reproductive Toxicology; 2003;17(2): 
137. 
 
Fulder S, Tanne M. Ginger as an anti-nausea remedy in pregnancy – the issue of safety. HerbalGram 1996; 
38:47-50. 
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Gaffney L, Smith CA. Use of complementary therapies in pregnancy: The perceptions of obstetricians and 
midwives in South Australia.  Australian and New Zealand Journal of Obstetrics and Gynaecology 2004; 
44(1):24-29. 
 
Ghafouri M. Management of nausea and vomiting of pregnancy. Women's Health Care: A Practical 
Journal for Nurse Practitioners, 2008; 7 (11): 18-24.  
 
Goodwin TM, Poursharif B, Korst LM, et al. Secular trends in the treatment of hyperemesis gravidarum. 
Am J of Perinatology 2008; 25 (3):141-147. 
 
Grant KL, Lutz RB. Ginger. American journal of health-system pharmacy 2000; 57(10):945-947. 
 
Hansen W.F., Peacock AE. Yankowitz  J. Safe prescribing practices in pregnancy and lactation. 
(2002) Journal of Midwifery and Women's Health, 2002; 47 (6): 409-421. 
 
Hardy M; Udani J. Does ginger help with symptoms of nausea in early pregnancy? Alternative Therapies 
in Women's Health, 2004; 6 (4): 25-9. 
 
Hoffman, T. Ginger: an ancient remedy and modern miracle drug. Hawaii Med J 2007;56 (12):326-7. 
 
Hollyer T, Boon H, Georgousis A, et al. The use of CAM by women suffering from nausea and vomiting 
during pregnancy. BMC Complement Altern Med 2002;2. 
 
Holst L, Wright D,Haavik S, Nordeng H. The use and the user of herbal remedies during pregnancy. 
Journal of Alternative & Complementary Medicine, 2009; 15 (7): 787-92.  
 
Hunter LP; Sullivan CA; Young RE; Weber CE. Nausea and vomiting of pregnancy: clinical management. 
American Journal for Nurse Practitioners, 2007; 11 (8): 57-60, 63-7. 
 
Isaacs A, Isaacs S. Hyperemesis Gravidarum: review. Obstetrics and Gynaecology Forum,2007;17(4)  
 
Jackson, E A. Is ginger root effective for decreasing the severity of nausea and vomiting in early 
pregnancy?  Journal of Family Practice, 2001; 50 (8): 720. 
 
Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy; Cochrane Database of 
Systematic Reviews, 2010 (9). 
 
Jueckstock JK., Kaestner R., Mylonas I.  Managing hyperemesis gravidarum: A multimodal challenge. 
 BMC Medicine, 2010; 8, art. no. 46. 
 
Junge T. Antiemetic properties of ginger. Surgical Technologist, 2007; 39 (9): 397-401.  
 
Katagiri F, Itoh H, Takeyama M. Effects of sho-hange-ka-bukuryo-to on gastrointersitnal peptide 
concentration in the plasma of healthy human subjects. Biological bulletin 2004;27(10):1674-1678. 
 
Keegan GT; Keegan L. The use of ginger to alleviate nausea. Alternative Therapies in Women's Health, 
2006; 8 (8): 57-61. 
 
Kim DR , Connolly KR, Cristancho P, Zappone M, Weinrieb RM.  Psychiatric consultation of patients 
with hyperemesis gravidarum.  Archives of Women's Mental Health, 2009; 12 (2): 61-67. 
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APPENDIX 6.8: Risk of biased judgments in included studies 
 
Basirat 2009 
 
Chittumma 2007 
 
Ensiyeh 2009 
ITEM Author’s 
judgments 
Description 
Adequate sequence 
generation? 
 
Yes A table of random numbers was used. 
Adequate allocation 
concealment? 
 
Yes Treatment codes were kept in sequence in a sealed black envelope that could not be read 
through. 
Adequate blinding? 
 
No Neither the physicians not the subjects knew the composition of the biscuits.  
BUT 3 subjects in the ginger group did not want to continue eating the biscuits due to the 
hot spicy taste, so they could identify the treatment. 
Incomplete outcome data 
addressed?  
 
Yes Reasons for all missing participants described  
Free of selective reporting 
 
Yes Primary and secondary outcomes clearly stated and discussed. 
Free of other bias? 
 
Yes  
ITEM Author’s 
 judgment 
Description 
Adequate sequence 
generation? 
 
Yes “Table of random numbers with block of four” 
Adequate allocation 
concealment? 
 
Yes “treatment code was concealed… in sequence in sealed opaque envelope… 
drawn in ascending consecutive order”  
 Codes broken only at end of the study. 
Adequate blinding? 
 
No Codes were kept strictly confidential and broken only at end of the study,  
BUT 4 pts in ginger group could correctly identify what they were taking. 
 
Incomplete outcome data 
addressed?  
 
Unclear 3 subjects did not return for follow-up, no reasons provided. They were excluded from 
the analysis. 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
No Some participants used cold medications, headache medications, and other ginger 
products. (confounder) 
Dietary advice was given to both groups to adjust food intake to help reduce nausea and 
vomiting.  
This could be a confounder, as some may have followed this advice and may have s 
symptom relief due to dietary changes 
ITEM Author’s 
judgments 
Description 
Adequate sequence 
generation? 
 
Yes “Randomised into 2 groups, using a table of random numbers” 
Adequate allocation 
concealment? 
 
Unclear Capsules were packed in an envelope. No additional information 
Adequate blinding? 
 
Unclear Mentioned “double-blind”. No further information. 
Incomplete outcome data 
addressed?  
 
Unclear 1 woman did not return for follow-up, no reasons provided, she was simply excluded due to  
no data collected.  
Free of selective 
reporting? 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
No Verbal informed consent only, no written consent. 
Dietary advice was given to both groups to adjust food intake to help reduce nausea and 
vomiting.  
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Fischer-Rasmussen 1991 
 
Keating 2002 
 
Ozgoli 2009 
This could be a confounder, as some may have followed this advice and may have symptom  
relief due to dietary changes. 
ITEM Author’s 
judgment 
Description 
Adequate sequence 
generation? 
 
Yes Cross-over design. Each patient became her own control.  
The hospital’s dispensary randomized the packages. 
Adequate allocation 
concealment? 
 
Unclear No information given 
Adequate blinding? 
 
Yes Hospital’s dispensary randomized the packages. 
 “the code remained sealed until the study had been completed” 
Incomplete outcome data 
addressed?  
 
Yes All missing participants well described and reported on 
Free of selective reporting 
 
Yes Outcomes clearly stated and reported 
Free of other bias? 
 
Unclear Ethics approval on reported. IV medication were continued to prevent dehydration.  
ITEM Author’s 
judgment 
Description 
Adequate sequence 
generation? 
 
Yes “Computer generated numbers matching the numbers on identical appearing bottles of 
 ginger or placebo syrup” 
Adequate allocation 
concealment? 
 
Yes “identical appearing bottles of ginger or placebo syrup” Syrup prepared by independent  
company. 
Adequate blinding? 
 
No One woman could not tolerate the taste of the ginger, stopped treatment. 
Incomplete outcome data 
addressed?  
 
Yes Reasons for missing participants well described 
Free of selective reporting 
 
No At beginning of article the authors state that the purpose of the study is to assess the 
acceptance  
and clinical value of the ginger syrup, but there is no reporting on the acceptance.  
Free of other bias? 
 
Unclear              Statistical analysis was not applied due to small nr of pts in each group. 
Treatment was for 14 days, but results given on values for 9days. 
Dietary advice was given to both groups to adjust food intake to help reduce nausea and 
vomiting.  
This could be a confounder, as some may have followed this advice and may have 
symptom  
relief due to dietary changes 
ITEM Author’s 
judgement 
Description 
Adequate sequence 
generation? 
 
Unclear “The participants were randomly assigned” 
Adequate allocation 
concealment? 
 
Unclear No information given 
Adequate blinding? 
 
Yes “Single blind” “ The participants were blinded to the contents of the capsules” 
Incomplete outcome data 
addressed?  
Yes Reasons for all missing participants described 
Free of selective reporting 
 
Yes Primary and secondary outcomes clearly stated and discussed 
Free of other bias? 
 
Unclear Dietary advice was given to both groups to adjust food intake to help reduce nausea and 
vomiting. This could be a confounder, as some may have followed this advice and may  
have symptom relief due to dietary changes.  
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Pongrojpaw 2007 
 
Smith 2004 
 
Sripramote 2003 
 
 
 
 
ITEM Author’s 
judgments 
Description 
Adequate sequence generation? 
 
Unclear “were randomly allocated.” No further information given. 
Adequate allocation 
concealment? 
 
Unclear “Capsules were identical in size, color and odor.” No further information 
Adequate blinding? 
 
Unclear In abstract it is called a double-blind RCT, but no further info given on blinding of 
personnel.  
Incomplete outcome data 
addressed?  
 
Unclear No reasons provided for the 19 subjects lost to follow-up 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
No The researchers decided on a lower dose of Dimenhydrinate (the control)  than was 
used in  
previous studies, and that is usually prescribed, because they wanted to improve  
compliance and avoid loss to follow-up.   This lower dose could lead to lower scores.  
ITEM Author’s 
judgments 
Description 
Adequate sequence 
generation? 
 
Yes “Computer generated randomization schedule used balanced variable blocks,  
prepared by researcher not involved in the trial.” 
Adequate allocation 
concealment? 
 
Unclear “capsules were contained in an opaque brown soft gel capsule”  
Adequate blinding? 
 
No  Participants were blinded,and computer operater blinded. BUT some ginger users,  
and vit B6 users correctly identified what they were taking (unblinding) 
 
Incomplete outcome data 
addressed?  
Unclear Not all clear reasons for lost to follow-up – “forms not returned, and other”, also  
“Discontinued ginger” in both groups – unclear. 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
Unclear Participants were allowed to continue with other meds.  
Documentation at start and end of study. No diff between 2 groups,  
and the analyses were adjusted for this variable. (bias?) 
 
ITEM Author’s 
 judgment 
Description 
Adequate sequence generation? 
 
Yes “…pharmacist no responsible for patient care used random numbers to prepare 
 treatment assignments with block of four.” 
Adequate allocation 
concealment? 
 
Unclear “.. assignment in sequence in sealed opaque envelopes that were drawn in ascending 
consecutive order.”  
BUT the vit B6 capsules weighed less than the ginger capsule. (10mg vs 500mg, in 
identical capsules). 
Adequate blinding? 
 
Yes “treatment codes were kept strictly confidential for blinding the physician and subjects,  
and were broken at the end of the study” 
Incomplete outcome data 
addressed?  
 
Unclear No reasons given for the 10 subjects lost to follow-up. 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
No Dietary advice was given to both groups to adjust food intake to help reduce nausea 
 and vomiting. This could be a confounder, as some may have followed this advice  
and may have symptom relief due to dietary changes 
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Vutyavanich 2001 
 
Willetts 2003 
 
 
 
 
 
 
 
 
ITEM Author’s 
 judgment 
Description 
Adequate sequence generation? Yes ‘a researcher who was not responsible for patient care, used a table of random numbers 
to prepare the  
treatment assignment” 
Adequate allocation 
concealment? 
Yes “sealed black envelopes that could not be read through” 
Adequate blinding? 
 
Yes “list that reveled drug codes given to patients were kept strictly confidential…not 
accessible to  
the physicians” Pre-trial testing showed that participants could not correctly identify 
what they took.  
Incomplete outcome data 
addressed?  
 
 
No 
3 missing participants in placebo group did not return for follow-up.  (Intent-to-treat 
analysis was done  
by assuming the 3 missing pts in placebo group values as high as the best pt in ginger 
group.) 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
No Dietary advice was given to both groups to adjust food intake to help reduce nausea and 
vomiting. 
 This could be a confounder, as some may have followed this advice and may have 
symptom  
relief due to dietary changes 
ITEM Author’s 
 judgment 
Description 
Adequate sequence 
generation? 
 
Yes “ randomization was done by Eurovita Pty Ltd using randomization blocks of six” 
Adequate allocation 
concealment? 
 
Yes “…sealed envelopes…posted to us.” Both capsules were wax sealed and identical in 
appearance. 
Adequate blinding? 
 
Yes Double blind – the participants, administrators ad those assessing the outcomes were all 
blinded. 
Incomplete outcome data 
addressed?  
 
Yes All missing participants are described in detail. Lost participants were excluded from 
analysis. 
Free of selective reporting 
 
Yes Outcomes clearly stated and discussed 
Free of other bias? 
 
Unclear Eurovita Pty Ltd was responsible for the randomization, and they funded the study. (??) 
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